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ABSTRACT 
Identification of a novel enhancer region 1.7 Mb downstream of the c-myc gene 
controlling its expression in hematopoietic stem and progenitor cells 
The transcription factor and proto-oncogene c-Myc is a central regulator of cellular 
proliferation, growth, metabolism and differentiation in many cell types including stem 
cells. Although it is known that c-Myc expression is tightly controlled and can drive 
tumorigenesis if de-regulated, the mechanisms of its transcriptional regulation remain 
largely elusive. Besides its promoter, which is not sufficient to account for endogenous 
c-myc expression, only a few cis-regulatory elements have been defined. The c-myc 
gene is located on mouse chromosome 15 within a 4 Mb-long gene-poor region, which 
coincides with a large topologically associating domain (TAD). At the distal end of this 
TAD, 1.7 Mb downstream of the mouse c-myc gene, we identified a cluster of 
enhancer-associated chromatin marks which were present only in hematopoietic tissues. 
A LacZ reporter gene inserted next to this cluster showed specific expression in 
hematopoietic stem cells (HSCs) and progenitor cells. Mice homozygous for a deletion 
of this enhancer region showed decreased myeloid and B cells, while HSCs, multipotent 
progenitors and megakaryocytes accumulated in the bone marrow. Mutant HSCs were 
non-functional, as they lost multipotency and showed differentiation defects at the 
progenitor level, which resulted in their accumulation in vivo. This phenotype closely 
mimicked the phenotype of mice in which the c-myc gene was conditionally deleted by 
the Cre/loxP technique in the adult hematopoietic system using MxCre (MxCre; c-
mycflox/flox). Importantly, gene expression analysis showed that the deletion of this 
enhancer region led to a dramatic reduction of c-myc expression in HSCs, multipotent 
progenitors and most mature cell types. Furthermore, compound heterozygous mice 
with one allele carrying the enhancer deletion and a c-myc null allele on the other 
chromosome displayed hematopoietic defects highly similar to MxCre; c-mycflox/flox 
animals, demonstrating genetic allelism between the c-myc coding region and the newly 
identified enhancer region. Altogether, these data provide genetic evidence that this 
enhancer region directly controls, in cis, c-myc expression in HSC/progenitor cells. 
Within the 126 kb enhancer region 8 modules of sizes between 0.4 kb and 1.9 kb were 
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identified and analyzed for relative enrichment of the enhancer-associated H3K27ac 
histone mark by ChIP/qRT-PCR. This was performed in different hematopoietic 
lineages and revealed that distinct enhancer modules differentially control c-myc 
expression in granulocytes or HSC/progenitors. Interestingly, this evolutionary highly 
conserved enhancer region was shown to be focally amplified in a number of tumor 
samples from patients with acute myeloid leukemia (AML), suggesting that this 
enhancer may be a critical component driving increased c-MYC expression found in 
certain leukemias. In summary, we identified a very distant hematopoietic and 
stem/progenitor specific enhancer region for c-myc and provide genetic data supporting 
its critical function as a key regulatory region in normal hematopoiesis and a putative 
role in human AML. 
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ZUSAMMENFASSUNG 
Identifizierung einer neuen Enhancerregion 1.7 Mb strangabwärts des c-myc 
Gens, die dessen Transkription in hämatopoietischen Stamm- und Vorläuferzellen 
steuert 
Der Transkriptionsfaktor c-Myc ist ein Proto-Onkogen und ein zentraler 
Regulator von zellulärer Proliferation, Wachstum, Metabolismus und Differenzierung in 
vielen Zelltypen einschließlich Stammzellen. Obwohl bekannt ist, dass die Expression 
von c-Myc streng kontrolliert erfolgt und bei Fehlregulation zu Tumorgenese führen 
kann, bleiben die Mechanismen seiner transkriptionellen Regulation weitestgehend 
unklar. Neben seinem Promoter, der alleine nicht ausreicht, um die endogene 
Expression von c-myc zu ermöglichen, wurden bisher nur wenige cis-regulierende 
Elemente bestimmt. Das c-myc Gen befindet sich auf dem Maus-Chromosom 15 in 
einer 4 Mb-langen, genarmen Region, die sich mit einer topologisch assoziierenden 
Domäne (TAD) überschneidet. Am distalen Ende dieser TAD, 1.7 Mb strangabwärts 
des murinen c-myc Genes, haben wir eine Gruppe von Enhancer-assoziierten 
Chromatinmodifikationen identifiziert, die ausschließlich in blutbildenden Geweben 
vorhanden waren. Ein LacZ Reportergen, das neben dieser Gruppe ins Genom eingefügt 
wurde, zeigte spezifische Expression in hämatopoetischen Stamm- (HSZ) und 
Vorläuferzellen. Mäuse, in denen diese Region homozygot deletiert wurde, zeigten eine 
verringerte Anzahl an myeloischen und B Zellen, während sich HSZ, multipotente 
Vorläuferzellen und Megakaryozyten im Knochenmark anreicherten. Die HSZ waren 
nicht funktionell, denn sie zeigten den Verlust ihrer Multipotenz und 
Differenzierungsdefekte beginnend auf der Vorläuferstufe, die zur Akkumulierung 
dieser Vorläuferzellen in vivo führte. Dieser Phänotyp glich in großem Maße dem 
Phänotyp von Mäusen, in denen das c-myc Gen mittels des Cre/loxP-Verfahrens durch 
MxCre im adulten hämatopoetischen System konditionell deletiert wurde (MxCre; c-
mycflox/flox). Genexpressionsanalysen zeigten, dass die Deletion der Enhancerregion zu 
einer dramatischen Verminderung der c-myc Expression in HSZ, multipotenten 
Vorläuferzellen und den meisten reifen Zelltypen führte. Doppelt heterozygote Mäuse, 
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die ein Allel mit deletiertem Enhancerbereich sowie ein deletiertes c-myc Allel auf dem 
anderen Chromosom besaßen, zeigten äußerst ähnliche hämatopoetische Defekte wie 
MxCre; c-mycflox/flox Tiere. Dies belegte den genetischen Allelismus zwischen der c-
myc kodierenden Region und der neu identifizierten Enhancerregion. Insgesamt 
erbringen unsere Daten den genetischen Beweis, dass diese Enhancerregion die 
Expression von c-myc direkt und in cis in HSZ und Vorläuferzellen reguliert. Innerhalb 
der 126 kb umfassenden Enhancerregion identifizierten wir 8 Module mit Größen 
zwischen 0.4 kb und 1.9 kb und untersuchten die relative Anreicherung der Enhancer-
assoziierten Histonmodifikation H3K27ac durch ChIP/qRT-PCR. Dies wurde in 
verschiedenen hämatopoietischen Zelltypen durchgeführt und zeigte, dass ausgewählte 
Enhancermodule die Expression von c-myc in Granulozyten oder HSZ/Vorläuferzellen 
differenziell steuert. Interessanterweise wurde eine fokale Amplifizierung dieser 
evolutionär hochkonservierten Enhancerregion in einer Reihe von Tumorproben von 
Patienten mit akuter myeloischer Leukämie (AML) nachgewiesen, was darauf 
hindeutet, dass dieser Enhancer entscheidend an der erhöhten Expression von c-MYC 
beteiligt ist, die in einigen Leukämien beobachtet wurde. Zusammenfassend lässt sich 
sagen, dass wir eine sehr weit entfernt gelegene Enhancerregion für c-myc identifiziert 
haben, die spezifisch für das hämatopoetische System, insbesondere für Stamm- und 
Vorläuferzellen ist. Unsere Daten belegen die entscheidende Funktion dieses 
Enhancerbereichs als regulatorische Schlüsselregion in der normalen Blutbildung und 
zeigen eine mögliche Rolle bei der humanen AML auf. 
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 1 INTRODUCTION 
1.1 Regulation of gene expression 
The complete hereditary information of an eukaryotic organism is comprised in 
the series of deoxyribonucleic acid (DNA) base pairs which are packed and organized in 
chromosomes. This information provides the blueprint for each cell to fulfill all 
biological reactions that constitute the living organism. The most well characterized 
class of elements within this information are the protein coding genes, hence it was 
termed the “genome”. However, analysis of the human sequence limited their number to 
roughly 20,500 protein coding genes, which comprise only 1.5% of all base pairs of the 
human genome. Thus the largest part of the genome consists of non-coding sequences 
(CLAMP et al. 2007; LANDER et al. 2001; VENTER et al. 2001). 
Almost every cell within an individual contains the same genomic set of 
instructions since they originate from a single zygote. However, cell types differ greatly 
in their appearance and function. This diversity originates from different gene 
expression patterns in each cell type, thus regulating their differentiation or their 
response to internal or external stimuli. Since the process of gene expression requires a 
tight and highly specific adjustment, various regulatory mechanisms exist at different 
levels. The two main steps for the transmission of the genetic information from DNA 
into protein are transcription and translation. In the process of transcription the gene 
serves as a template for the generation of a messenger RNA (mRNA) molecule. This 
molecule is subsequently exported from the nucleus into the cytoplasm where the 
encoded genetic information is translated into a sequence of amino acids of a 
polypeptide. Both steps are tightly regulated and followed by further regulatory 
mechanisms like splicing, 5’-capping, 3’-polyadenylation, export regulation and mRNA 
decay of the transcript or folding, cutting, chemical modification and degradation of the 
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polypeptide (LACKNER and BAHLER 2008; WALSH et al. 2005). The following chapters 
focus on regulatory mechanisms of the transcription. 
1.1.1 Transcriptional machinery 
The transcription of genes is performed by RNA polymerases. Eukaryotes possess 
three types of this enzyme, each of them specialized in the production of certain types 
of RNA species. RNA-Polymerase I is responsible for the synthesis of most rRNAs that 
are part of the ribosomes. RNA Polymerase II (RNAPII) is responsible for the synthesis 
of messenger RNAs (mRNAs) and most small nuclear RNA (snRNAs) and microRNAs 
(miRNAs). RNA Polymerase III synthesizes transfer RNAs (tRNAs), the 5S subunit of 
ribosomar RNAs (rRNAs) and furthermore some small RNAs (WHITE 2011). Most 
attention was drawn to the function of RNAPII as it mediates transcription of the 
protein coding genes. The RNAPII cannot bind to the DNA and start transcription on its 
own but requires certain factors, the general transcription factors (GTFs). Together 
these proteins form the pre-initiation complex (PIC) at the promoter (chapter 1.1.2.1.1), 
which is sufficient to account for a basal transcription level. Besides the GTFs a large, 
multisubunit complex termed Mediator assists in transcriptional stimulation. Altogether 
theses factors form the RNAPII transcriptional machinery (WOYCHIK and HAMPSEY 
2002). 
The assembly of the transcriptional machinery happens stepwise starting with the 
binding of the TATA-binding protein (TBP) as part of GTF TFIID near the site of 
transcription initiation on the template DNA. This complex serves as a platform for the 
assembly of the other GTFs TFIIA, TFIIB, TFIIE, TFIIF and TFIIH, which allow in 
concert the positioning of the RNAPII to the DNA strand. Local melting of the DNA at 
the transcription start site supports the open complex formation. Phosphorylation on 
serine 5 (Ser5P) of the RNAPII of the carboxy-terminal domain (CTD) domain of its 
largest subunit allows clearance and escape of the complex from the promoter region. 
The RNAPII is subsequently released from the promoter region, leaves the scaffold 
complex behind and forms a fully functional elongation complex, which goes along 
with another phosphorylation step (Ser2P). This complex moves down the DNA strand 
in the 3’ to 5’ direction inserting the ribonucleotides adenine, cytosine, guanine and 
uracil into a growing strand of RNA. At the termination site transcription stops, the 
RNAPII complex is disassembled and recycled to its unphosphorylated form by a 
phosphatase (HAHN 2004; MASTON et al. 2006; REINBERG et al. 1998). 
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1.1.2 Transcriptional regulation 
Transcriptional regulation occurs primarily at the level of transcription initiation, 
but also the release from promoter-proximal pausing emerges as another level of 
regulation (ADELMAN and LIS 2012). The assembly of the RNAPII complex is regulated 
through the integrated activity of different regulatory elements and their cognate 
transcription factors. Cis-regulatory elements can be divided into two categories, 
proximal regulatory elements, like promoters, and distal regulatory elements, like 
enhancers, silencers, insulators and locus control regions that are reported to be located 
up to 1 Mb pairs away from the promoter (MASTON et al. 2006; RIETHOVEN 2010). 
1.1.2.1 Cis-regulatory elements 
1.1.2.1.1 Promoters 
The promoter is a stretch of DNA located close to the transcription start site (TSS) 
of a gene and mediates the initiation of transcription. It is composed of a core promoter, 
which directs the transcriptional machinery to the TSS, and proximal promoter 
elements, which contain multiple binding sites for activator proteins (MASTON et al. 
2006). The core promoter typically spans up to 1000 base pairs and can have a complex 
structure. Sequence elements found common to many core promoters include the TATA 
element (TBP-binding site), Inr (initiator element), BRE (TFIIB-recognition site), DPE 
(downstream promoter element), DCE (downstream core element) and MTE (motif ten 
element). These elements possess characteristic consensus sequences and are located at 
specific distances relative to the TSS. They mediate the binding of several GTFs and 
cofactors, thus enabling the assembly of the pre-initiation complex (SMALE and 
KADONAGA 2003). 
The TATA box was first believed to be highly conserved and an essential part of 
every promoter, however sequencing and gene analysis efforts in recent years 
diminished the prevalence of the TATA element. Similarly it was found that all human 
core promoters are very diversely organized. Less than half of ~10,000 analyzed 
predicted promoters contain the most abundant Inr element, while other elements are 
represented at even lower frequencies (GERSHENZON and IOSHIKHES 2005). Also the 
combination of different elements within a single promoter varies and it was shown that 
initiation of the transcription at promoters is driven by synergy of its core elements. 
However, identification of promoter sequences cannot solely rely on the known core 
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elements. More motifs remain to be determined, which is in the focus of bioinformatics 
analyses. 
One feature observed in 72% of human promoters is the abundance of CpG 
islands (SAXONOV et al. 2006). In regulatory sequences CpGs remain unmethylated 
whereas in most other regions the cytosine within CpGs is methylated thus increasing 
the probability of the cytosine becoming mutated to adenosine. Therefore the 
enrichment of CpGs can be used as a tool for mapping promoter sequences (IOSHIKHES 
and ZHANG 2000). 
Another part of the promoter structure consists of proximal promoter elements. 
They were identified in 1982 by linker-scanning mutagenesis (MCKNIGHT and 
KINGSBURY 1982). This study localized transcriptional regulatory elements towards the 
region approximately 100 bp upstream of the TSS. Motifs present within this region are 
binding sites for transcriptional activators. The relative locations of these activator 
binding sites and the core promoter elements determine the directionality of 
transcription (MASTON et al. 2006; SMALE and KADONAGA 2003). 
Transcription initiation at promoter usually occurs according to two patterns, 
termed focused and dispersed transcription initiation (JUVEN-GERSHON and KADONAGA 
2010). The former is associated with a transcription start from a single TSS or a 
localized cluster of TSSs in less than 10 bp and is used predominantly in simple 
organisms. The latter displays multiple but weak start sites over a broad region of 50 to 
100 nucleotides. In vertebrates, focused transcription is observed with the minority of 
promoters that typically belong to regulated promoters whereas dispersed transcription 
is typically associated with constitutive promoters in CpG islands. Differences in the 
presence of core promoter elements have been observed for these two types of 
transcription initiation. Notably, also intermediate promoters exist that share 
characteristics of both modes, multiple weak start sites with one dominant peak (JUVEN-
GERSHON and KADONAGA 2010; SANDELIN et al. 2007). 
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Figure 1.1: Distal regulatory elements 
Transcription can be induced by enhancers and reduced by silencers. Insulators block enhancer 
or silencer activity when they are located in between the regulatory element and the target gene 
promoter by DNA loop formation. Locus control region (LCR) is composed of several elements 
that act in concert on multiple genes in a locus. Black arrows indicate the transcriptional activity 
of the promoters of target genes (blue). 
1.1.2.1.2 Enhancers 
Enhancers are distal elements that activate transcription of their respective target 
gene (Figure 1.1). They act on genes of the same DNA molecule, however most 
enhancers in the vertebrate genome are located more than 1000 bp away from their 
target gene (VISEL et al. 2009). The first enhancer was described in 1981 in SV40 DNA 
sequences, showing that transcription is activated independent of the enhancers 
location, distance or orientiation relative to its target gene (BANERJI et al. 1981). The so 
far greatest distance of an enhancer was observed for the limb enhancer of Shh, which is 
located 1 Mb upstream of its target gene (LETTICE et al. 2003). However, although 
enhancer and target gene might be far away from each other on the DNA strand, they 
are thought to come into close proximity by 3-dimensional folding of the chromatin 
(SCHOENFELDER et al. 2010) (discussion of interaction models in chapter 1.1.3.3). 
Enhancers contain multiple binding sites for several different transcription factors. 
The motif composition but also the way these sequence motifs are arranged within the 
enhancer are essential for the transcriptional regulation (SPITZ and FURLONG 2012). In 
enhancer structures called enhanceosomes binding of the transcription factors in a 
characterized interferon-β enhancer. Expression is only driven when eight transcription 
factors are binding cooperatively to the enhancer (PANNE 2008). Therefore expression 
of the target gene interferon-β can be switched on rapidly, which might be critical in the 
response to a viral infection. However, many enhancers are organized in a less ordered 
manner, where binding of a subset of transcription factors is sufficient to activate 
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transcription and the positioning is less strict. The binding dynamics of additional 
transcription factors can modulate the target gene expression, thus having an additive 
effect (ARNOSTI and KULKARNI 2005; KULKARNI and ARNOSTI 2003). In contrast to the 
enhanceosome regulation this more flexible enhancer structure rather allows a fine-
tuning of the target gene expression. 
Due to the differential expression and activity of transcription factors in different 
cell types the regulation of transcriptional activity by enhancers is tissue- and/or 
developmental stage-specific (ONG and CORCES 2011). 
The ways how enhancers activate transcription can occur at multiple levels. On 
the one hand recruited transcription factors regulate the transcriptional machinery, either 
by increasing its recuitment and therefore the initiation of transcription, but also the 
elongation and termination of transcription can be regulated. On the other hand 
enhancers function by mediating local remodelling of the chromatin, thus leading to an 
open formation with increased accessibility (ONG and CORCES 2011). 
Recently a more direct interaction between enhancers and the transcriptional 
machinery was discovered. A genome-wide study in mouse cortical neurons revealed 
binding of the RNAPII to a subset of enhancers and moreover the bidirectional 
expression of short, non-coding RNAs, termed enhancer RNAs (eRNAs). eRNA 
expression was correlated to mRNA synthesis from nearby genes and at least for the 
example given in the study seemed to require interaction with the relevant promoter. It 
is proposed that they might be necessary for the maintenance of an open chromatin 
state, however function and mechanism of eRNAs remain to be elucidated (KIM et al. 
2010). 
1.1.2.1.3 Silencers 
Silencers have a negative effect on the transcription of their target gene (Figure 
1.1). Like enhancers they can be located at distant sites of the promoter, but they can 
also be located close by as well as in exons and introns of genes. Silencers contain 
binding sites for transcription factors that exhibit a repressive function, therefore these 
are called repressors. In some cases these factors recruit other corepressors to exert their 
repressive influence (OGBOURNE and ANTALIS 1998). 
One example for silencer sequences is the polycomb response element (PRE). The 
first PRE was discovered in 1991 in Drosophila using a reporter construct with the 
mini-white gene that leads to a dark eye color (KASSIS et al. 1991). An insertion of a 
2.4-kb fragment into the mini-white vector led to a white eye color of the flies, 
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suggesting that the reporter gene was completely silenced. The DNA fragment was then 
shown to contain two PREs, binding sites for polycomb repressive complexes (PRC) 
(AMERICO et al. 2002; DEVIDO et al. 2008; KASSIS 1994). Several motifs have been 
identified to account for PRC binding in Drosophila, however for a long time 
mammalian sequences were not identified until the recent discovery of two murine 
PREs (SING et al. 2009; WOO et al. 2010). Apart from that PRCs are recruited indirectly 
by several DNA-binding targeting factors (BEISEL and PARO 2011). 
Polycomb repressive complexes are large complexes build of polycomb group 
(PcG) and other proteins. Originally PcG proteins were discovered as regulators of the 
homeotic (Hox) genes controlling the body segmentation in Drosophila (LEWIS 1978). 
Several genome-wide studies in flies, mice and humans revealed that PRCs have beside 
the Hox genes a multitude of predominantly development related targets (BOYER et al. 
2006; LEE et al. 2006; NEGRE et al. 2006; SCHWARTZ et al. 2006; TOLHUIS et al. 2006). 
Depending on the composition of the subunits two major PRCs have been identified: 
PRC1 and PRC2. PRC2 contains a methyltransferase as catalytical subunit that 
mediates di- and trimethylation of lysine 27 of histone H3 (H3K27me2/H3K27me3) 
(CAO et al. 2002; CZERMIN et al. 2002; KUZMICHEV et al. 2002; MÜLLER et al. 2002), 
which act as repressive epigenetic marks (PENGELLY et al. 2013). In turn, H3K27me3 is 
recognized by a subunit of PRC1 complexes (FISCHLE et al. 2003; MIN et al. 2003). 
PRC1 contains two ubiquitin E3 ligases that monoubiquitinates histone H2A at lysine 
residue 119 (WANG et al. 2004). This histone mark is associated with transcriptional 
silencing mediated by chromatin compaction and RNAPII pausing (STOCK et al. 2007). 
In addition a direct interaction between the PcG protein EZH2 and DNA methyl 
transferases (DNMTs) has been shown, thus linking histone and DNA methylation at 
repressed promoters (VIRE et al. 2006). 
In summary PcG proteins are important epigenetic regulators for the transcription 
of many developmental genes. PREs have been predominantly identified in flies but 
also mouse and are examplary for silencers. 
1.1.2.1.4 Insulators 
Insulators are also known as boundary elements and they restrict the activity of 
enhancers or silencer by blocking their interaction with the promoter. Two distinct (but 
not exclusive) functions can be attributed to an insulator. Either the insulator marks the 
border between regions of heterochromatin and euchromatin (barrier insulator), thus 
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preventing the spread of repressive chromatin or it prevents enhancer-promoter or 
silencer-promoter communication (known as blocking activity) (MASTON et al. 2006). 
The barrier activity is thought to be mediated by recruitment of gene-activating 
factors or histone-modifying enzymes that render the chromatin permissive thus 
blocking the spread of heterochromatin (BUSHEY et al. 2008; MASTON et al. 2006). 
For the enhancer blocking activity three potential mechanisms were postulated 
(BUSHEY et al. 2008). One model proposes that the insulator mimics the promoter 
structure, thus recruiting the transcriptional machinery. In this case the insulator would 
compete with the real promoter for interaction with the enhancer (GEYER 1997). In 
support with this model enhancer DNA and insulator DNA were shown to colocalize 
(YOON et al. 2007; ZHU et al. 2007). However, experiments where the position of the 
insulator was changed relative to the promoter-enhancer structure revealed that insulator 
function was dependent on the position in between enhancer and promoter, but not 
outside this structure (GOHL et al. 2011). This challenged the first model as one could 
have expected activity also when the insulator is positioned on the opposite site of the 
enhancer. 
The second model suggests that the insulator directly acts as a physical barrier 
that stops the RNAPII from proceeding along the strand towards the promoter (ZHAO 
and DEAN 2004). However, some insulators were shown to be located in introns, still 
they were functional without truncating the gene product (GEYER and CORCES 1992). 
Furthermore, loss of insulator activity was shown for an insulator being inserted with 
two copies as opposed to a single copy in between an enhancer and promoter (CAI and 
SHEN 2001; MURAVYOVA et al. 2001). These two examples argue against a universal 
application of this mechanism for insulator function. 
The third model proposes the formation of distinct compartments in the genome. 
It is assumed that elements can only interact when they are part of the same 
compartment (Figure 1.1). Such a partitioning is thought to occur by formation of DNA 
loops, that are formed by interaction between two insulators. One molecule involved in 
this loop formation is the CCCTC-binding factor (CTCF). Genome-wide studies 
revealed that a lot of CTCF-binding sites are located in between genes that display 
reduced correlation in gene expression compared to adjacent genes that are not 
separated by CTCF-binding sites (HUANG et al. 2007). Indeed CTCF-focused chromatin 
interaction analyses revealed that CTCF interactions lead to higher order chromatin 
organization. However, the results not only supported a role for CTCF in enhancer 
blocking function but also provided evidence that CTCF binding is necessary for a 
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number of enhancers to activate their target genes (HANDOKO et al. 2011). These results 
are in agreement with a more global chromatin organization that will be discussed in 
chapter 1.1.3.3. 
In summary insulators are genetic boundary elements that block the interaction 
between enhancers and promoters. This is achieved by two main functions, however the 
detailed mechanisms still remain to be elucidated. 
1.1.2.1.5 Locus Control Region (LCR) 
A locus control region is defined as a cis-acting sequence element consisting of 
multiple regulatory elements that confer tissue-specific, copy-number dependent but 
position independent expression of a gene cluster (GROSVELD et al. 1987). Several 
LCRs have been identified in vertebrates, the most well studied is the LCR regulating 
the mouse β-globin locus (LI et al. 2002). 
Transgenic mice carrying a 5 kb fragment of the β-globin locus still express the β-
globin gene, however only at a very small fraction of the normal rate. Thus the more 
distant genomic region surrounding the β-globin gene was investigated for regulatory 
activity. 5 Sites showing hypersensitivity for DNase I treatment (5’HS1-5; chapter 
1.1.3) are located 6 - 22 kb 5’ to the first globin gene in the locus. Only if these sites 
were included, the LCR was fully functional and transgenic mice expressed the β-globin 
gene at normal levels (GROSVELD et al. 1987). 
Experiments where the β-globin LCR was coupled to a LacZ gene driven by a 
Hsp68 promoter revealed LacZ expression not only in erythrocytes but also in the yolk 
sac, the tissue in which the Hsp68 promoter is normally active (TEWARI et al. 1996). 
This result suggests that the promoter structure contributes to the tissue-specificity and 
is not solely defined by the LCR. 
Molecular dissection of the single HSs revealed enhancer (5’HS2-4) and insulator 
(5’HS5) functions within the distal part of the LCR. Enhancer activity was detectable in 
transient transfection assays for 5’HS2, whereas 5’HS3 and 5’HS4 only exhibited 
enhancer activity when they were integrated into chromatin (HARDISON et al. 1997). 
Thus regulation by these two enhancers seems to be dependent on chromatin alterations. 
Further hints come from the observation that β-thalassemia patients with a deletion 
upstream of 5’HS1 but intact globin locus show no expression of the globin genes due 
to alterations in the chromatin conformation (FORRESTER et al. 1990). Indeed interaction 
studies reveal that active transcription coincides with loop formation that brings the 
LCR in close proximity to the globin genes (TOLHUIS et al. 2002). 
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In summary a LCR is a multi-component regulatory element where the single 
elements within the LCR act cooperatively and synergistically. 
1.1.2.2 Epigenetic regulation of the chromatin structure 
As it has become apparent already in the description of the regulatory elements 
the chromatin structure plays an essential role in the regulation of gene expression. In 
eukaryotic cells the DNA is tightly packed into chromatin within the nucleus. The basic 
unit of the chromatin is the nucleosome, which consists of ∼146 bp of DNA that is 
wrapped around a histone octamer (LUGER et al. 1997). The complete folding of the 
DNA leads to an organized structure with specific regions that are relatively 
uncondensed (euchromatin) and other regions that are densely packed (heterochromatin) 
(CAMPOS and REINBERG 2009). Transcriptional activity of genes is dependent on their 
chromatin structure as only euchromatin allows accessibility for most DNA-binding 
factors. The assembly and compaction of the chromatin is regulated by several 
epigenetic mechanisms, including posttranslational modifications of histone proteins, 
DNA methylation and ATP-dependent remodeling (KOUZARIDES 2007). 
1.1.2.2.1 Histone modifications 
Typically the histone octamer consists of two copies of each of the core histone 
proteins: H2A, H2B, H3 and H4. Histones are highly basic proteins, thus they are able 
to efficiently bind the negatively charged DNA. The N-terminal tails of the histones are 
protruding outward from the nucleosome and are therefore accessible for histone 
modifying enzymes as well as for proteins that recognize these modifications. For this 
reason most modifications occur at this tail, however also the short but accessible C-
terminus can be modified. Histone modifications exert their function in two ways, either 
directly by changing the overall structure of the chromatin or by regulating the binding 
of effector molecules. Posttranslational modifications include acetylation, methylation, 
phosphorylation, ubiquitylation, and ADP-ribosylation of the histone proteins 
(BANNISTER and KOUZARIDES 2011). 
1.1.2.2.1.1 Histone acetylation 
All four core histones can be acetylated at several specific lysine residues (K), 
which is catalyzed by histone acetyltransferases (HATs). This modification is reversible 
as acetyl residues can be removed by histone deacetylases (HDACs). Histone 
acetylation is generally associated with transcriptionally active chromatin. The 
acetylation causes a decrease in the net positive charge of the N-terminal tail resulting 
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in a lower affinity for the negatively charged DNA. Therefore the chromatin has a more 
open structure and provides increased accessibility of regulatory factors to the DNA 
(GRUNSTEIN 1997). Additionally to the effect on histone charge histone acetylation can 
serve as a binding motif for regulators. Some transcription coactivators and chromatin 
remodeling complexes contain a domain termed bromodomain that is specific to the 
recognition of histone acetylation (WINSTON and ALLIS 1999). 
1.1.2.2.1.2 Histone methylation 
The two core histones H3 and H4 can be methylated at several lysine (K) and 
arginine (R) residues by methyltransferases. Compared to histone acetylation the 
functions of histone methylation are more diverse. In part this can be attributed to the 
more complex modification pattern as lysine residues can be mono-, di- or 
trimethylated, arginine residues can be mono- or dimethylated. In general methylation is 
associated with both transcriptional activation as well as repression. This is mostly 
regulated by promoting binding of activators and blocking of repressors (examples 
shown in (FLANAGAN et al. 2005; LI et al. 2006; NISHIOKA et al. 2002; SCHNEIDER et 
al. 2004)). In higher eukaryotes methylation of the fourth lysine residue at histone H3 
(H3K4me) is generally associated with active promoter structures, whereas 
trimethylation of the 9th and 27th lysine residue of the same histone (H3K9me3 and 
H3K27me3) has been reported to mediate repressive function (compare polycomb 
repressive complexes, chapter 1.1.2.1.3) (KOUZARIDES 2007). However, in embryonic 
stem cells the existence of so-called bivalent domains has been reported. These cells 
exhibit both active H3K4me and repressive H3K27me marks at promoters of genes 
encoding developmentally important transcription factors (BERNSTEIN et al. 2006). It is 
assumed that this feature keeps the genes in a repressed but primed state to allow 
activation when the right signals are received. Another example for histone methylation 
is the methylation of the ninth lysine residue of histone 3 (H3K9), which marks 
transcriptionally silent heterochromatin (BARSKI et al. 2007; LEHNERTZ et al. 2003). 
1.1.2.2.2 Chromatin remodeling 
Chromatin remodeling is an important process of gene regulation as it enables 
access of transcription factors to specific genes and facilitates transcription elongation. 
Also other processes are dependent on chromatin remodeling, such as DNA repair, 
replication or chromatin assembly. It is catalyzed by chromatin remodeling complexes 
(CRCs) that use the energy from ATP hydrolysis to exchange or eject histones and to 
reorganize nucleosomes. They lack intrinsic DNA sequences that trigger them to their 
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target sites, hence they are typically recruited by sequence-specific transcription factors 
(NEELY et al. 1999; YUDKOVSKY et al. 1999). In eukaryotes five main families of CRCs 
are known: SWI/SNF, ISWI, CHD and INO80 and SWR1 (SAHA et al. 2006). 
Dependent on protein domains and subunits within the complex the functions of the 
different family members are different. The well characterized SWI/SNF complex for 
example contains a bromodomain in the ATPase subunit thus it recognizes acetylated 
histones (HASSAN et al. 2002) (see also chapter 1.1.2.2.1.1). The organization of 
multiple bromodomains within a complex can specify the selectivity of the complex 
towards particular nucleosomes (KASTEN et al. 2004). 
1.1.2.2.3 DNA methylation 
Gene expression can be also controlled by another epigenetic mechanism, the 
methylation of DNA. DNA methyltransferases (DNMTs) are responsible for the 
addition of methyl residues to the cytosine nucleotides, converting them to 5-
methylcytosine (GOLL and BESTOR 2005). Usually only cytosine residues located next 
to guanine nucleotides can be methylated (CpG). Across the human genome 60-80% of 
all CpGs are methylated. Methylated cytosine residues within CpGs spontaneously 
deaminate without being repaired, therefore due to the evolutionary mutagenesis CpGs 
are underrepresented in the human genome (JABBARI and BERNARDI 2004). However, 
the human genome possesses several areas with high C+G content that show low DNA 
methylation. These areas are termed CpG islands and are often associated with 
promoters (DEATON and BIRD 2011) (see chapter 1.1.2.1.1). 
Methylation of CpG islands located at TSSs is associated with long-term gene 
silencing and occurs e.g. in X-chromosome inactivation, genomic imprinting or for 
genes expressed predominantly in germ cells. In general CpG island methylation blocks 
the start of transcription (JONES 2012). The mechanism of silencing is not clear yet, it is 
thought to occur either by direct inhibition of transcription factor binding or by indirect 
recruitment of chromatin-modifying enzymes mediated by methyl-binding domain 
(MBD) proteins (DEATON and BIRD 2011). Also, there is a strong correlation between 
CpG islands and PRC2 binding, however sequence-specific DNA binding proteins that 
guide the PRC2 complex to CpG islands have not yet been identified in mammals 
(ZHOU et al. 2011). 
A study in plants connects chromatin remodeling with DNA methylation by 
showing that incorporation of the histone variant H2A.Z by a SWR1 complex protects 
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gene promoters from DNA methylation. Deficiency of H2A.Z leads to general 
hypermethylation and therefore to gene silencing (ZILBERMAN et al. 2008). 
1.1.3 Identification of enhancers 
Many protein-coding genes have been identified due to an apparent phenotype as 
e.g. a disease that becomes evident upon mutation. Similarly some enhancers have been 
found as their mutation lead to diseases like thalassaemias (HBB enhancer), preaxial 
polydactyly (SHH enhancer) or Hirschsprung’s disease (RET enhancer) (VISEL et al. 
2009). Apart from such apparent phenotypes the identification of enhancers is a major 
challenge. However, they display certain features that can be used for their prediction 
and identification. 
1.1.3.1 Evolutionary conservation 
As mentioned in the beginning only 1.5% of the base pairs in the human genome 
encode for protein coding genes (CLAMP et al. 2007; LANDER et al. 2001; VENTER et al. 
2001). The availability of further genome sequences from other organisms revealed a 
high conservation rate for these genes. However, comparison of the whole sequence of 
mouse and human demonstrated that ∼5% of the human genome is under evolutionary 
constraint (WATERSTON et al. 2002) thus implying that these regions serves a sequence 
dependent function. Hence, 3.5% of the genome seems to contain functional elements 
without encoding a protein. A large cohort of putative enhancer elements defined by 
comparative analysis from human to fish and human to rodents have been tested for 
enhancer activity in vivo using a LacZ reporter assay in transgenic mouse embryos. 45% 
of the tested elements displayed tissue-specific enhancer activity at embryonic day (E) 
11.5. This read-out most probably even underestimates the actual proportion of 
enhancers by restricting the analysis to a single time point (PENNACCHIO et al. 2006). 
Therefore comparative genomics can provide a potent approach for the prediction of 
regulatory elements. However, some functional enhancers have been identified that lack 
sequence conservation thus this feature is not always a property of enhancers (FISHER et 
al. 2006; HARE et al. 2008; MCGAUGHEY et al. 2008). 
1.1.3.2 Transcription factor binding and chromatin state 
Enhancers act as binding sites for several transcription factors which often exert 
chromatin-modifying activity thereby changing the local chromatin state. The 
development of techniques like ChIP-chip and ChIP-seq offers a genome-wide view on 
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transcription factor binding sites and the chromatin state and assists in functional 
annotation of the genome. Different combinations of histone variants, histone 
modifications, DNase I hypersensitivity and binding of cofactors mark e.g. gene bodies, 
promoters or regulatory elements (ZHOU et al. 2011) (Figure 1.2). Approaches to 
confine enhancer related features will be discussed in the following paragraph. 
 
Figure 1.2: Histone modifications used for functional annotation of the mammalian 
genome 
Reported histone modifications particularly enriched in each functional element are indicated 
adjacent to the respective structure (ZHOU et al. 2011). 
The accessibility of the chromatin can be identified by assessment of the 
sensitivity for DNase I treatment (BIRNEY et al. 2007; BOYLE et al. 2008; CRAWFORD et 
al. 2006a; CRAWFORD et al. 2006b; SABO et al. 2004a; SABO et al. 2004b; THURMAN et 
al. 2012; XI et al. 2007). However, DNase I hypersensitivity sites (DHS) mark not only 
enhancers but also other regulatory regions such as promoters, silencers, insulators and 
locus control regions. 
In another approach the acetyltransferase and transcriptional coactivator p300 was 
used. Studies fo the IFNβ enhanceosome showed that p300 is associated with active 
transcription (MERIKA et al. 1998). Genome-wide ChIP-seq for p300 in different 
embryonic mouse tissues revealed between 500 to 2500 potential enhancer regions. 
Functional validation of 86 predicted elements using the same approach as mentioned 
above augmented the prediction rate from 45% by comparative genomics to 87% 
(VISEL et al. 2009). The strength of this method over comparative genomics was further 
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shown by identification and validation of weakly conserved enhancers from 
developmental heart tissue (BLOW et al. 2010). 
Analysis of distal p300-binding sites for certain histone methylations revealed an 
enrichment for H3K4 monomethylation (H3K4me1) with a concurrent absence of 
H3K4 trimethylation (H3K4me3). This distinguishes enhancers from active promoters 
marked by H3K4me3 (HEINTZMAN et al. 2007). Furthermore, the acetylation of the 27th 
lysine residue at histone H3 (H3K27ac) could also be linked to enhancers (HEINTZMAN 
et al. 2009) which was validated by two other studies. Moreover, these studies indicate 
that enrichment for H3K27ac distinguishes active from poised enhancers compared to 
H3K4me1 alone (CREYGHTON et al. 2010; RADA-IGLESIAS et al. 2011). 
In summary an integrative analysis based on data about sequence conservation, 
transcription factor and cofactor binding sites, nucleosome positioning and histone 
modifications provides a powerful tool for the prediction of enhancers. However, 
enhancer prediction does not provide information about the spatiotemporal activity of 
the enhancer and which genes are targeted. Thus enhancer activity needs to be validated 
in functional assays (VISEL et al. 2009). 
1.1.3.3 Long-range interaction between enhancer and promoter 
The sonic hedgehog (Shh) enhancer displays with 1 Mb the so far greatest 
distance between an enhancer and its target promoter (LETTICE et al. 2003). It serves 
also as an example for an enhancer that is separated by another gene (Rnf32) from its 
target gene and that is located in an intron of another gene. Hence, enhancers are often 
located at a distant site and thus need to apply certain mechanism(s) to communicate 
specifically with their target promoter. 
Several models have been proposed for enhancer function. One is called the 
“tracking” model where an enhancer-bound complex scans along the DNA sequence 
until it reaches the promoter and then would activate transcription. Another more 
indirect model based on nuclear positioning proposes that an active enhancer brings the 
promoter into regions of the nucleus that are transcriptionally active (PTASHNE 1986). 
However, the most widely favored model is based on the interaction between the 
enhancer and the promoter that is achieved by looping out of the intervening DNA. 
Advances over the last years in elucidating the interaction between promoters and 
enhancers have been summarized in recent reviews (BULGER and GROUDINE 2011; 
PLANK and DEAN 2014). 
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The global structure of the genome has been assessed by chromosome 
conformation capture assays (3C) and its derivative technologies (4C, 5C, Hi-C). These 
methods are based on crosslinked cells or nuclei that are subjected to digestion with 
restriction enzymes. Subsequently religation is promoted, however under dilute 
conditions so that religations only occur among crosslinked fragments. The religation 
frequency is then quantified and provides a linear mapping of DNA interactions, either 
locally of globally (DE WIT and DE LAAT 2012). 
The first global study on the human genome using Hi-C showed the clustering of 
active regions as well as of inactive regions, respectively (LIEBERMAN-AIDEN et al. 
2009). However, this study had only a limited sequency depth of 1 Mb which was 
outreached by the study performed in Bing Ren’s lab (DIXON et al. 2012). With a 
resolution of 40-60 kb they discovered that the mammalian genome is organized in so 
called topologically associating domains (TADs) that are 500 kb to 3 Mb in size. The 
TAD structure is highly conserved in different cell types as well as from human to 
mouse. The borders of the domains are called boundaries and have been shown to be 
enriched for CTCF sites. TADs encompass genomic regions that display a high 
frequency of interactions within the TAD but much less frequently to sequences of 
another TAD. Functional relevance for the TAD structure was given by a study that 
showed that disruption of a TAD boundary in the X chromosome resulted in new 
chromosomal contacts and long-range transcriptional misregulation (NORA et al. 2012). 
Furthermore, analysis of regulatory landscapes defined large regulatory domains that 
strongly correlate with the TAD domains (SYMMONS and SPITZ 2013). However, 
interactions within a TAD have been reported to vary in a tissue-specific manner 
(PHILLIPS-CREMINS et al. 2013). 
Insights into more specific interactions between enhancer and promoter structures 
come from ChIA-PET (chromatin interaction analysis by paired-end tag sequencing) 
experiments that combine the technology of ChIP with 3C-type analysis. RNAPII 
centered analysis of human and murine cell lines of progressive lineage commitment 
revealed extensive colocalization among promoters and distal-acting enhancers (LI et al. 
2012; ZHANG et al. 2013). 
In summary theses interaction studies support a model of DNA looping to get 
enhancers and promoters in close proximity. However, the molecular mechanisms 
driving these interactions are yet unknown. 
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1.2 The hematopoietic system 
1.2.1 Hematopoietic stem cells 
The blood system is one of the most highly regenerative adult tissues with billions 
of cells being produced every day that perform different specialized tasks. Red blood 
cells (erythrocytes) are the most abundant cells and transport oxygene to the peripheral 
tissues. White blood cells (leukocytes) are cells of the immune system that battle against 
infections and phagocyte foreign invaders. Furthermore, the blood contains a large 
number of platelets (thrombocytes) that prevent bleeding by forming blood clots 
(ALBERTS et al. 2008). Due to the high turn-over of these blood cells they have to be 
replaced efficiently by precursor cells. The question of the existence of a common 
precursor cell for the various cell types in the blood system emerged already end of the 
19th century. However, due to the lack of experimental methods it took several decades 
until definitive evidence of hematopoietic stem cells (HSCs) was proved (RAMALHO-
SANTOS and WILLENBRING 2007). In 1956 two groups showed that the blood system of 
irradiated recipient mice was repopulated by donor cells after transplantation of spleen 
or bone marrow cells from mice or rats (FORD et al. 1956; NOWELL et al. 1956). Work 
of James Till, Ernest McCulloch and co-workers in the 1960s proved that a subset of 
bone marrow cells was able to form colonies of myeloid and erythroid cells in the 
spleens of irradiated mice (BECKER et al. 1963; TILL and MCCULLOCH 1961). By 
demonstrating that spleen colonies were formed even after secondary transplantation the 
defining properties of HSCs were established – multipotency and self-renewal 
(SIMINOVITCH et al. 1963). Tracking of single cells by inducing chromosomal 
aberrations revealed that these splenic colonies developed from a single precursor cell, 
thus proving differentiation of a single precursor cell into different lineages (WU et al. 
1967). These findings were until then however limited to the myeloid/erythroid lineage. 
Although it was later shown that these spleen colonies preferentially reflect progenitor 
potential the initial definition of HSCs remained valid. The definitive proof that single 
bone marrow cells were able to generate cells of the myeloid and the lymphoid lineage 
came another decade later in long-term transplantation experiments (ABRAMSON et al. 
1977). Since then major effort was put on prospective isolation and detailed 
characterization of this rare population, however transplantation assays still serve as 
gold standard in functional evaluation of HSCs. 
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1.2.1.1 Functional assays for hematopoietic stem cells 
Several in vitro and in vivo methods have been developed to adress the functional 
evaluation of HSCs and to distinguish them from other hematopoietic cell types such as 
progenitors or terminally differentiated cells. In vitro assays such as colony-forming 
unit (CFU) assays provide information about the function of progenitors rather than 
HSCs, but have the advantage of giving a read-out within a short time. To assess self-
renewal potential, quantity and quality of HSCs time-consuming long-term assays have 
to be performed. 
Among the in vitro assays the CFU assay is the most commonly used (CASHMAN 
et al. 1983). A given population is cultured for 7 to 14 days in a semi-solid methyl-
cellulose cultur medium supplemented with defined growth factors. The progeny of 
single progenitors forms distinct colonies that remain well separated, thus their number 
can be quantified microscopically. In addition this assay gives information about the 
differentiation potential towards certain lineages. More immature progenitors form 
mixed colonies containing different cell types whereas colonies of a single cell type 
derive from more restricted progenitors. This CFU assay allows a read-out mostly for 
myeloid restricted progenitors. The in vitro assessment of lymphocyte lineages in CFU 
assays requires more specialized culture conditions (PURTON and SCADDEN 2007; 
SCHMITT and ZUNIGA-PFLUCKER 2002; WHITLOCK and WITTE 1982). 
The cobblestone area-forming cell (CAFC) assay is used to estimate the frequency 
of HSCs or progenitors in a given cell population. It is based on long-term culture 
together with a stromal cell layer, assuming that only HSCs can retain their clonogenic 
potential for a prolonged time. A CAFC integrates into the layer and forms a 
cobblestone area that can be quantified (PLOEMACHER et al. 1989). Although this assay 
most probably does not quantify solely HSCs it reflects at least a more immature 
population as compared to the CFU assay (VAN OS et al. 2004). A similar approach is 
taken by the long-term culture-initiating cell (LTC-IC) assay where cells are also grown 
on stromal layers for more than 4 weeks and subsequently analyzed for their colony-
forming ability (SUTHERLAND et al. 1989). It remains controversial if these assays truly 
pinpoint HSC frequencies, however results obtained from assays with refined 
conditions were reported to give a good correlation compared to in vivo transplantation 
assays (WOEHRER et al. 2013). 
The earliest in vivo stem cell assay was the spleen colony forming unit (CFU-S) 
assay as described above for the experiments of TILL and MCCULLOCH (1961). For this 
INTRODUCTION 
 
 19
assay cells are injected intravenously into irradiated recipient mice and form 
macroscopic colonies in the spleen within 10 to 14 days. Although splenic progenitors 
are able to repopulate the recipient mice for the first 2 to 3 weeks, they lack long-term 
reconstitution ability (PURTON and SCADDEN 2007). Therefore this assay, similar to the 
in vitro assays described above, gives conclusions about progenitor potential rather than 
stem cell potential of the tested cells. 
The only experimental approach to evaluate frequency and potential of bona fide 
HSCs is given by long-term repopulating assays since only HSCs are able to serially 
reconstitute the entire blood system over the life-time of an organism. In these in vivo 
assays, bone marrow cells are transplanted into recipient mice. Donor and recipient cells 
can be distinguished using either cytogenetic, immunological or biochemical markers. 
A widespread method is the use of congenic mice that differ in the Ly-5 antigen 
(CD45), which is expressed on all bone marrow derived cells except erythrocytes and 
platelets (KOMURO et al. 1975; MILLER et al. 1985; RALPH and BERRIDGE 1984; SCHEID 
and TRIGLIA 1979; SPANGRUDE et al. 1988; SYKES et al. 1989). Donor cell engraftment 
can thus be followed by peripheral blood analysis over time as well as bone marrow 
analysis after several months. Multipotent progenitors can reconstitute the blood system 
of lethally irradiated recipients up to several months, however they are not able to do so 
in a secondary or tertiary transplant. Thus serial rounds of transplantation allow the 
discrimination between multipotent progenitor cells and HSCs by defining their long-
term repopulation capacity (LEMISCHKA et al. 1986). 
In competitive transplantation assays cells of interest are transplanted together 
with a competitor cell population containing a known number of HSCs in a defined 
ratio into recipients. This assay allows determining the frequency of repopulating units 
(RU), being a measure for the functional potential of HSCs within the tested cell 
population compared to a control population (HARRISON et al. 1993; YUAN et al. 2005). 
Although this assay allows evaluation about the reconstitution potential of the different 
lineages, it does not provide information on the HSC frequency in the tested population. 
The most common assay to determine HSC frequencies is the limiting dilution assay. 
Decreasing cell numbers of donor populations are transplanted together with a standard 
dose of competitor bone marrow (SZILVASSY et al. 1990; TASWELL 1981). Determining 
the number of non-engrafted mice in each dilution allows calculation of the competitive 
repopulating units (CRUs) and therefore the frequency of HSCs based on Poisson 
statistics. So far HSCs cannot be isolated to 100% purity (chapter 1.2.1.2), thus enriched 
populations are still heterogeneous and have different potentials to contribute to blood 
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lineages. Single cell transplantation assays allow functional and quantitative read-out of 
single cells instead of cell populations, however such experiments are technically 
challenging, time-consuming and expensive (DYKSTRA et al. 2007; EMA et al. 2006; 
YAMAMOTO et al. 2013). 
In research transplantation assays are usually performed with recipient mice that 
are preconditioned for example by lethal irradiation in order to empty the HSC niche 
and thus allow for donor cell engraftment. However, it has to be kept in mind that 
irradiation significantly damages cells and tissues within the bone marrow and induces a 
state of severe inflammation, which both may influence HSC homing, engraftment and 
function. To avoid this effect mutant mouse models can be used, which allow long-term 
engraftment without conditioning of the recipient mice, as for example mice with 
mutations of the receptor tyrosine kinase c-Kit, such as c-kitW/Wv mice (MILLER and 
EAVES 1997; NOCKA et al. 1990; WASKOW et al. 2009). Using such mouse strains in 
transplantation assays allows the analysis of HSCs under more physiological  
conditions. 
1.2.1.2 Identification of hematopoietic stem cells by cell surface markers 
Since HSCs were discovered scientists continously worked on defining markers 
that help to recognize and isolate HSCs prospectively. Initially HSCs were reported to 
be enriched in cells that are negative for lineage markers such as the B cell marker 
B220, the granulocyte markers CD11b and Gr-1 as well as the T cell markers CD4 and 
CD8 (MÜLLER-SIEBURG et al. 1988; MÜLLER-SIEBURG et al. 1986). Additionally these 
studies showed that HSCs express the cell surface protein Thy-1 at low levels, a marker 
that was also included when Sca-1 was identified to positively mark HSCs (SPANGRUDE 
et al. 1988). This combined marker set enriched the stem cell purity from 1 HSC in 105 
in total bone marrow cells to 1 HSC in 30 Lin-Thy1lowSca-1+ cells. The immuno-
phenotype of HSCs was further refined by adding the stem cell factor receptor c-Kit 
(IKUTA and WEISSMAN 1992; OGAWA et al. 1991). Since then, the marker combination 
Lin-Sca-1+c-kit+ (LSK) has been generally used for HSC enrichment. Although all HSC 
activity resides in this population, it is still a heterogeneous mixture of HSCs and other 
non-self-renewing progenitor cells. Thus in the following years other markers were 
identified to further enrich for HSCs within the LSK population. LSK cells negative for 
CD34 or Flk2/Flt3 (CD135) purify HSCs up to 1 in 5 cells (ADOLFSSON et al. 2001; 
CHRISTENSEN and WEISSMAN 2001; OSAWA et al. 1996). Moreover the CD34 marker 
distinguishes between long-term (CD34-) and short-term (CD34+) reconstituting 
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capacity. An alternative gating strategy was proposed by the Morrison group, which 
investigated the expression of members of the signaling lymphocytic activation 
molecule (SLAM) protein family on HSCs (KIEL et al. 2005). Based on this study HSCs 
are positive for CD150 and negative for CD48. Combined with the LSK marker set the 
SLAM markers identify HSCs to almost 50% purity. Other positive markers for HSCs 
are endoglin, EPCR and ESAM, but these seem not to add further enrichment (BALAZS 
et al. 2006; CHEN et al. 2002; OOI et al. 2009; YOKOTA et al. 2009). 
Another method to isolate HSCs is based on their high efflux activity (BAINES and 
VISSER 1983; BERTONCELLO et al. 1985; GOODELL et al. 1996; WOLF et al. 1993). 
Staining with intravital dyes such as the mitochondrial-binding dye Rhodamine 123 or 
the DNA-binding dye Hoechst 33342 allows identification of HSCs as low retaining 
cells. Visualization of Hoechst 33342 efflux by emitting at two wavelengths serves to 
identify the so called side population enriched for HSCs. Stringent gating for Hoechst 
staining in combination with LSK and CD34 marker was shown to enrich for HSCs to 
96% purity (MATSUZAKI et al. 2004). However, this technique is prone to technical 
variability and has to be performed conscientiously (PURTON and SCADDEN 2007). 
The study of WILSON et al. was the first to combine LSK with the Slam markers, 
CD34 and CD135 in a single assay providing a close enrichment for HSCs as opposed 
to multipotent progenitor populations present within the LSK population (WILSON et al. 
2008). 
1.2.1.3 Development of hematopoietic stem cells 
Hematopoiesis during mammalian development occurs in multiple waves. The 
first murine hematopoietic progenitors emerge in the yolk sac at E7.5. In order to meet 
the immediate demand of oxygene supply in the developing embryo, they produce 
mainly primitive erythroid cells, which appear only transiently between 7 and 12 days 
postcoitus (dpc). The observation that blood cells and blood vessels are in close 
proximity led to the hypothesis of a common ancestor, the hemangioblast (MURRAY 
1932; SABIN 1920). Studies using an embryonic stem (ES) cell differentiation assay 
identified the blast colony-forming cell (BL-CFC) in vitro (CHOI et al. 1998). Cells with 
highly similar characteristics of these BL-CFCs were found in the gastrulating mouse 
embryo further supporting the existence of the hemangioblast (HUBER et al. 2004). 
Despite this early occurrence of hematopoietic progenitors, explanted cells from early 
yolk sac are neither able to generate lymphoid progeny nor reconstitute adult mice 
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hematopoiesis, suggesting that this site is not the source of definitive HSCs (CUMANO et 
al. 1996; CUMANO et al. 2001). 
The second wave of hematopoiesis is initiated at E8.25 in the yolk sac, allantois 
and paraaortic splanchnopleura, where hematopoietic progenitors display multipotent 
capacity but still lack self-renewal capacity. Transient erythromyeloid progenitors 
colonize the liver by E9.5 to E10.5, where they further mature to release definitive 
erythrocytes to the circulation at E11.5 (MCGRATH et al. 2011). These definitive 
erythroid cells differ from primitive erythroid cells e.g. by their size, the time point of 
enucleation, the tissues they are found in and the form of globin genes being expressed 
(BARON 2013). The first definitive HSCs occur from E10.5 to E11.5 in an 
intraembryonic region surrounding the dorsal aorta called the aorta-gonad-mesonephros 
(AGM) region and in the vitelline and umbilical arteries (DE BRUIJN et al. 2000; 
MEDVINSKY and DZIERZAK 1996; MÜLLER et al. 1994). These possess fully functional, 
long-term multilineage engraftment and repopulation capacity. Also the placenta 
appears to contain HSCs and some studies suggest that it is a true site of HSC 
generation (GEKAS et al. 2005; LEE et al. 2010; RHODES et al. 2008). From E11.5 
onwards HSCs are spread through circulation into the fetal liver, thymus and spleen 
(JOHNSON and MOORE 1975) (Figure 1.3). The fetal liver serves as a site for massive 
HSC expansion and differentiation (EMA and NAKAUCHI 2000; MORRISON et al. 1995). 
The skeletal system starts to develop from E12.5, creating a niche for adult HSCs. 
Vascularization of the bones allows the migration of hematopoietic cells towards the 
bone marrow from E15.5 onwards. However, despite the presence of circulating 
functional HSCs already at that time these cells only start populating the bone marrow 
from E17.5 onwards (CHRISTENSEN et al. 2004). This delay implies that up to this time 
point the fetal bone marrow lacks attraction signals such as the cytokine SDF1 and other 
factors supporting HSC engraftment (ARA et al. 2003; MIKKOLA and ORKIN 2006). 
Perinatal HSCs are still highly proliferative and expand in the bone marrow. By 3 to 4 
weeks after birth they switch to a more quiescent phenotype characteristic of adult bone 
marrow HSCs (BOWIE et al. 2007; BOWIE et al. 2006). 
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Figure 1.3: Timeline of hematopoietic events in the developing mouse 
Arrows above the timeline indicate the onset of specific hematopoietic cell generation. Arrows 
below indicate the earliest time of colonization of the secondary hematopoietic territories 
(DZIERZAK and SPECK 2008). 
1.2.2 The hematopoietic hierarchy 
HSCs are characterized by their multipotency, self-renewal capability as well as 
proliferative potential. These characteristics are experimentally proven by 
transplantation experiments in which a single HSC serially reconstitutes all myeloid and 
lymphoid lineages over a prolonged time (chapter 1.2.1.1). Since HSCs represent only a 
small fraction of all bone marrow cells, mature effector cells however have to be 
replenished to billions of cells every day, lineage commitment occurs through extensive 
amplification steps on several progenitor levels. This hematopoietic hierarchy is 
classically viewed as a linear branching model with the HSC (LSK CD150+CD48-
CD135-CD34-) residing at its top (Figure 1.4) (BRYDER et al. 2006). HSCs are largely 
quiescent with about 80-90% of the cells in the G0 phase of the cell cycle. Label-
retaining assays have revealed that the HSC population consists of two distinct 
populations: highly dormant HSCs that divide only about 5 times per lifetime of the 
animal, and activated HSCs that divide approximately once per month. The population 
of dormant HSCs harbors the vast majority of long-term self-renewal activity (WILSON 
et al. 2008). 
In the classical bifurcation model (Figure 1.4), HSCs give rise to the multipotent 
progenitor population 1 (MPP1) by gain of CD34 expression. These cells are also often 
referred to as ST-HSCs because they have lost self-renewal capacity, but have not yet 
undergone any fate decision (CABEZAS-WALLSCHEID AND TRUMPP, unpublished data). 
Subsequent multipotent progenitor populations 2 to 4 (MPP2, 3 and 4) have been 
described based on expression of cell surface markers and their cycling behavior.   
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These have just recently been defined more closely in a global transcriptomics, 
proteomics and epigenomics study performed by our group (CABEZAS-WALLSCHEID et 
al. 2014). This study revealed by reconsitution assays that MPP2 cells are multipotent 
whereas MPP3 and MPP4 populations show a differentiation bias towards myeloid or 
lymphoid cell types, respectively. In the next step of lineage commitment multipotent 
progenitors give rise to two oligopotent progenitors, the common myeloid and common 
lymphoid progenitors (CMP and CLP) (AKASHI et al. 2000; KONDO et al. 1997). CMPs 
then give rise to granulocyte-macrophage progenitors (GMPs) and megakaryocyte-
erythrocyte progenitors (MEPs). These in turn are restricted to generating granulocytes 
and macrophages or erythrocytes and platelets, respectively. CLPs exclusively give rise 
to B cells, T cells and natural killer (NK) cells. Both CMPs and CLPs are proposed to 
give rise to dendritic cells (MANZ et al. 2001). 
 
Figure 1.4: Hierarchical organization of the hematopoietic system 
Classical view of the hematopoietic hierarchy with the HSC at the top of the hierarchy, 
containing the highest self-renewal capacitiy and long-term multilineage reconstitution capacity 
(BRYDER et al. 2006). Self-renewal capacity is gradually lost until the multipotent progenitors 
branch off into myeloid or lymphoid restricted oligopotent progenitors which further differentiate 
towards lineage restricted progenitors that finally give rise to mature effector cells. Recent 
studies suggest the presence of a direct link between HSCs and the megakaryocytic lineage. 
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Recent studies have challenged this classical view of the hematopoietic hierarchy 
by demonstrating a strong heterogeneity within the HSC pool. MÜLLER-SIEBURG et al. 
identified lineage biased HSCs by using limiting dilution assays dividing the HSC pool 
into myeloid-biased, lymphoid-biased and balanced HSCs based on the ratio of 
lymphoid to myeloid cell output (MÜLLER-SIEBURG et al. 2004; MÜLLER-SIEBURG et al. 
2002). Another classification was based on myeloid to lymphoid chimerism levels 
taking the competitor level into account, hence leading to the definition of 4 different 
classes of HSCs (α, β, γ and δ) (BENZ et al. 2012; DYKSTRA et al. 2007). α and β HSCs 
were both able to reconstitute myeloid and lymphoid cells in secondary transplantations. 
However, α HSCs showed a higher myeloid cell output, while β HSCs were biased 
towards lymphoid cells.  γ HSCs are not serially transplantable despite robust 
engraftment for 6-7 months and δ HSCs show only limited self-renewal capacity 
therefore closely resembling the MPP1 population. A third challenging study was 
performed by ADOLFSSON et al. which proposed the presence of lymphoid-primed 
multipotent progenitor cells (LMPPs) that give rise to B and T cells as well as 
granulocytes and macrophages, but lack erythro-megakaryocytic potential (ADOLFSSON 
et al. 2005). This study suggested an earlier branching point of a megakaryocyte/ 
erythrocyte progenitor population (MkEPs) that occurs before separation of the 
lymphoid and myeloid lineage. These MkEPs reside within the CD135- fraction of LSK 
cells whereas LMPPs are CD135+. In contrast a subsequent study suggested that at least 
a minor fraction of the CD135+ LMPP population still retains megakaryocyte-erythroid 
potential (FORSBERG et al. 2006). Furthermore, a recent study combined a paired 
daugther cell analysis with single cell transplantations (YAMAMOTO et al. 2013). This 
analysis suggested first that a single division of LSK CD34- HSCs can result in several 
types of committed progenitors and second that the HSC compartment contains a 
myeloid restricted progenitor population which retains long-term self-renewal 
capability. These myeloid restricted progenitors comprise progenitors with 
differentiation potential equivalent to CMPs and MEPs as well as sole megakaryocyte 
potential. Therefore this study proposes a myeloid-biased branch in the hematopoietic 
hierarchy and additionally challenges the hypothesis that long-term self-renewal is a 
unique property of multipotent stem cells. Further proof of a close hierarchical relation 
between HSCs and megakaryocytes emerged from a study, which identified von 
Willebrand factor (vWF) positive cells as platelet-primed HSCs at the apex of the HSC 
hierarchy (SANJUAN-PLA et al. 2013). These cells showed enhanced short- and long-
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term platelet reconstitution and also had the ability to generate vWF- lymphoid-biased 
HSCs. 
In summary the classical hierarchical model of hematopoiesis is subject to 
changes due to the appearance of increasing numbers of HSC and progenitor subtypes. 
Single cell assays revealed great heterogeneity of several immunophenotypically 
defined stem and progenitor populations and call for further refinement. Future studies 
will add more information to these differentiation processes and also to their regulation. 
1.3 The oncogenic transcription factor Myc 
c-Myc was initially identifed as the cellular homologue of the v-myc oncogene in 
the avian myelocytoma virus MC29, which causes leukemia and sarcoma in chicken 
(SHEINESS et al. 1978; VENNSTROM et al. 1982). Its oncogenic potential in humans 
became apparent by its altered expression in Burkitt lymphoma patients. In these 
patients the c-Myc coding region is translocated, so that it is under the control of 
immunoglobulin gene enhancer elements (DALLA-FAVERA et al. 1982; TAUB et al. 
1982). Soon after c-Myc’s discovery two more family members, N-Myc and L-Myc, 
were identified in neuroblastoma cell lines/tumors and small lung cell carcinomas, 
respectively (KOHL et al. 1983; NAU et al. 1985; SCHWAB et al. 1983). 
Approximately 70% of human cancers are associated with overexpression or 
deregulation of c-Myc. However, this is not driven by activating mutations within the 
coding sequence, instead chromosomal translocation and gene amplification cause 
oncogenic activation (MEYER and PENN 2008). In leukemias and lymphomas c-Myc 
overexpression is often caused by translocations whereas in solid tumors it is commonly 
driven by amplification of the c-Myc gene (DANG 2012). 
1.3.1 Myc on the molecular level 
1.3.1.1 Molecular function of Myc 
The myc gene encodes for a basic-helix-loop-helix leucine zipper (bHLH-Zip) 
transcription factor that can act as an activator and repressor. The mechanisms how it 
regulates its multiple targets have been nicely summarized in two review articles 
(ADHIKARY and EILERS 2005; VAN RIGGELEN et al. 2010) (Figure 1.5). 
Myc binds to E-box sequences (CACGTG), thereby regulating the respective 
target genes (BLACKWELL et al. 1993; BLACKWELL et al. 1990). However, Myc can 
only bind these sequences when it is bound to its partner protein Max (Myc-associated 
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factor X) (AMATI et al. 1993; BLACKWOOD and EISENMAN 1991; BLACKWOOD et al. 
1992). This heterodimer recruits a co-activator complex (TRRAP) and histone 
acetylases (HATs) such as GCN5 and TIP60, which leads to the activation of target 
genes (BOUCHARD et al. 2001; FRANK et al. 2003; FRANK et al. 2001; MCMAHON et al. 
2000). Max itself however can also form homodimers or heterodimers. As a homodimer 
Max neither activates nor represses transcription at E-box containing promoters. In 
contrast upon dimerization with Mad family proteins like Mad1-4 and Mnt (AYER et al. 
1993; HURLIN et al. 1997; HURLIN et al. 1996; ZERVOS et al. 1993) it performs 
repressive functions by recruitment of histone deacetylases (HDACs) via Sin3 (AYER et 
al. 1995; HASSIG et al. 1997; LAHERTY et al. 1997; SCHREIBER-AGUS et al. 1995). Mad 
proteins are often accumulated in differentiating cells, thus leading to repression of 
Myc-induced proliferative genes (ADHIKARY and EILERS 2005). 
 
Figure 1.5: Gene regulation by Myc 
 A Myc forms heterodimers with Myc-associated factor X (Max) that bind to the E-Box sequence 
motif. This leads to recruitment of cofactors, including histone acetylases (HATs) like GCN5, 
TIP60 and TRRAP (part of a large HAT complex) and therefore by opening the chromatin to an 
activation of transcription. However, Max can also dimerize with Mad family proteins (MXD), 
which antagonizes Myc-Max binding to E-boxes. MXD-Max dimers recruit histone deacetylases 
(HDACs), resulting in transcriptional repression. B Myc-Max dimers can be recruited by the 
transcription factor Miz1 to core promoter elements of several promoters (initiator element - Inr), 
leading to transcriptional repression via recruitment of DNA-methyltransferase 3a (DNMT). C 
Myc also forms Max-independent complexes with transcription factor IIIB (TFIIIB) to promote 
the transcription of RNA polymerase III targets. This involves recruitment of TRRAP and GCN5. 
A, acetylation; M, methylation; TSS, transcription start site (VAN RIGGELEN et al. 2010). 
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Two other important interaction partners of Myc are the zinc finger proteins Miz1 
and Sp1, which can recruit Myc-Max also to promoters lacking the E-box sequence 
CACGTG. Miz1 itself is a transcriptional activator when bound to the promoter in the 
absence of Myc (GARTEL et al. 2001; PEUKERT et al. 1997). By binding to Miz1, Myc-
Max causes transrepression of specific Miz1 target genes, which is in part mediated by 
DNA methylation (BRENNER et al. 2005). 
A third way of Myc regulation emerged from Max-independent complex 
formation with TFIIB, thereby promoting transcription catalzyed by RNA polymerase 
III (GOMEZ-ROMAN et al. 2003; STEIGER et al. 2008). 
1.3.1.2 Target genes and regulation mechanisms of Myc 
The global search for Myc target genes revealed that Myc binds very ubiquitously 
throughout the genome to a myriad of genomic sites encompassing up to 15% of all 
genes but also including some intergenic sites (BIEDA et al. 2006; CAWLEY et al. 2004; 
FERNANDEZ et al. 2003; LI et al. 2003; ORIAN et al. 2003; PATEL et al. 2004; ZELLER et 
al. 2006). However, not all genes bound by Myc are associated with increased 
expression, which could be explained by either lack of necessary coactivators or by its 
repressive function (e.g. via Miz1). Within the list of target genes several functional 
groups have been identified by gene ontology analysis (Figure 1.6). 
 
 
Figure 1.6: Gene ontology analysis of Myc target genes 
Distribution of Myc target genes by gene ontology (GO) analysis as determined in (DANG et al. 
2006). Statistically overrepresented GOs are highlighted in red. 
INTRODUCTION 
 
 29
c-Myc potently stimulates proliferation and inhibits differentiation. Exemplary for 
the regulation of the cell cycle, c-Myc represses expression of the cell cycle inhibitor 
p21 and regulates expression of several cyclins and cyclin-dependent kinases (CDKs), 
thus mediating its cell cycle promoting function (BOUCHARD et al. 2001; CLAASSEN and 
HANN 2000; HERMEKING et al. 2000; SEOANE et al. 2002; SEOANE et al. 2001; WU et 
al. 2003). Another prominent function that is regulated by c-Myc is the protein 
synthesis, which occurs through multiple mechanisms (VAN RIGGELEN et al. 2010). On 
the one hand c-Myc regulates the RNAPII-mediated transcription of ribosomal proteins 
and auxiliary cofactors but also translation initiation factors and other translation 
modifiers. On the other hand transcription of rRNAs and tRNAs via RNA polymerase I 
and III is regulated by c-Myc. Moreover c-Myc has been reported to have a non-
transcriptional role in modulating translation. This includes first, the phosphorylation of 
RNAPII at its CTD, driving it into the elongation phase. Second c-Myc augments cap-
dependent translation (COLE and COWLING 2008; COWLING and COLE 2007). 
Regulation of microRNAs (miRNAs) opens another field of c-Myc activity. For 
instance oncogenic miRNAs such as miR-17-92 cluster, are activated, tumor suppressor 
miRNAs, such as let-7 are repressed by c-Myc (CHANG et al. 2008; CHANG et al. 2009; 
O'DONNELL et al. 2005). Finally, another non-transcriptional regulation has been 
observed for DNA replication as c-Myc binds to the pre-replicative complex and 
increases activity at DNA replication origins (DOMINGUEZ-SOLA et al. 2007). In 
summary, many genes regulated by c-Myc are directed towards cell cycling and cell 
growth, the latter regulated by changes in ribosome biogenesis, protein synthesis, and 
metabolism. 
Transcription was long thought to be regulated mainly at the level of recruitment 
of the transcriptional machinery (see chapter 1.1.2). However, recent data suggest that 
promoter-proximal pausing is a general feature of RNAPII transcription in mammals 
and that c-Myc plays a major role in the release auf RNAPII from this state (RAHL et al. 
2010). Two studies on activated lymphocytes, ES cells and tumor cells attribute a 
general function to c-Myc as an universal amplifier of transcription (LIN et al. 2012; 
NIE et al. 2012). It is shown that elevated levels of c-Myc do not lead to binding and 
activation of new target genes with e.g. lower affinity non-canonical E-box sequences 
but to increased expression of already previously bound c-Myc targets. However, this 
general amplification model has been partly challenged by two recent publications, 
showing that c-Myc indeed selectively regulates gene expression (SABÒ et al. 2014; 
WALZ et al. 2014). Although SABÒ et al. also observed the general increase in mRNA 
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production this seemed to be rather an indirect effect mediated by c-Myc target genes. 
In contrast to the amplifier model studies, which question a direct suppressive function 
of c-Myc, they identified genes with differential expression, including genes that are 
repressed by c-Myc, which is mediated by Miz1 interaction (WALZ et al. 2014). 
Therefore besides transcription regulation by increased c-Myc promoter binding other 
factors direct the specific induction of target gene, making c-Myc regulation an 
interplay between chromosome structure, c-Myc-DNA binding affinity and other 
transcription factors. 
1.3.1.3 Transcriptional regulation of Myc levels 
c-Myc plays a critical role in many different pathways and is essential for normal 
cell function. However, it exerts oncogenic function if deregulated, therefore its 
expression needs to be tightly regulated. This occurs by many signals on multiple 
levels. Under normal physiological conditions c-Myc levels are relatively low and 
additionally c-Myc has a short half-life both on mRNA and protein level (LIU and 
LEVENS 2006). Thus small changes can yield large consequences and therefore 
regulation mechamisms exist at transcriptional, translational and posttranslational levels 
(KING et al. 2013; LEVENS 2010; PENN et al. 1990a; PENN et al. 1990b; REAVIE et al. 
2013). Focus in this chapter will be set on the transcriptional regulation. 
The c-Myc gene consists of three exons, however the prevalent c-Myc protein 
variant is encoded by exons 2 and 3 only. Transcription initiation starts from the two 
major TATA-containing promoters P1 and P2 at the 5’ end of exon I, while other minor 
promoters are used to a lesser extent. Upon translocation in some Burkitt lymphoma 
patients P1 and P2 are displaced and c-Myc is driven from promoter P3. Extensive 
research has been done on the transcriptional control of c-Myc promoters. This very 
complex regulation has been summarized by Wierstra and Alves (WIERSTRA and ALVES 
2008). In general the c-Myc promoter integrates transcription factor input and a 
multitude of signaling pathways as e.g. from mitogens, growth factors and cytokines. Of 
note, this regulation has been shown to be highly dependent on the cellular context. 
Furthermore, chromatin remodeling and the methylation state of the DNA influences 
promoter regulation as does the DNA conformation and topology (LIU and LEVENS 
2006). 
Expression of a reporter gene driven by the c-Myc promoter failed to recapitulate 
normal c-Myc expression, even if 50 kb of the flanking regions were included (LAVENU 
et al. 1994; MAUTNER et al. 1996). Thus, although c-Myc promoter regulation is already 
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very complex, further control elements have to be located outside this 50 kb fragment 
that are necessary for normal c-Myc expression. 
1.3.2 Physiological functions of Myc 
1.3.2.1 Function of Myc in development and stem cells 
The first attempt to assess c-Myc function in cellular proliferation, differentiation 
and embryogenesis by generating homozygous c-myc knockout (KO) mice revealed that 
the null mutation is embryonic lethal between 9.5 and 10.5 days of gestation. 
Homozygous embryos displayed a reduced body size and a strong delay in development 
with some pathologic abnormalities. Heterozygous deletion of c-myc did not display 
any morphological changes in embryos, however adult females were less fertile (DAVIS 
et al. 1993). Next, the generation of several mouse lines with stepwise decreasing c-
Myc levels allowed a closer look at its physiological consequences not only in embryos 
but also in adult mice. Reduction of c-Myc expression went along with progressive 
growth and body size reduction. In contrast to Drosophila dMyc mutants that show 
reduced cell size but unchanged cell numbers, murine c-Myc mutants have reduced cell 
numbers without a change in cell size (JOHNSTON et al. 1999; TRUMPP et al. 2001). First 
observations pointed to an involvement of the hematopoietic system in the c-myc KO 
phenotype, which is subject of the following chapter. 
Conditional deletion of c-myc using several tissue-specific Cre recombinases was 
investigated for a number of tissues and revealed a role for c-Myc in intestinal crypt 
formation, cell size and ploidy of liver cells, the number of neuronal stem cells, 
proliferation of renal stem and progenitor cells, differentiation in pancreatic cells, the 
mammary gland and melanocyte development (BAENA et al. 2005; BETTESS et al. 2005; 
BLANCO-BOSE et al. 2008; BONAL et al. 2009; COUILLARD and TRUDEL 2009; MUNCAN 
et al. 2006; NAGAO et al. 2008; PSHENICHNAYA et al. 2012; STOELZLE et al. 2009; 
ZANET et al. 2005). 
Deletion of N-myc led to embryonic lethality at E10.5 to E12.5 and embryos 
displayed neuroectodermal and heart abnormalities (CHARRON et al. 1992; SAWAI et al. 
1993; STANTON et al. 1992). Conditional deletions revealed involvement of N-Myc in 
proliferation and survival of neural and retinal progenitors, lung epithelial cells, limb 
bud mesenchyme, ear development and hair cell formation (HATTON et al. 2006; 
KNOEPFLER et al. 2002; KOPECKY et al. 2011; KOPECKY et al. 2012; MARTINS et al. 
2008; OKUBO et al. 2005; OTA et al. 2007). 
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Expression of L-Myc is normally detected in cerebellar cortex, cerebellum, lung, 
kidney, and intestine tissues. However, in contrast to the other two family members L-
myc KO mice are viable without an apparent phenotype (HATTON et al. 1996). 
In summary straight and conditional deletions demonstrated a critical role for Myc 
in embryonic development and especially in stem and progenitor cells (LAURENTI et al. 
2009). In addition gain of function studies underline its role in proliferation and 
differentiation, as e.g. shown for skin stem cells (BERTA et al. 2010; OSKARSSON et al. 
2006; WATT et al. 2008). 
Not surprisingly, also a role for c-Myc in embryonic stem (ES) cells has been 
identified. Murine ES cells express elevated levels of Myc and their growth usually 
depend on the growth factor LIF (leukemia inhibitory factor). However, a mutant Myc 
version capable to escape GSK3β dependent degradation kept the self-renewal and 
pluripotency state of ES cells independent of leukemia inhibitory factor (LIF). In 
contrast expression of a dominant negative form of Myc antagonized self-renewal and 
promoted differentiation (CARTWRIGHT et al. 2005). Although no gros effect on ES 
cells has been reported for the single deletion of c-myc or N-myc, conditional knockout 
of both myc genes in murine ES cells exhibited severely disrupted self-renewal, 
pluripotency and survival along with enhanced differentiation (SMITH et al. 2010; 
VARLAKHANOVA et al. 2010). 
1.3.2.2 Function of Myc in hematopoietic cells 
The studies summarized so far in chapter 1.3.2.1 do not explain in detail the 
primary reason for the embryonic lethality of c-myc KO mice. Besides some non-
hematopoietic defects these embryos had severe defects in establishing the primitive 
yolk sac hematopoiesis. Those few cells formed failed on colony formation assays 
(TRUMPP et al. 2001). More light was shed on the involvement of the hematopoietic 
system by using a Sox2Cre recombinase, which deleted c-myc specifically in the 
epiblast while trophoectoderm and primitive endoderm structures retained wild type c-
myc. Embryos with this tissue-restricted deletion appeared morphologically normal, not 
exhibiting any obvious proliferation defect. Thus most of the developmental defects 
observed in c-myc KO embryos were attributed to placental insufficiency. However, 
embryos with epiblast-specific c-myc deletion did only survive until E12 and were 
completely pale as they lacked red blood cells both in the liver and dorsal aorta. Thus 
the hematopoietic system is particularly dependent on c-Myc function (DUBOIS et al. 
2008). 
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1.3.2.2.1 Deletion of c-myc in hematopoietic stem cells 
The role of Myc in adult HSCs has been addressed by our and other laboratories 
using conditional deletion by the MxCre recombinase (BAENA et al. 2007; GUO et al. 
2009; WILSON et al. 2004). Following induction by polyinosinic-polycytidylic acid 
(polyI:C) Mx1-promoter driven Cre led to an efficient deletion of c-myc in 
hematopoietic cells already at the stem cell level (KÜHN et al. 1995). Mice suffered 
from severe anemia and a loss of most committed hematopoietic lineages, while HSCs 
accumulated in the bone marrow (WILSON et al. 2004). In contrast overexpression of c-
Myc led to a loss of HSCs. HSC accumulation upon c-myc deletion was accompanied 
by upregulation of several adhesion molecules such as N-cadherin and integrins. Based 
on these results a model was proposed where c-Myc does not impair self-renewal and 
proliferative capacity of HSCs but that they are retained in the niche by high expression 
of adhesion molecules and fail to differentiate (Figure 1.7). In conclusion, c-Myc 
controls the balance between HSC self-renewal and differentiation. 
 
 
 
Figure 1.7: c-Myc controls the balance between HSC self-renewal and differentiation 
Quiescent hematopoietic stem cells (HSCs) expressing low levels of c-Myc are retained in the 
stem cell niche by modest expression of the indicated cell surface receptors. The response of 
HSCs to mitogenic signals is dependent on c-Myc levels. A c-Myc deletion leads to upregulation 
of adhesion molecules that retain both daughter cells in the niche, thereby promoting expansion 
of HSCs at the expense of differentiation. B Induced c-Myc expression leads to downregulation 
of adhesion molecules, thereby attachment to the niche is untightened. This daughter cell 
differentiates towards a committed progenitor (CP) while the daughter cell with low c-Myc 
expression remains as HSC in the niche. C High expression of Myc switches the balance 
towards differentiation leading to exhaustion of the stem cell pool (adapted from (WILSON et al. 
2004)). 
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Another study using the same mouse model focused on the lineage commitment 
of c-Myc deficient HSCs (GUO et al. 2009). Consistent with the previously published 
data by WILSON et al. they observed anemia and leukopenia as well as an increase in 
LSK cells in mice conditionally deleted for c-myc. However, they also observed a 3- to 
5-fold increase in platelet numbers, which was the result of enhanced 
megakaryopoiesis. c-Myc deficiency led to a smaller size of megakaryocytes with lower 
polyploidy, however maturation and platelet formation was not impaired. Finally they 
showed that the thrombocytosis phenotype was the result of HSC cell intrinsic defects. 
1.3.2.2.2 Deletion of c-myc and N-myc in hematopoietic stem cells 
The fact that c-Myc deficient HSCs were not impaired in their proliferative 
potential was thought to be due to compensation by other Myc family members. 
Therefore LAURENTI et al. investigated the effect of N-myc as well as combined c- and 
N-myc deletion in HSCs (LAURENTI et al. 2008). Whereas N-Myc deficiency alone did 
not impact on HSC numbers or function, simultaneous deletion of c- and N-myc resulted 
in severe pancytopenia and rapid lethality of the mice. The HSC pool as well as most 
progenitors and differentiated cell types were depleted due to impaired proliferation, 
differentiation and increased apoptosis. Strikingly, the most primitive dormant HSCs, 
which give rise to highly proliferative progenitor, survived without expression of c-Myc 
and N-Myc under homeostatic conditions. 
In conclusion of the described functions of Myc in different stem cell types, 
requirement for Myc activity seems to correlate with the proliferative status of the stem 
cell. While Myc ensures proliferation and self-renewal in actively dividing stem cells, 
dormant non-dividing stem cells are independent of Myc activity. For these cells 
overexpression of Myc rather induces their exit form the normal stem cell compartment 
(LAURENTI et al. 2009; WATT et al. 2008; WILSON et al. 2004). 
1.3.3 The c-myc/Pvt1 gene locus 
The c-myc gene is located in the 8q24 region in the human genome and at 
61.8 Mb region on chromosome 15 in the mouse genome. The murine c-myc gene is 
located in the middle of a 4 Mb-long, gene-poor region (Figure 1.8). Right next to c-
myc is the Pvt1 gene located. In humans expression of this long non-coding RNA 
(lncRNA) has been reported to be low in normal tissue, but highly expressed in many 
transformed cell lines (CARRAMUSA et al. 2007). Moreover, copy number of PVT1 was 
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co-increased in more than 98% of cancers with increased copy numbers of MYC 
(TSENG et al. 2014). 
1.3.3.1 Conservation of the c-myc/Pvt1 flanking locus 
By comparison of genomic sequences from different species conserved areas 
within the genomes can be identified. Despite being gene poor the flanking regions of 
the c-myc/Pvt1 locus are highly conserved both on the synteny as well as the sequence 
level between mouse and human (Figure 1.8). Pairwise alignment of both sequences 
revealed 48% conservation of the sequence between A1bg and c-myc and between Pvt1 
and Gsdmc. In contrast the gene poor regions centromeric to A1bg and telomeric to 
Acdy8 show lower conservation (38% and 31%, respectively). As high conservation in 
non-coding areas of the genome points towards a functional role of these sequences 
such as in transcriptional regulation (see chapter 1.1.3.1) the c-myc/Pvt1 flanking region 
is likely to contain regulatory elements. 
 
Figure 1.8: Conservation of the c-myc/Pvt1-flanking locus in humans 
The mouse (grey) and human (purple) c-myc/Pvt1 flanking locus displays a high synteny 
(visualized using the VISTA Browser (MAYOR et al. 2000)). Pairwise alignment of the mouse and 
human sequence reveals a higher conservation of the c-myc/Pvt1 flanking locus sequence 
(spanning the sequence between A1bg and Gsdmc) as compared to the gene poor regions on 
the centromeric side of A1bg and the telomeric side of Acdy8 (alignment of mm9 and hg19 
genomes using UCSC genome browser). Overall nucleotide alignment indicates that 40% of the 
human genome can be aligned to the mouse genome. 
Gene duplication events early during evolution resulted in the formation of the 
different Myc family members (ATCHLEY and FITCH 1995). Also the synteny of the N-
myc locus is highly preserved as the locus possesses the paralogous genes Trib2, 
Fam84a and Fam49a. A knock-in study, in which the c-myc coding region was replaced 
by that of N-myc, showed that N-Myc can replace c-Myc without any survival or 
reproductive consequences and only mild effects on skeletal muscle, body weight, and 
cell growth response (MALYNN et al. 2000). These results suggested that Myc 
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expression and function is not only determined by the coding sequences but also by 
distinct cis-regulatory elements in the genomic context. 
1.3.3.2 Long-range regulatory elements in the c-myc/Pvt1 flanking locus 
Global analysis of a diverse set of tissues and cell types in the mouse provided a 
map of cis-regulatory sequences, pointing towards a multitude of potential enhancers in 
the entire c-myc/Pvt1 flanking locus (SHEN et al. 2012). Indeed, recent studies have 
identified in this region distant enhancer modules that physically contact the c-myc 
promoter (AHMADIYEH et al. 2010; HALLIKAS et al. 2006; POMERANTZ et al. 2009; 
SOTELO et al. 2010). These regions contain disease related single nucleotide 
polymorphisms (SNPs) linked to prostate, breast and colon cancer. Deletion of such a 
potential enhancer region important for colorectal cancer susceptibility located 335 kb 
upstream of c-myc did not change c-myc expression in vivo but conferred resistance to 
intestinal tumors (SUR et al. 2012). 
Work by our collaborators recently proved the existence of very remote cis-acting 
enhancers that control c-myc expression in the developing face (USLU et al. 2014). 
These enhancer elements are spread across a large area of the non-coding region located 
telomeric to the c-myc/Pvt1 flanking locus. Deletion of this region alters the facial 
morphology in mouse embryos mildly and leads sporadically to a cleft lip/cleft palate 
phenotype. 
 
 2 AIM OF THE THESIS 
c-Myc is an essential transcription factor regulating a myriad of genes in human 
and mouse. Therefore it controls critical pathways that act in concert for proper 
functioning of the cell. Deregulation of c-Myc can have serious consequences as 
evidenced by its involvement in many types of cancer. Since Myc as discovered many 
studies aimed to illuminate the regulatory mechanisms of c-Myc expression. Despite 
these efforts, not all regulatory elements that account for proper c-Myc expression were 
identified. Since most of these studies were focused on the vicinity of the c-myc gene, 
we hypothesized that there are enhancer elements that are located more distantly. In line 
with this hypothesis, the c-myc gene is flanked by a large non-coding region that is 
highly conserved, suggesting the presence of regulatory elements within this locus. 
Indeed, our collaborators identified enhancer activity in the developing face within a 
large part of this non-coding region located telomerically of c-myc (USLU et al. 2014). 
Deletion of this broad region abolishes c-Myc expression in this tissue. Since many 
regulatory enhancers are acting in a tissue-dependent manner and due to Myc’s 
important function in HSCs, we focused our study on the hematopoietic system. First, 
we aimed to characterize the broad deletion of the region covered by the embryonic face 
enhancer. Then, by using a set of transgenic mouse lines carrying a regulatory sensor 
integrated into the genome, we aimed to screen the c-myc/Pvt1 flanking locus for 
regulatory input. Following this screen the specificity of these elements needed to be 
determined. The consequences of this deletion would then be further indicative for the 
functional role of the enhancer element in the hematopoietic system. In summary, our 
study aimed at defining distal regulatory elements of the murine c-myc gene in 
hemaopoietic stem cells. Finally, we wanted to extend this regulatory input to the 
human c-MYC gene and investigate its implication in leukemia. 
 3 RESULTS 
 
3.1 Strategy for the transposon-mediated generation of 
transgenic mice 
The group of François Spitz at the European Molecular Biology Laboratory 
(EMBL) in Heidelberg is interested in the identification of regulatory sequences and 
understanding how their arrangement controls gene expression. For this purpose they 
developed an in vivo system based on the transposition of Sleeping Beauty transposons 
called GROMIT (Genome Regulatory Organization Mapping with Integrated 
Transposons) (RUF et al. 2011). These transposons contain a regulatory sensor 
composed of a LacZ gene driven by a minimal promoter. The promoter region 
corresponds to a 50 bp long fragment adjacent to the start site of the human β-globin 
gene (YEE and RIGBY 1993) and does not show specific activity when inserted into the 
mouse genome. However, it is very sensitive to endogenous regulatory input, therefore 
LacZ reporter expression reflects the presence of cis-regulatory elements. These 
elements are either in close proximity to the genomic site of the insertion or distant but 
acting in a long-range manner. 
The incorporation of this regulatory sensor within the Sleeping Beauty transposon 
allows a fast and simple way to remobilize the sensor in vivo. Transposition is induced 
by a hyperactive form of the Sleeping Beauty transposase (HSB16) (BAUS et al. 2005) 
under the control of a mouse Prm1 promoter fragment. Transposase expression is 
therefore restricted to spermatogenesis (PESCHON et al. 1989). Male mice carrying the 
transposon and the transposase transgene are bred to wild type females and the progeny 
is screened for new insertions. In contrast to other transposons the Sleeping Beauty 
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transposon does not show an integration bias towards particular regions like 
transcription start sites, gene bodies or intergenic sequences (HORIE et al. 2003; RUF et 
al. 2011; YANT and KAY 2003). However, it preferentially integrates close to its starting 
site (KENG et al. 2005; LUO et al. 1998), therefore new insertions are frequently 
observed within 1 to 2 Mb distance to the initital insertion. This feature allows the fast 
generation of mice with different insertions within a particular region of interest. 
The transposon contains in addition to the regulatory sensor a loxP site (SAUER 
and HENDERSON 1988; STERNBERG and HAMILTON 1981), which can be used for Cre-
mediated chromosomal rearrangements (HERAULT et al. 1998; RUF et al. 2011; WU et 
al. 2007). The recombination can lead to either deletion, duplication or inversion of the 
sequence between two insertion loci. After recombination the reporter remains present 
at the locus, thus allowing the comparison of reporter expression at the breakpoints with 
reporter expression after the recombination event. 
Dr. Veli V. Uslu, postdoctoral fellow in François Spitz’ laboratory, generated 
multiple mouse lines carrying the transposon on chromosome 15 at different positions 
in the flanking region of the c-myc gene (USLU et al. 2014). Furthermore, he generated 
several mouse lines carrying deletions or duplications in that region. Using these mice 
he analyzed the c-myc/Pvt1 flanking region for regulatory elements in E11.5 embryos 
and identified distant cis-acting enhancers that control c-myc expression in the 
developing face (USLU et al. 2014). 
3.2 Deletion of a 882 kb long region downstream of c-myc 
impacts on the hematopoietic system 
Since c-myc plays an important role in the hematopoietic system (chapter 1.3.2.2) 
we first aimed to analyze the influence of a large deletion in the c-myc/Pvt1 flanking 
locus on hematopoietic cells, knowing that this region contains enhancer elements 
acting on c-myc in the embryonic face. Cre-mediated recombination between transposon 
insertion 8a (located 800 kb telomeric to c-myc) and 17a (located 1.7 Mb telomeric to c-
myc) led to the generation of del(8-17) mice carrying a 882 kb deletion between both 
insertions (Figure 3.1) (RUF et al. 2011; USLU et al. 2014). 
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Figure 3.1: The c-myc/Pvt1 gene locus is flanked by a large non-coding region 
Organization of the mouse locus on chromosome 15. Protein coding genes are indicated by 
black arrows, non-coding genes by grey arrows. The two transposon insertions 8a and 17a are 
depicted that were used to generate the del(8-17) deletion (red bar). 
Homozygous del(8-17) mice were born in normal mendelian ratios and did not 
show gross abnormalities at the day of birth. However, further monitoring revealed that 
these mice have a postnatal growth defect and showed some postnatal mortality until 
weaning age (USLU et al. 2014). Similarly, mice with a heterozygous c-myc deletion 
and accordingly diminished c-myc expression levels also displayed a reduction in body 
size (TRUMPP et al. 2001), however this did not result in postnatal mortality. Assuming 
that the enhancer is only active in specific tissues but leads to a greater reduction of c-
myc expression levels in these tissues as compared to overall heterozygous deletion of 
c-myc, one or more of these affected tissues can account for the postnatal mortality. 
3.2.1 Effect of del(8-17) on the distribution of hematopoietic cells in 
the bone marrow 
Due to postnatal mortality we sacrificed mice at day 10 after birth for the analysis 
of the hematopoietic system. At this age, homozygous del(8-17) mice were 30.4%±5.3 
smaller than wild type mice (Figure 3.2 A). The number of bone marrow (BM) cells 
was reduced almost to a similar extent as it is indicated by the BM cellularity (Figure 
3.2 B,C). However, analysis of the BM by flow cytometry revealed a strongly disturbed 
appearance of mature hematopoietic effector cells (Figure 3.2  D,E). While numbers of 
red blood cells (Ter119+) and T cells (CD4+, CD8+) remained unchanged, numbers of B 
cells (B220+) and granulocytes (CD11b+ Gr-1+) were dramatically reduced. In contrast, 
del(8-17) mice did have increased numbers of megakaryocytes (Mgk; CD41+). These 
changes in the distribution of differentiated cells closely resembled the phenotype of 
adult mice with conditional deletion of c-myc in the hematopoietic system induced by 
MxCre (GUO et al. 2009; WILSON et al. 2004). 
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Figure 3.2: The deletion del(8-17) disturbs the differentiated cells 
Comparison of 10 days old wild type (Wt) or heterozygous Wt/del(8-17) mice to homozygous 
del(8-17) mice. A Body weight. B Number of BM cells from two femurs, tibias, ilia, and the 
vertebrae. C BM cellularity. D Representative flow cytometry profiles of BM cells stained for 
differentiated cell types. E Quantitative and statistical analysis of numbers of differentiated cell 
types in the BM (B, B cells; T, T cells; RBC, red blood cells; Mgk, megakaryocytes). 
Data shown are mean (±SEM) values (n = 5-16). Statistical significance is indicated for the 
comparison of del(8-17) to Wt mice; **p≤0.01; ***p≤0.005; ****p≤0.001. 
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The aforementioned conditional deletion of c-myc has been shown to result in an 
accumulation of hematopoietic stem and progenitor cells (HSPCs; Lineage- Sca-1+ 
cKit+ (LSK)) in the BM (GUO et al. 2009; WILSON et al. 2004), therefore we analyzed 
the BM cells of del(8-17) mice for this HSPC population. The frequency of LSK cells 
was about 10-fold higher in homozygous del(8-17) mice than in wild type mice. Due to 
the decrease in total BM cells (Figure 3.2 B) the net increase of LSK cells was 7.6-fold 
(Figure 3.3 A, B). 
 
 
Figure 3.3: The deletion del(8-17) leads to an increase of the hematopoietic stem and 
progenitor cell population 
Comparison of the hematopoietic stem and progenitor compartment in the BM of 10 days old 
wildtype (Wt), heterozygous Wt/del(8-17) mice and homozygous del(8-17) mice. A 
Representative flow cytometry plot of Lin- gated and LSK gated BM cells. B Quantitative and 
statistical analysis of stem and progenitor cell numbers in the BM. 
Data shown are mean (±SEM) values (n = 5-16). Statistical significance is indicated for the 
comparison of del(8-17) to Wt mice; ***p≤0.005; ****p≤0.001. 
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WILSON et al. and GUO et al. used the cell surface marker CD135 (Flk2/Flt3R) to 
further define the HSCs within the LSK cell population. Conditional deletion of c-myc 
led to an enrichment specifically in LSK CD135- cells, thus the authors concluded that 
HSCs accumulated in the BM of c-myc deficient mice. To investigate the HSC 
population in del(8-17) mice we used CD34 (OSAWA et al. 1996) and the Slam markers 
CD150 and CD48 (KIEL et al. 2005) in addition to the LSK marker set. This analysis 
revealed that the number of HSCs defined by LSK CD150+ CD48- CD34- was almost 4-
fold increased (Figure 3.3 D). Even more prominent was the increase of the CD48+ 
population within the LSK population (Figure 3.3 A). These cells correspond to the 
multipotent progenitor populations MPP2 (LSK CD150+ CD48+ CD34+), MPP3 and 4 
(LSK CD150- CD48+ CD34+). Quantification of these populations revealed a 14-fold 
and 6-fold increase of MPP2 and MPP3/4 respectively (Figure 3.3 D). In summary, 
dramatic accumulation of late multipotent progenitor cells but not HSCs or MPP1 cells 
account for the increase of LSK cells. 
3.2.1.1 Deletion of del(8-17) keeps stem and progenitor cells in a more 
active state 
Since c-Myc is known to play an important role in the control of proliferation we 
assessed the cycling behavior of stem and progenitor cells in the BM of del(8-17) mice. 
We stained BM cells of del(8-17) mice for intracellular Ki67, only expressed by cycling 
cells, combined with Hoechst33342, which stains DNA stochiometrically. This staining 
allows the identification of cells in the G0 (Ki67negHoechstlow), the G1 
(Ki67posHoechstlow) and the S, G2 and M (Ki67posHoechsthigh) phases of the cell cycle. 
Wild type HSCs displayed only very low cycling activity and 90% of the cells were in 
G0 (Figure 3.4 A,C). Upon differentiation along the multipotent progenitor populations 
the cell cycle stage moved progressively from G0 to G1 (Figure 3.4 A,D,E,F). 
Strikingly only 35% of del(8-17) HSCs were in G0. Also the other progenitor 
populations displayed a significantly reduced number of cells in G0 compared to wild 
type cells except for the MPP3/4 population where the level of cells in G0 is already 
very low. Only the HSC population exhibited a slight increase in cells that are actively 
cycling, which might account for the accumulation of HSPCs in the BM of del(8-17) 
mice. Overall deletion of del(8-17) kept stem and progenitor cells in a more active state. 
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Figure 3.4: The deletion del(8-17) leads to a more active cell cycle state of hematopoietic 
stem and progenitor cells 
Cell cycle analysis by Ki67/Hoechst33342 staining of hematopoietic stem and progenitor cells of 
10 days old wild type (Wt), heterozygous Wt/del(8-17) or homozygous del(8-17) mice. A 
Representative flow cytometry profiles of cells gated for the indicated populations. B-F 
Quantitative and statistical analysis of the cell cycle in the indicated populations. 
Data shown are mean (±SEM) values (n = 3-5). Statistical significance is indicated for the 
comparison of the G0 cell cycle phase between del(8-17) and Wt mice; **p≤0.01; ****p≤0.001. 
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3.2.2 The accumulation of del(8-17) stem and progenitor cells already 
manifests in the fetal liver 
During embryonic development HSCs are not located initially in the BM but 
migrate through different embryonic tissues. As described in chapter 1.2.1.3 the first 
functional HSCs could be isolated from the AGM region of mouse embryos starting 
from E10.5 (DE BRUIJN et al. 2000; DZIERZAK and SPECK 2008; KUMARAVELU et al. 
2002; MEDVINSKY and DZIERZAK 1996; MÜLLER et al. 1994). From E11.5 they start to 
colonize the fetal liver where they undergo expansion and maturation, followed by 
migration to the BM from E17.5 onwards (MIKKOLA and ORKIN 2006). Fetal HSCs in 
the liver are markedly different to adult HSCs especially regarding their cell cycle status 
and proliferative capacity (BOWIE et al. 2007; BOWIE et al. 2006). 
 
Figure 3.5: Accumulation of hematopoietic stem and progenitor cells in the liver of 
newborn del(8-17) mice 
Comparison of the hematopoietic stem and progenitor compartment in the liver of 10 days old 
wild type (Wt), heterozygous Wt/del(8-17) or homozygous del(8-17) mice. A Representative 
flow cytometry profiles of Lin- gated and LSK gated liver cells. B Quantitative and statistical 
analysis of stem and progenitor cell numbers in the liver. 
Data shown are mean (±SEM) values (n = 3-6). Statistical significance is indicated for the 
comparison of del(8-17) to Wt mice; *p≤0.05; **p≤0.01. 
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Since we analyzed the del(8-17) mice at the age of 10 days and observed an 
accumulation of stem and progenitor cells in the BM with a more active cell cycle 
profile we wanted to assess the number of HSCs in the liver of these animals. In this 
quantification HSCs and MPPs were characterized without gating for CD34 as 
expression of this marker on HSCs changes during developmental stages (MATSUOKA et 
al. 2001). Similar to the accumulation in the BM the number of LSK cells in the liver 
was increased by more than 3-fold (Figure 3.5 A,B). Again correlating to the BM this 
accumulation was mainly due to the increase of MPP2 (7.5-fold) and MPP3/4 (2.5-fold) 
whereas the HSC/MPP1 population displayed only a non-significant 1.8-fold increase 
(Figure 3.5 A,C). 
 
Figure 3.6: Accumulation of hematopoietic stem and progenitor cells in the fetal liver of 
del(8-17) mice 
Comparison of the hematopoietic stem and progenitor compartment in the liver of heterozygous 
Wt/del(8-17) and del(8-17) embryos at E15.5. A Representative flow cytometry profiles of Lin- 
gated and LSK gated liver cells. B Frequency of hematopoietic cells (CD45+) in the fetal liver. C 
Frequency of LSK cells within the blood cell population in the fetal liver. C Frequency of 
HSC/MPP1, MPP2 and MPP3/4 cells within the blood cell population in the fetal liver. E,F 
Absolute frequencies of the populations shown in C and D. Data shown are mean (±SEM) 
values (n = 1-2). 
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In a pilot experiment with 1 and 2 mice per genotype we stained fetal liver cells 
from E15.5 embryos for hematopoietic stem and progenitor populations. In addition the 
CD45 marker was used to identify hematopoietic cells among the hepatocytes. The fetal 
livers of embryos carrying the del(8-17) deletion contained 4-fold less CD45+ blood 
cells compared to the control liver (Figure 3.6 A,B), however among these blood cells 
the frequency of HSC and MPP populations was strongly increased (Figure 3.6 C,D). 
With regard to the reduced amount of CD45+ blood cells the absolute amount of HSC 
and MPP cells in the liver might have been unchanged. However, absolute frequencies 
still showed an increase for each population (Figure 3.6 E,F). In summary the 
phenotype we observed in the BM of newborn mice already manifests in the fetal liver 
where a number of HSCs is retained at least till day 10 after birth. 
3.2.3 The del(8-17) deletion leads to reduced c-myc expression in 
stem and progenitor cells 
Since these mice displayed a very similar phenotype compared to the conditional 
c-myc deletion and we knew about potential regulatory input of the deleted region on c-
myc we next assessed the expression of c-myc and other nearby genes in the c-myc/Pvt1 
flanking region. For this purpose we sorted LSK cells as well as myeloid committed 
progenitor cells (LS-K) and analyzed the mRNA levels by qRT-PCR. c-myc levels 
dropped dramatically upon del(8-17) deletion in LSK cells to 3% of wildtype levels. 
However, LS-K cells showed only a minor reduction to 65% of wildtype levels. In 
contrast Fam49b, a gene located 210 kb telomeric from the deletion breakpoint did not 
show a significant change in expression. Furthermore, Gsdmc expression levels were 
very low (data not shown) and we could not detect Pvt1. 
 
 
Figure 3.7: Analysis of gene expression in the c-myc/Pvt1 flanking locus upon del(8-17) 
Relative mRNA expression levels of c-myc (A) and Fam49b (B) measured by qRT-PCR in LSK 
and LS-K BM cells from 10 days old wildtype and del(8-17) mice. Data shown are mean (±SEM) 
values (n = 4-8). 
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3.2.4 Competitive transplantation reveals a critical role for the del(8-
17) region for HSC self renewal and differentiation 
The lack of many mature effector cells, the accumulation of stem and progenitor 
cells in the BM of del(8-17) mice and the fact that c-myc levels were significantly 
reduced in LSK cells led us to test the self renewal and differentiation potential of 
del(8-17) HSCs by a reconstitution experiment. Lethally irradiated mice transplanted 
solely with conditionally c-myc deleted BM cells did not survive (WILSON et al. 2004). 
As a similar phenotype for the transplantation of del(8-17) BM cells could be expected 
we decided to co-transplant competing wild type BM cells that generate a functional 
hematopoietic system and thus ensure the survival of the recipient mice. We isolated 
BM cells of 10 days old del(8-17) and control mice and transplanted them together with 
CD45.1/2 BM cells from an adult mouse in an overall 80:20 ratio intravenously into 
lethally irradiated CD45.1+ mice. Due to the higher frequency of stem cells in the BM, 4 
times more HSCs from del(8-17) mice as from wild type mice were transplanted. The 
engraftment was monitored over time by bleeding the mice every 4 weeks and 
determining the percentage of CD45.2+ in the blood. As shown in Figure 3.8 B del(8-
17) derived cells did not contribute to the peripheral blood already 4 weeks after 
transplant while control cells efficiently reconstituted the periphery. After 16 weeks 
mice were sacrificed and the engraftment was analyzed in the BM. Similar to the 
peripheral blood differentiated cell types were hardly reconstituted by del(8-17) HSCs, 
however the stem cell compartment was reconstituted to 63% (Figure 3.8 C,D). 
Multipotent progenitor populations MPP1, MPP2, MPP3/4 and myeloid committed 
progenitors LS-K of del(8-17) transplanted mice showed a gradually declining 
contribution to the BM from 62% to 24% (Figure 3.8 D). 
In summary these results show that del(8-17) HSCs were functionally defective as 
they were unable to reconstitute mature hematopoietic lineages upon transplantation in 
a competitive setting. At the same time del(8-17) HSCs retained their self-renewal 
capacity as they remained present and accumulated in the BM to an amount of 68% of 
wild type levels. 
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Figure 3.8: Competitive transplantation shows an impaired differentiation potential but 
retained self-renewal of del(8-17) HSCs 
BM cells of 10 days old CD45.2+ del(8-17) or wild type mice were transplanted together with 
competing CD45.1/2 BM cells in an overall 80:20 ratio intravenously into lethally irradiated 
CD45.1+ recipient mice. The engraftment of the CD45.2+ was monitored by bleeding the mice 
every 4 weeks, after 16 weeks the blood and the BM was analyzed for engraftment of different 
cell populations. A Representative flow cytometry profiles of the input ratio as well as 
engraftment of peripheral blood cells in recipient mice 16 weeks after transplant. B Percentage 
of CD45.2+ cells in the peripheral blood of recipient mice over time. C Representative flow 
cytometry profiles of the LSK input ratio as well as engraftment of different stem and progenitor 
cells in the BM of recipient mice 16 weeks after transplant. D Percentage of CD45.2+ cells from 
different populations in the BM of recipient mice. 
Data shown are mean (±SEM) values (n = 6-8). Statistical significance is indicated for the 
comparison of del(8-17) to Wt mice; **p≤0.01; ****p≤0.001. 
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3.3 Enhancer activity in the c-myc gene desert 
The del(8-17) region does not contain any protein coding gene (chapter 1.3.3, 
Figure 3.1), nevertheless its deletion causes a dramatic downregulation of c-myc in 
HSPCs and a similar phenotype as mice with a conditional deletion of c-myc in 
hematopoietic cells. As described in chapter 3.1 Dr. Veli V. Uslu generated several 
mouse lines carrying insertions of the LacZ reporter gene at different positions in the c-
myc/Pvt1 flanking locus. The positions of selected insertions are indicated in Figure 
3.9 A. To screen for possible regulatory input we assessed the expression of these 
enhancer sensors in several hematopoietic cell types. 
We used fluorescein di-(β-D-galactopyranoside) (FDG), a fluorogenic substrate of 
galactosidase, to measure LacZ expression in BM cells (GUO and WU 2008). After 
hypotonic loading of the substrate into the cells galactosidase cleaves FDG and 
releases the fluorescent product FITC, which can then be detected by flow 
cytometry. We found that when the transposon is inserted at position 17a, the sensor 
showed strong LacZ expression in HSPCs (LSK) as well as myeloid committed 
progenitors (LS-K). LacZ expression from 17a was however very weak in cells positive 
for the lineage markers (Figure 3.9 B,C). We then assessed LacZ expression in separate 
stainings for more defined stem and progenitor (Figure 3.9 D), committed progenitor 
(Figure 3.9 E) and differentiated cell populations (Figure 3.9 F) to see if different cell 
types show distinct enhancer activity. Within the LSK population LacZ expression 
declined slightly from HSC to MPP3, while MPP4 showed similar levels as HSCs. 
Among the committed progenitor populations GMPs had the highest enhancer activity 
in a similar range as HSCs and MPP4 cells, while LacZ expression in CMPs, MEPs and 
CLPs was slightly reduced. Among the differentiated cell types only very subtle LacZ 
expression could be observed, which was highest in erythroblasts and megakaryocytes 
(Figure 3.10 C). Interestingly, other insertions showed hardly any expression, only a 
weak, but significant LacZ signal, was detected for 14c and 16a in hematopoietic stem 
and precursor cells (Figure 3.10 A,D). Thus, this hematopoietic specific expression of 
the enhancer sensor seemed to be limited to the distal part of the c-myc/Pvt1 flanking 
locus and it did not extent as a large regulatory domain (SYMMONS et al. 2014) 
contrarily to other enhancers identified in the region (USLU et al. 2014). 
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Figure 3.9: Enhancer activity at the distal end of the c-myc/Pvt1 flanking locus 
A Murine c-myc gene locus on chromosome 15 with flanking regions. Protein coding genes are 
indicated by black arrows, non-coding genes by grey arrows. Location of insertion sites of 
transposons are indicated, deletions are depicted as red bars. B Representative flow cytometry 
histograms of FDG stained hematopoietic cells. C Quantification of LacZ expression in BM stem 
and progenitor cells (LSK), myeloid committed progenitors (LS-K) and differentiated (Lin+) cells 
of wild type (Wt), heterozygous 17a and heterozygous del(15-17) mice measured by FDG 
staining. Bars represent the mean fluorescent intensity (geometric mean) ±SEM and vertically 
plotted values represent the percentage of positively stained cells ±SD. D-F LacZ expression as 
in C in immunophenotypically more defined (D) hematopoietic stem and multipotent progenitor 
populations, (E) committed progenitor populations and (F) mature effector cells. Data shown are 
mean values from two independent experiments (n = 3). 
 
To further characterize the function of this enhancer region, we assessed LacZ 
expression in hematopoietic cells from mice carrying deletions within this region as 
they retained the LacZ reporter gene at the breakpoint (Figure 3.9 A). Besides del(8-17) 
two more deletions were tested that encompass the sequence in between transposons 
14b and 17a (del(14-17)) or 15a and 17a (del(15-17)) (Figure 3.9 A). All three deletions 
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have the insertion 17a as the telomeric breakpoint, however they differ in size, i.e. 
882 kb for del(8-17), 367 kb for del(14-17) and 259 kb for del(15-17). We found that all 
deletions showed a concomitant loss of LacZ expression in the different hematopoietic 
cell types, indicating that only the very telomeric part of the c-myc/Pvt1 flanking locus 
is required for this activity (Figure 3.9 and Figure 3.10). This regulatory region is more 
than 1.4 Mb away from the c-myc gene. 
 
 
Figure 3.10: Enhancer activity across the c-myc gene desert 
A-C Representative flow cytometry histograms of FDG stained hematopoietic cells from wild 
type and heterozygous mice with insertions at 17a, 3a, 14b or 16a. D-F Quantification of LacZ 
expression in BM stem and progenitor cells (LSK), myeloid committed progenitors (LS-K) and 
differentiated (Lin+) cells of wild type (Wt) and heterozygous mice with the indicated insertions 
measured by FDG staining. Bars represent the mean fluorescent intensity (geometric mean) 
±SEM and vertically plotted values represent the percentage of positively stained cells ±SD. 
Data shown are mean values (n = 2) representative from two independent experiments (n = 3). 
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3.4 Identification of regulatory elements in the c-myc/Pvt1 
flanking locus 
3.4.1 The c-myc gene is located in a TAD domain 
The spatial organization of the genome is intrinsically tied to its biological 
function, therefore several key aspects can be learned about the relationship between 
higher order chromatin structure and genome function from global studies of 3D 
genome organization. Hi-C is a method based on Chromosome Conformation Capture 
(3C), in which chromatin is crosslinked with formaldehyde, resulting in covalent links 
between spatially adjacent chromatin segments. Next, the chromatin is digested with a 
restriction enzyme and the resulting sticky ends are filled with biotinylated nucleotides. 
Re-ligation is performed under conditions that lead to the creation of chimeric 
molecules consisting only of fragments that are covalently linked, i.e. they were 
originally in close spatial proximity. After shearing of the DNA these molecules are 
isolated by streptavidin beads. DNA sequencing reveals a genome-wide interaction map 
that can be visualized as two-dimensional contact matrices for each chromosome or 
specific regions (LIEBERMAN-AIDEN et al. 2009). 
The REN lab performed as part of the MOUSE ENCODE PROJECT Hi-C analyses of 
embryonic stem cells and terminally differentiated cell types of human and mouse 
(DIXON et al. 2012). Due to their high sequencing depth they could observe highly self-
interacting regions that appear as triangles in the two-dimensional heat map. These 
large, megabase-sized local chromatin interaction domains were termed topological 
associating domains (TAD) and were bounded by narrow segments where the 
chromatin interactions appeared to end abruptly, the TAD boundaries. Of note it was 
observed that TADs are stable across different cell types and also throughout both 
organisms tested, suggesting that they reflect an inherent property of mammalian 
genomes. 
Hi-C data can be accessed at http://yuelab.org/hi-c/database.php where genomic 
interactions are graphically illustrated as a heat-map for a selected region in a chosen 
cell type. Analysis of the c-myc/Pvt1 flanking locus in murine embryonic stem cells 
revealed that the c-myc gene is located in the middle of a large TAD domain that spans 
over 3 Mb and ends telomerically close to the Gsdmc cluster (Figure 3.11). We located 
the enhancer activity to the del(15-17) region, which is more than 1.4 Mb away from 
the c-myc gene. Still it belongs to the same TAD domain as can be seen in Figure 3.11, 
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making the interaction between the enhancer within the del(15-17) region and the c-myc 
promoter region a likely event. The genes located at the telomeric site of the del(15-17) 
region belong to the neighboring TAD, therefore a cis-regulation of these genes by an 
enhancer element within the del(15-17) region is unlikely as the probability of physical 
interaction is very low. Accordingly we did not observe changes in Fam49b expression 
in del(8-17) LSK cells (Figure 3.7) although this gene is located closer to the enhancer 
containing del(15-17) region than c-myc. 
 
Figure 3.11: The c-myc/Pvt1 flanking locus is located in a large TAD domain 
Heat map of Hi-C data of mouse embryonic stem cells (ESC) for the c-myc/Pvt1 flanking locus 
accessed at http://yuelab.org/hi-c/database.php. Interaction between two loci is viewed as the 
point where the diagonals originating from each locus intersect. Black bars represent separate 
mouse ESC TAD domains. Genes and deletion are depicted as in Figure 3.9 A. 
3.4.2 Enhancer associated chromatin marks define a distal hemato-
poietic enhancer cluster (DHEC) 
To identify regions that regulate c-myc expression during hematopoiesis, we 
examined publicly available chromatin profiles from hematopoiesis-related tissues 
(Figure 3.12) (SHEN et al. 2012). RNA-seq and promoter-associated marks (H3K4me3, 
H3K36me3, Pol2) confirmed that the c-myc-TAD is located in a large gene desert, 
comprising only c-myc and the non-coding Pvt1 gene, flanked centromerically by A1bg 
and Fam84b and telomerically by the Gsdmc gene cluster. Enhancer-associated marks 
(H3K27ac, H3K4me1) highlighted a number of peaks across this interval in 
hematopoietic tissues: two isolated peaks are located centromerically (450-550 kb from 
c-myc), a proximal cluster of multiple peaks overlapping with Pvt1 (from 50 kb to 
450 kb away from c-myc), and another very remote cluster of peaks located at the distal 
end of the TAD, 1.7 Mb away from c-myc. This distal hematopoietic enhancer cluster 
(DHEC) was observed in BM, bone marrow derived macrophages (BMDM) and fetal 
RESULTS 
 
 55
liver, but not in other non-hematopoietic tissues, suggesting that this region may act as a 
tissue-specific enhancer. 
 
Figure 3.12: Regulatory elements in the c-myc gene desert 
Murine c-myc gene locus on chromosome 15 with flanking regions. Annotated genes are 
indicated. Top lines show chromatin modifications in different hematopoietic tissues associated 
with promoter and active transcription (H3K4me3 and H3K36me3). Middle lines show chromatin 
modifications in different hematopoietic tissues associated with enhancers (H3K4me1 and 
H3K27ac). Bottom lines show chromatin modifications in different non-hematopoietic tissues 
associated with enhancers (H3K4me1 and H3K27ac). Only hematopoietic tissues show 
enhancer marks at the distal end of the c-myc/Pvt1 flanking locus, entitled DHEC. 
Abbreviations: DHEC: distant hematopoietic enhancer cluster; H3K4m3: trimethylation of 4th 
lysine residue of histone 3; H3K4m3: monomethylation of 4th lysine residue of histone 3; 
H3K27a: acetylation of 27th lysine residue of histone 3; BMDM: BM derived macrophages; 
CH12: B-cell lymphoma cell line (GM12878 analog); MEL: leukemia cell line (K562 analog); 
BAT: Brown adipocytes tissue; ES-E14: mouse embryonic stem cell line E14; MEF: mouse 
embryonic fibroblast; Olfact: Olfactory bulb; Smint: Small intestine. 
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3.5 Characterization of the DHEC by del(15-17) deletion 
3.5.1 Effect of del(15-17) deletion on the distribution of hemato-
poietic cells in the bone marrow 
The greatest part of the DHEC is located within the del(15-17) region therefore 
we had the possibility to address the phenotypical consequences upon its deletion in 
homozygous del(15-17) mice. In contrast to del(8-17) mice (chapter 3.2), where the 
deletion encompassed the DHEC and additional 774 kb of its centromerically located 
sequence, this smaller deletion did not lead to postnatal lethality. Instead, del(15-17) 
mice were viable, fertile and did not show any overt phenotype. 
Although the body weight of adult del(15-17) mice was within the normal range 
we observed a significant reduction in BM cellularity (Figure 3.13 A,B) as compared to 
control mice having one c-myc allele flanked by loxP sites. This genomic modification 
did not alter c-myc expression levels as shown by TRUMPP et al. (2001), neither in a 
heterozygous nor homozygous setting. 
Similar to what we found in mice carrying the 882 kb deletion, we found a more 
than 3-fold accumulation of LSK cells (Figure 3.13 C). Further refinement of this 
population using the Slam markers CD150 and CD48 as well as CD135 and CD34 
(CABEZAS-WALLSCHEID et al. 2014; WILSON et al. 2008) revealed an accumulation of 
the multipotent progenitor populations MPP2, 3 and 4, whereas the number of HSCs 
and MPP1 remained unchanged (Figure 3.13 D,E). Flow cytometric analysis of the 
mature lineages in the BM revealed a strong decrease in granulocytes and B cells while 
the number of T cells, macrophages (CD11b+ Gr-1-) and erythrocytes remained 
unchanged. In contrast the number of megakaryocytes defined by expression of CD41 
increased significantly (Figure 3.13 F,G). Thus the hematopoietic phenotype closely 
resembled the one found in 10 days old del(8-17) mice, suggesting that the overall 
changes in the hematopoietic system regarding stem, progenitor and differentiated cell 
populations did not account for the postnatal lethality and reduced body size of del(8-
17) pups. 
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Figure 3.13: Deletion of the del(15-17) region leads to an accumulation of multipotent 
progenitor cells and a disturbed appearance of mature effector cells 
Comparison of adult homozygous del(15-17) mice to control c-myc+/flox mice. A Body weight. B 
BM cellularity per g body weight. D Representative flow cytometry profiles of Lin- gated and LSK 
gated BM cells. E Quantitative and statistical analysis of stem and progenitor cell numbers in 
the BM (n = 4-5). F Representative flow cytometry profiles of BM cells stained for differentiated 
cell types. E Quantitative and statistical analysis of numbers of differentiated cell types in the 
BM (B, B cells; T, T cells; RBC, red blood cells; Mgk, megakaryocytes) (n = 5). 
Data shown are mean (±SEM) values. Statistical significance is indicated; *p≤0.05; **p≤0.01; 
***p≤0.005; ****p≤0.001. 
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3.5.2 Del(15-17) HSCs reconstitute stem and progenitor cells but lack 
differentiation potential after competitive transplantation 
To investigate the repopulation potential of del(15-17) HSCs we performed a 
competitive transplantation assay in a similar setting as for the del(8-17) mice (chapter 
3.2.4). Since del(15-17) mice did not show any postnatal lethality as opposed to del(8-
17) mice (chapter 3.2), we could transplant adult BM cells to assess HSCs function. In 
contrast the previous transplantation had to be performed with BM cells from 10 days 
old mice due to their postnatal lethality. Since HSCs pass through some essential 
changes during development, they might exhibit different characteristics in 
transplantation experiments compared to adult HSCs (MIKKOLA and ORKIN 2006). 
BM cells were harvested from homozygous del(15-17) as well as wild type mice 
(CD45.2) and were intravenously transplanted into lethally irradiated congenic 
recipients (CD45.1) together with BM competitor cells (CD45.1/2) in a 80:20 ratio. 
Since the absolute frequency of HSCs in the BM of the donor del(15-17) mice was 
higher than in the control donor mouse the amount of transplanted HSCs was 4-fold 
higher. 
Already 4 weeks post transplant, del(15-17) HSCs failed to reconstitute the 
peripheral blood compartments of recipient mice (Figure 3.14 B). Strikingly, analysis of 
BM chimerism 16 weeks after transplantation revealed an accumulation of del(15-17) 
HSCs (Figure 3.14 C,D). The accumulation of immunophenotypically defined 
multipotent progenitor cells observed in del(15-17) mice did not become evident in 
competitively transplantated mice. Although under homeostatic conditions del(15-17) 
HSCs are capable to generate macrophages, T cells, red blood cells and megakaryocytes 
at normal or even increased numbers, almost no mature effector cell type was derived 
from del(15-17) HSCs in the transplantation situation. Red blood cells and platelets do 
not express the hematopoietic cell marker CD45, therefore they are usually not 
evaluated in transplantation assays. However, very early erythrocyte progenitors and 
megakaryocytes still express intermediate levels of CD45 (DARZYNKIEWICZ et al. 
2009), therefore we also assessed the BM chimerism of recipient mice for CD71+ 
erythrocyte progenitors (EP) and CD41+ megakaryocytes (Mgk). Donor derived cells 
were detectable from both populations in mice transplanted with wild type BM cells, 
however del(15-17) HSCs did hardly give rise to these cell types. 
In summary, del(15-17) HSCs accumulated almost to wild type levels in the BM 
of transplanted mice. While control donor HSCs generated normal proportions of stem 
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and progenitor cell types as well as of mature lineages, del(15-17) chimerism levels 
decreased continuously along the hematopoietic hierarchy. 
 
 
Figure 3.14: Competitive transplantation shows an impaired differentiation potential but 
retained self-renewal of del(15-17) HSCs 
BM cells of adult CD45.2+ del(8-17) or wild type mice were transplanted together with 
competing CD45.1/2 BM cells in an overall 80:20 ratio intravenously into lethally irradiated 
CD45.1+ recipient mice. The engraftment of the CD45.2+ was monitored by bleeding the mice 
every 4 weeks, after 16 weeks the blood and the BM was analyzed for engraftment of different 
cell populations. A Representative flow cytometry profiles of the input ratio as well as 
engraftment of peripheral blood cells in recipient mice 16 weeks after transplant. B Percentage 
of CD45.2+ cells in the peripheral blood (PB) of recipient mice over time. C Representative flow 
cytometry profiles of the HSC input ratio as well as engraftment of different stem and progenitor 
cells in the BM of recipient mice 16 weeks after transplant. D Percentage of CD45.2+ cells from 
different populations in the BM of recipient mice. 
Data shown are mean (±SEM) values (n = 6-8). Statistical significance is indicated for the 
comparison of del(8-17) to Wt mice; *p≤0.05; ***p≤0.005; ****p≤0.001. 
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3.6 The DHEC is acting in cis on c-myc 
3.6.1 Compound heterozygous mice prove allelism between DHEC 
and c-myc 
Deletion of the del(15-17) region and therefore of the DHEC led to a phenotype 
closely related to the phenotype observed by deleting c-myc in hematopoietic cells 
(GUO et al. 2009; WILSON et al. 2004). In addition deletion of the del(8-17) region that 
also encompasses the DHEC led to a dramatic c-myc downregulation in a population 
containing stem and progenitor cells, suggesting that the DHEC acts upstream of c-myc 
in these cells. To prove if this regulation is direct we crossed a heterozygous del(15-17) 
mouse with heterozygous c-mycKO mice (c-mycflox/KO) to generate compound 
heterozygous mice carrying one enhancer deletion allele and one c-myc null allele 
(del(15-17)/c-mycKO). Similar results described in this chapter were obtained by using 
del(14-17)/c-mycKO mice (data not shown). 
Heterozygosity for either c-myc deletion (c-mycKO/Wt) or the enhancer deletion 
(del(15-17)/c-mycflox) did not lead to any overt changes compared to c-mycflox/Wt mice 
(hereafter also termed wild type mice). Compound heterozygous mice however 
demonstrated very similar hematopoietic defects to that shown by homozygous del(15-
17) mice, thereby proving allelism between c-myc and the enhancer region (Figure 
3.15). The BM cellularity was significantly decreased whereas the LSK population 
increased about 4-fold (Figure 3.15 A,B). HSC and MPP1 populations did not differ in 
absolute cell numbers, but the multipotent progenitor populations MPP2, 3 and 4 
expanded (12.8-fold; 8.9-fold; 3.5-fold respectively; Figure 3.15 C,D). 
Among the differentiated cell types granulocyte and B cell numbers dropped 
dramatically, while macrophage and T cell numbers remained stable and the number of 
megakaryocytes increased. In contrast to the previously described phenotype of 
homozygous del(15-17) mice compound heterozygotes displayed a reduced number of 
erythrocytes (62.3% of wild type levels). Thus, c-myc expression of the two alleles in 
homozygous del(15-17) seemed to be sufficient to allow for normal erythrocyte cell 
numbers (Figure 3.13 F), whereas compound heterozygous mice displayed a mild 
haploinsuffiency (Figure 3.15 C,D). In support of this conclusion the erythrocyte 
population of heterozygous c-mycKO/Wt mice decreased to 87.3% of wild type levels, 
however not significantly. 
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Figure 3.15: Compound heterozygous mice display a similar phenotype as homozygous 
del(15-17) mice 
Comparison of adult c-mycflox/Wt, c-mycflox/KO, del(15-17)/c-mycflox and del(15-17)/c-mycKO mice. 
A BM cellularity per g body weight. B Quantitative and statistical analysis of LSK cell numbers 
in the BM. C Representative flow cytometry profiles of BM cells stained for hematopoietic stem 
and progenitor cells as well as for differentiated cell types. D Quantitative and statistical analysis 
of stem and progenitor cell numbers in the BM. E Quantitative and statistical analysis of 
numbers of differentiated cell types in the BM (B, B cells; T, T cells; RBC, red blood cells; Mgk, 
megakaryocytes). 
Data shown are mean (±SEM) values (n = 4). Statistical significance is indicated; **p≤0.01; 
***p≤0.005; ****p≤0.001. 
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To also address the functional ability we performed a colony-forming unit assay. 
Using this system it is possible to quantify differentiation potential of multipotent and 
lineage-restricted progenitors in vitro (chapter 1.2.1.1). Isolated BM cells from control 
(del(15-17)/c-mycflox) and compound heterozygous (del(15-17)/c-mycKO) mice were 
cultured in M3434 medium, a semi-solid methylcellulose medium supplemented with 
nutrients and cytokines. Within ten days the progenitors from control BM cells did 
proliferate, resulting in the formation of discrete colonies. In contrast del(15-17)/mycKO 
progenitors showed a greatly reduced colony formation (Figure 3.16 A,C). In addition 
colonies were much smaller in size and cell number (Figure 3.16 B), thus proving that 
del(15-17)/mycKO progenitor cells have a defect in differentiation towards mature cells. 
 
Figure 3.16: Compound heterozygous mice display reduced colony formation ability 
20.000 BM cells of del(15-17)/c-mycflox and del(15-17)/c-mycKO mice were seeded into 
supplemented methylcellulose medium and evaluated after 10 days. A Pictures of 
representative dishes. B Microscope images of representative colonies. C Quantitative and 
statistical analysis of counted colony numbers. 
Data shown are mean (±SEM) values (n = 4). Statistical significance is indicated; **p≤0.01. 
3.6.2 Gene expression upon deletion of the DHEC 
We sought to determine the relevance of the DHEC for endogenous gene 
expression in hematopoietic cells in detail. This issue was already addressed using the 
del(8-17) mice which showed a reduction of c-myc expression to barely detectable 
levels in LSK cells (Figure 3.7). Next we wanted to examine expression levels in better 
defined stem and progenitor populations and also committed progenitor and 
differentiated cell types. For this reason we sorted the different cell types from 
compound heterozygous mice as well as c-mycflox/Wt (wild type) and heterozygous c-
mycKO/Wt mice and performed qRT-PCR analyses. Wild type expression of c-myc was 
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highest in stem and progenitor populations as opposed to the differentiated cell types 
(Figure 3.17 A). In detail, HSCs, MPPs, GMPs and MEPs showed equal c-myc 
expression levels, whereas CMP levels were almost 2-fold higher and CLP levels 2-fold 
decreased as compared to the HSC level. Differentiated cell types reached only between 
0.5% (granulocytes) to 26.7% (megakaryocytes) of HSC level as illustrated in Figure 
3.17 A. Upon deletion of the DHEC c-myc expression was lost in HSCs, all MPPs, 
CMP, GMP and CLP cells. It was also strongly reduced in most mature cell types, 
except T-cells. Expression of c-myc in megakaryocyte-erythrocyte progenitor cells 
(MEP) was less affected as it was only reduced to 48.3% of c-mycKO/Wt and 30.6% of c-
mycflox/Wt levels. In contrast to these effects on hematopoietic cell types, deletion of 
del(15-17) had no effect on c-myc expression in other tissues, such as the embryonic 
face, limbs, heart and liver (USLU et al. 2014). 
Moreover we determined expression levels of genes flanking the DHEC. Gsdmc 
expression is very low in HSPCs as we have seen before in del(8-17) LSK cells (chapter 
3.2.3), therefore we determined the expression of another telomerically located gene. As 
expected Ddef1 expression was not significantly changed by the DHEC deletion (Figure 
3.17 C). On the centromeric side Pvt1 expression was hardly detectable. Fam84b 
expression was not significantly diminished upon deletion of the DHEC, instead we 
observed significantly upregulation for some progenitor cell types and granulocytes 
(Figure 3.17 D). 
To check for compensatory mechanisms we also determined N-myc expression in 
all samples. In contrast to c-myc, N-myc was highly expressed only in HSCs and 
decreased steadily in subsequent populations. These results overall confirmed the 
published gene expression levels of the Myc family members and proved the 
predominant role of c-myc in the hematopoietic system while only the most primitive 
cells at the top of the hierarchy concomitantly expressed c-myc and N-myc (LAURENTI et 
al. 2008). Interestingly, we found that deletion of the DHEC led to a compensatory 
upregulation of N-myc in most populations (Figure 3.17 B). Of note, N-myc levels were 
not changed in HSCs suggesting that in these cells no transcriptional feedback loop is 
active. 
Together, these data showed that the del(15-17) region is allelic to c-myc, proving 
that the DHEC acts as a very distant, yet critical cis-acting enhancer for c-myc in almost 
all hematopoietic cell types except T cells and MEPs. 
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Figure 3.17: Relative gene expression in compound heterozygous mice 
mRNA expression of c-myc (A), N-myc (B), Ddef1 (C) and Fam84b (D) by hematopoietic cells 
of the BM was measured by qRT-PCR in c-mycflox/Wt, c-mycKO/Wt and del(15-17)/c-mycKO mice. 
The scale for N-myc expression levels (B) is separated; values to the left of the dashed line 
refer to the left scale, values to the right of the dashed line to the right scale. 
Data shown are mean (±SEM) values (n = 3-4); Statistical significance is indicated; *p≤0.05; 
**p≤0.01; ***p≤0.005; ****p≤0.001. 
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3.7 Reduction of the distance between c-myc and DHEC does 
not impact on cell frequencies within the hematopoietic system 
Next, we were wondering if a reduction of the distance between the DHEC and c-
myc would impact on its regulation. In a pilot experiment we analysed a del(8-14) 
mouse compared to a wild type mouse and took the frequencies of hematopoietic cell 
types as an immediate readout for a potential change in regulation. This deletion excised 
a 516 kb region between the insertions 8a and 14b (Figure 3.9), thus reducing the 
distance from 1.7 Mb to 1.2 Mb. 
BM cell numbers were in the normal range upon deletion of the del(8-14) region 
(Figure 3.18 A). Flow cytometric analysis did not reveal strong differences in most 
quantified hematopoietic populations (Figure 3.18 B-D). Only the number of LSK cells 
was decreased to 78% of wild type level, which was mostly due to a reduction in 
numbers of MPP4 cells. However, this tendency is rather contrary to the phenotype 
upon deletion of the DHEC. Although a larger cohort of mice have to be analyzed to 
validate this initial experiment and gene expression levels have to be determined, these 
data suggested that a reduction of the distance between the DHEC and the c-myc gene 
by deletion of the 516 kb spanning del(8-14) region did not impact on c-myc expression 
in hematopoietic cells. Furthermore, this experiment proved that the centromeric part 
indeed did not account for the hematopoietic phenotype observed in del(8-17) mice. 
Thus, although the del(8-14) region exhibited enhancer activity regulating c-myc in the 
developing face (USLU et al. 2014), these regulatory elements seem not be active in 
hematopoietic cells. This is in accordance with the locally restricted sensor expression 
in hematopoietic cells (chapter 3.3) and the broader sensor expression in the embryonic 
face (USLU et al. 2014). 
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Figure 3.18: A reduced distance between the DHEC and c-myc does not change 
hematopoietic cell frequencies 
Comparison of adult wild type and del(8-14) mice. A Number of BM cells. B-D Quantitative 
analysis of cell numbers of (B) differentiated cell types, (C) LSK cells and (D) stem and 
multipotent progenitor cell types in the BM. 
Data shown are values from an experiment with 1 mouse per genotype (n = 1). 
 
3.8 Deletion of the DHEC closely but not completely mimicks 
conditional deletion of c-myc 
So far the hematopoietic phenotype upon DHEC deletion has only been compared 
to data of c-myc deletion published a decade ago (WILSON et al. 2004). However, we 
were interested to directly compare both phenotypes and also to specify the c-myc 
deletion phenotype in greater detail using additional cell markers to define the 
hematopoietic stem and progenitor cell compartment. c-myc deletion in hematopoietic 
cells was achieved by treatment of MxCre c-mycflox/flox mice with polyinosinic-
polycytidylic acid (poly(I:C)), hereafter termed c-myc∆Mx. c-mycflox/flox mice that did not 
have the Cre transgene served as control mice. Since this mouse strain was on a 
C57Bl/6 background, but the del(15-17) mice that were used for this part of the 
experiments were on a mixed background we used separate control mice (c-myc+/flox). 
All mice were treated identically with poly(I:C) in order to control for interferon-
mediated effects. Interferons have been shown to directly induce proliferation of HSCs 
(BALDRIDGE et al. 2010; ESSERS et al. 2009; SATO et al. 2009), thus to circumvent this 
transient effect we analyzed the mice 4 weeks after the first poly(I:C) injection. At this 
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time point c-myc∆Mx mice were reported to display already a clear phenotype (WILSON 
et al. 2004). Del(15-17) mice treated with poly(I:C) did not show any differences to 
PBS treated animals (data not shown) and untreated del(15-17) animals (chapter 3.5). 
Hence, in the following part the differences of c-myc∆Mx mice to control mice and to 
del(15-17) deleted mice will be highlighted. 
c-myc∆Mx mice displayed a reduced body size to 82% of that of control mice 
(Figure 3.19 A), which was already apparent before treatment of the mice (data not 
shown). As lowered c-myc levels result in reduced body size (TRUMPP et al. 2001), the 
observation of a lower body weight suggested either a leakiness of the transgene and/or 
interferon production in the mice that can be caused e.g. by stress. The former situation 
would cause an overall c-myc downregulation in all cells of the body, the latter only 
reduced c-myc levels in MxCre targeted cell types. Which of the two scenarios (or both) 
were valid could be easily addressed by determining gene expression by qRT-PCR and 
the status of genomic deletion by PCR, however we did not address this question so far 
as it was not in the scope of this experiment. 
To account for the reduced body size the number of BM cells was corrected for 
the body weight. Both deletions, deletion of c-myc and deletion of the del(15-17) 
region, resulted in a similar reduction of the BM cellularity (Figure 3.19 B). 
 
 
Figure 3.19: The BM cellularity is equally reduced upon c-myc and del(15-17) deletion 
Comparison of mice with MxCre driven c-myc deletion and mice with del(15-17) deletion 
compared to the respective control mice. A Body weight before poly(I:C) injections. B BM 
cellularity 4 weeks after 1st poly(I:C) injection. 
Data shown are mean (±SEM) values (n = 6-18). Statistical significance is indicated for the 
comparison between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and del(15-17); 
***p≤0.005; ****p≤0.001. 
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3.8.1 HSC and progenitor populations upon c-myc deletion and 
DHEC deletion 
Flow cytometric quantification of the stem and progenitor cell compartment 
revealed a similar increase in the number of LSK cells as a result of both deletions 
(Figure 3.20 A,B). Our analysis revealed that the HSC and MPP compartments in BM 
cells of c-myc∆Mx mice very closely resembled that of del(15-17) mice (Figure 3.13 and 
Figure 3.20). In both cases the number of the most primitive cells, the HSC and MPP1 
cells, were unchanged compared to control populations (Figure 3.20 A,D). This is a 
striking new observation since so far it was reported that c-myc deletion would lead to 
an increase in HSCs (GUO et al. 2009; WILSON et al. 2004). However, at that time 
HSCs were only defined as LSK CD135- cells, a population comprising HSCs, MPP1, 
MPP2 and MPP3 cells using a much better defining marker combination (CABEZAS-
WALLSCHEID et al. 2014; WILSON et al. 2008). Instead of a change in HSC numbers 
both deletions led to an increase in the multipotent progenitor populations 2-4. 
Analysis of the LS-K population that contains myeloid committed progenitor cells 
revealed a strong decrease upon c-myc deletion to only 6.7% of control levels. The 
del(15-17) progenitors instead showed only a reduction to 48.6% of control LS-K cells 
(Figure 3.20 A,C). Further refinement of this committed progenitor population 
demonstrated a general loss of CLPs, CMPs, GMPs, and in particular MEPs (Figure 
3.20 A,E) upon c-myc deletion. These results stand in contrast to data from GUO et al. 
(2009), where c-myc deletion was associated with preservation of MEP cell numbers. 
The only difference that could explain this discrepancy lies in the design of the 
experiment. GUO et al. used mice that were 3 weeks old when they started the 
induction, while in our experiment we used adult mice. The dose of GUO et al. was 5 
times as much as we used so one might consider a less effective deletion. However, 
efficiency of deletion was checked in Lin- cells by PCR and showed a clear deletion 
(Figure 3.20 F). 
Del(15-17) mice showed a similar decrease for CLP and GMP cell numbers 
whereas CMP cell numbers remained present to 59% of control levels and MEPs even 
to 79%. This represented a remarkable difference between mice deleted for c-myc and 
mice deleted for the DHEC. Most likely this difference is linked to the intermediate c-
myc levels detected in MEPs upon DHEC deletion (Figure 3.17 A). 
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Figure 3.20: The distribution of stem, multipotent progenitor and committed progenitor 
cells is equally affected by c-myc and del(15-17) deletion except for CMPs and MEPs 
A Representative flow cytometry profiles of BM cells stained for stem, multipotent progenitor 
and committed progenitor cells. B-E Quantitative and statistical analysis of numbers of (B) LSK 
cells, (C) LS-K cells, (D) stem and multipotent progenitor cells and (E) committed progenitor 
cells in the BM. F Genotyping by PCR of c-mycflox/flox and c-myc∆Mx Lin- cells. 
Data shown are mean (±SEM) values (n = 6-17; except for C,E: n = 4-8). Statistical significance 
is indicated for the comparison between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and 
del(15-17); *p≤0.05; **p≤0.01; ***p≤0.005; ****p≤0.001. 
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To elucidate the cycling behavior of the stem and progenitor cell compartment we 
performed a cell cycle analysis by Ki67/Hoechst33342 staining in these cells (Figure 
3.21). Firstly, cell cycle analysis revealed a clear difference in the cycling behavior 
between the control mice of each mouse strain. Control mice of del(15-17) displayed a 
slightly higher proportion of cells in the G0 phase of the cell cycle for all multipotent 
progenitor populations which was most prominent in MPP2 cells. Since mice were age 
and sex matched and the flox allele should not have an influence on c-myc expression 
this difference had to originate from the different backgrounds of these mice (C57Bl/6 
for c-myc deleted mice and mixed background for del(15-17) mice). 
 
Figure 3.21: The effect of c-myc and del(15-17) deletion on the cell cycle profiles of 
hematopoietic stem and progenitor cell populations 
Cell cycle analysis by Ki67/Hoechst33342 staining of stem and multipotent progenitor cell types 
of c-myc deleted and del(15-17) mice compared to the respective controls. A Representative 
flow cytometry profiles of cells gated for the indicated populations. B-F Quantitative analysis of 
the cell cycle in the indicated populations. 
Data shown are mean (±SEM) values (n = 6-15). 
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Compared to their respective control mice, a reduction of cells in the G0 phase 
could be observed in LSK cells for both deletions. However, it was less extensive for 
the DHEC deletion and was mostly attributed to the reduction of quiescent cells in 
MPP3 and MPP4 cells. In contrast c-myc deletion showed a greater reduction, which 
was propagated not only by MPP3 and MPP4, although these cells amount for more 
than 3 quarter of the LSK cell compartment (WILSON et al. 2008) and thus cover most 
differences in smaller populations. Analysis of the most primitive HSC and MPP1 cells 
revealed a strong reduction in the proportion of cells being in the G0 phase and a higher 
proportion of cycling cells. 
The previous observation of increased megakaryocyte numbers in del(8-17), 
del(15-17) and compound heterozygous mice and the hypothesis of a potential short cut 
between the HSC compartment towards the megakaryocytic lineage prompted us to 
investigate the levels of the megakaryocytic cell surface marker CD41 in stem and 
multipotent progenitor cells. Cell surface staining of control BM cells mice and 
subsequent analysis by flow cytometry revealed the presence of CD41 expressing cells 
only in cell populations also expressing CD150 (HSC, MPP1 and MPP2) whereas 
MPP3 and MPP4 showed only a very low mean fluorescence intensity (Figure 3.22). 
Upon deletion of either c-myc or del(15-17) CD41 expression dropped significantly in 
HSCs and MPP1 while it increases in MPP4. Thus, both deletions lead to a similar shift 
of the proportion of CD41 expressing cells along the hierarchy towards the late 
multipotent progenitor cell population. 
 
Figure 3.22: Expression of CD41 in HSCs and multipotent progenitor cells is changed 
upon deletion of c-myc and del(15-17) 
A-D Representative flow cytometry histograms of CD41 expression in (A) c-mycflox/flox mice, (B) 
c-myc∆Mx mice, (C) c-myc+/flox mice and (D) del(15-17) mice. E Quantitative and statistical 
analysis of the mean fluorescence intensity (geometric mean) of CD41 expression in stem and 
progenitor cells. Data shown are mean (±SEM) values (n = 2-4). Statistical significance is 
indicated; *p≤0.05; **p≤0.01; ***p≤0.005. 
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3.8.2 Distribution of mature effector cells upon c-myc deletion and 
DHEC deletion 
Flow cytometric analysis revealed similar tendencies between conditional c-myc 
deletion and del(15-17) deletion compared to the respective controls for most 
differentiated cell types (Figure 3.23). Both deletions led to a decrease in the number of 
granulocytes, while megakaryocyte numbers increased. Macrophages and T cell 
numbers remained unaltered when compared to the control mice. 
 
Figure 3.23: The distribution of differentiated cell types is equally affected by c-myc and 
del(15-17) deletion except for erythrocytes 
A Representative flow cytometry profiles of BM cells stained for differentiated cell types. B 
Quantitative and statistical analysis of numbers of differentiated cell types in the BM (B, B cells; 
T, T cells; RBC, red blood cells; Mgk, megakaryocytes). 
Data shown are mean (±SEM) values (n = 6-17). Statistical significance is indicated for the 
comparison between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and del(15-17); *p≤0.05; 
****p≤0.001. 
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Total B cell numbers were less affected by conditional c-myc deletion than by 
del(15-17) deletion. However, the intensity of B220 fluorescence allowed 
distinguishing between mature (B220high) and immature (B220intermediate) B lymphocytes. 
Among these two populations, only the number of immature B cells was strongly 
reduced and this reduction had the same extend as for del(15-17) mice. The number of 
mature B cells was however unchanged in c-myc∆Mx mice. This could be explained by 
the longevity of the mature B cells as only 4 weeks had passed since the induction of 
the deletion (FULCHER and BASTEN 1997). 
 
Figure 3.24: The effect of c-myc and del(15-17) deletion on the cell cycle profiles of B 
cells 
Cell cycle analysis by Ki67/Hoechst33342 staining of B cells of c-myc deleted and del(15-17) 
mice compared to the respective controls. A Representative flow cytometry profiles of cells 
gated for the indicated populations. B-D Quantitative and statistical analysis of the cell cycle 
status in (B) overall B cells, (C) mature B cells and (D) immature B cells. 
Data shown are mean (±SEM) values (n = 6-12). Statistical significance is indicated for the 
comparison in G0 between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and del(15-17); 
*p≤0.05; ***p≤0.005; ****p≤0.001. 
90% of mature B cells of c-myc∆Mx mice were in the G0 phase of the cell cycle 
thus have reached their quiescent state (Figure 3.24 B). This resting population was 
virtually absent in the BM of del(15-17) mice (Figure 3.23). Among all present B cells 
in del(15-17) mice a proportion of 37% was in G0 phase of the cell cycle. Thus, these 
cells are in a more proliferative state similar to immature B cells of control mice (Figure 
3.24 D). However, the percentage of cells in G0 was significantly increased for mature 
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B cells (and the almost depleted immature B cells) of c-myc∆Mx mice, reflecting the 
proliferative function of c-Myc. In summary, although c-myc deleted mice had a defect 
in generating new immature B cells, mature B cells were still present in the BM. Since 
the del(15-17) deletion was not conditional but straight, the failure in B cell generation 
was constantly present and thus more apparent in the overall cell number. 
The analysis of the erythrocyte population in the BM of c-myc deleted mice 
revealed a decrease of the cell number to only 16% of the same population in control 
mice (Figure 3.23 B). As it can be seen from the representative flow cytometry profiles 
(Figure 3.23 A, second panel) all subpopulations within the Ter119+ population 
identified based on CD71 expression and cell size (FSC) were affected by this reduction 
in cell number, however the more immature cells (CD71+) showed the greatest effect. In 
contrast del(15-17) erythrocyte numbers were barely changed. This lack in changes in 
erythrocyte numbers was already apparent as del(15-17) mice did not show signs of 
anemia like pale feet as reported in animals with a complete deletion of c-myc in 
hematopoietic cells (GUO et al. 2009; WILSON et al. 2004). 
3.8.3 Erythrocytes are differentially affected in the peripheral blood 
upon c-myc or DHEC deletion 
The BM is the primary site of hematopoiesis in adult mice, generating billions of 
cells that enter the blood stream for circulation. Analysis of the peripheral blood of mice 
with either c-myc deletion or del(15-17) deletion showed a similar decrease in the white 
blood cell count to about half of the cell numbers in blood from control animals (Figure 
3.25 A). Both deletions led to increased platelet counts, which was more dramatic in c-
myc∆Mx mice than in del(15-17) mice. This thrombocytosis was accompanied by a 
significantly enlarged platelet size as it has been reported by GUO et al. (2009) for c-
myc deletion (Figure 3.25 B,C). 
The red blood cell count confirmed the reported anemia in c-myc∆Mx mice as it 
was dramatically decreased, leading to a watery appearance of the blood. This went 
along with an equally reduced hematocrit (volume of red blood cells relative to blood 
volume) and hemoglobin concentration (Figure 3.25 D-E). In contrast the blood of 
del(15-17) had a normal red appearance, however red blood cell counts and the 
hemoglobin concentration in blood of del(15-17) mice were also reduced but to a lesser 
extent than for c-myc∆Mx mice. Notably, the hematocrit showed only a slight, non-
significant reduction. In combination with the more reduced cell count this pointed 
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towards an increased volume of red blood cells (judged by the extent of fold changes in 
Figure 3.25 D,E). 
 
Figure 3.25: Peripheral blood analysis by an automated cell count reveals differences in 
the erythrocyte phenotype upon c-myc or del(15-17) deletion 
Quantitative and statistical analysis of peripheral blood properties from c-myc∆Mx and del(15-17) 
mice compared to the respective control mice determined by the automated Hemavet counter. 
A White blood cell count. B Platelet count (3 out of 16 values were above the detection limit of 
4000 and therefore counted as 4000). C Mean platelet volume. D Red blood cell count. E 
Hematocrit. F Hemoglobin concentration. 
Data shown are mean (±SEM) values (n = 6-18). Statistical significance is indicated for the 
comparison between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and del(15-17); *p≤0.05; 
****p≤0.001. 
This observation led us to analyze the morphological appearance of erythrocytes 
and platelets in both mouse strains by peripheral blood smears stained with May-
Grünwald/Giemsa. In this staining nuclei, granules of basophil granulocytes, granules 
of platelets and RNA molecules in the cytoplasm are stained by basic dyes, thus 
appearing purple, while red blood cells and granules of eosinophil granulocytes are 
stained by eosin and appear red. Besides of the apparent anemia deletion of c-myc 
promoted an aberrant red blood cell morphology. Erythrocytes were pale in color and 
contained a large, central pallor due to insufficient hemoglobin content. Additionally a 
higher number of large erythrocytes with a light blue staining appeared (Figure 3.26, 
green arrow heads) which are termed polychromatic erythrocytes. 
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Figure 3.26: Peripheral blood smears show anemia in c-myc∆Mx mice which is not 
apparent in del(15-17) mice 
A-D 20x and E-H 63x magnification of peripheral blood smears with May-Grünwald/Giemsa 
staining from (A,D) c-mycflox/flox mice, (B,E) c-myc∆Mx mice, (C,F) c-myc+/flox mice and (D,G) 
del(15-17) mice. Coloured arrow heads point at the following cell types: black=lymphocyte; 
purple=neutrophil; orange=platelet; red=erythrocyte; green=polychromatic erythrocyte. 
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Polychromatic cells are immature and recently released from the BM, which occurs e.g. 
in response to acute blood loss, hypoxia, or red blood cell destruction. Thus, their 
occurrence was in agreement with the strong anemia found in these mice. Furthermore, 
the erythrocytes showed a striking variation in cell size (Figure 3.26 B,F) which was 
quantified by measuring the cell perimeter (Figure 3.27 A). The median perimeter 
decreased significantly from 17.7 µm to 16.0 µm and the cell size showed a strong 
variability (quantified in (Figure 3.27 B). 
In contrast to the erythrocytes of c-myc∆Mx mice the morphological appearance of 
erythrocytes of del(15-17) mice was not dramatically changed. The perimeter of del(15-
17) erythrocytes showed a normal distribution width, however with an increased median 
perimeter (18.4 µm compared to 17.6 µm). At the same time these cells did not display 
hypochromasia. Instead, the hemoglobin content was in a normal range according to the 
increased cell size. Thus these observations confirmed the results of the automated cell 
counter (Figure 3.25). In addition no apparent increase in polychromatic cells was 
detectable. 
The peripheral blood smears additionally confirmed the thrombocytopenia for both 
deletions (Figure 3.26 B,F,D,H). Increased numbers of platelets were detecable, which 
sometimes formed aggregates (exemplary in Figure 3.26 H, orange arrow head). 
 
Figure 3.27: The size of erythrocytes in c-myc∆Mx mice is decreased and shows a higher 
variability 
Quantitative and statistical analysis of erythrocytes in peripheral blood smears (20x 
magnification) from c-myc∆Mx and del(15-17) mice compared to the respective control mice. A 
Cell size quantified by the perimeter. Data are represented as scatter dot plot with the median 
values and range (n = 8165-10926 from 4-5 images analyzed). B Variability in cell size. Data 
shown are the mean (±SEM) values (n = 4-5 images). 
Statistical significance is indicated for the comparison between c-mycflox/flox and c-myc∆Mx and 
between c-myc+/flox and del(15-17); ***p≤0.005; ****p≤0.001. 
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Analysis of erythroid progenitor populations in the BM revealed that the most 
immature proerythroblast population (EB) is slightly but significantly increased upon c-
myc deletion (Figure 3.28). Similar results were shown by GUO et al. (2009). The 
successive populations EryA, B and C mark progressive steps of erythroblast 
maturation (KOULNIS et al. 2011). These populations were strongly affected by c-Myc 
deficiency, with most impact on the first two populations. Erythroblast cell numbers of 
DHEC deleted mice however were not significantly changed at all levels, showing only 
a slight decrease for EryA cells. Thus c-Myc deficiency led to loss of erythroblast 
populations in the BM which was not detectable for DHEC deletion. 
 
 
Figure 3.28: BM erythroid progenitor numbers are decreased upon c-myc deletion 
A Representative flow cytometry profiles of BM cells stained for erythroblast populations, gated 
on Ter119+ cells. EryA cells are gated for CD71+ cells with high FSC, EryB cells are gated for 
CD71+ cells with low FSC and EryC cells are gated for CD71- cells with low FSC. B Quantitative 
and statistical analysis of numbers of (pro-)erythroblasts in the BM (EB, proerythroblasts; 
EryA/B/C, erythroblast progenitors). 
Data shown are mean (±SEM) values (n = 6-17). Statistical significance is indicated for the 
comparison between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and del(15-17); *p≤0.05; 
****p≤0.001. 
In summary deletion of c-myc promoted a strong anemia with anisocytosis, 
hypochromasia and polychromatosia of peripheral erythrocytes, whereas deletion of the 
DHEC caused mild anemia with a normochromatic macrocytosis. Both deletions 
however involved a strong thrombocytosis. 
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3.8.4 T cell development is impaired upon c-myc deletion but not 
upon DHEC deletion 
In normal hematopoiesis lymphoid progenitors originating from the BM migrate 
to the thymus, the site of T cell development and maturation. At this site T cell 
progenitor cells lack CD4 and CD8 expression and are referred to as double negative 
(DN) cells. Among these cells four early differentiation stages (DN1-4) have been 
defined based on the expression of the cell surface molecules CD25 and CD44. DN4 
cells differentiate further to the double positive stage (DP; CD4+CD8+), the last stage 
before final maturation to the CD4+ or CD8+ single positive (SP) cells. These cells leave 
the thymus and enter the peripheral circulation (PETRIE 2003). 
The number of T cells were not changed neither in the BM of c-myc∆Mx nor of 
del(15-17) mice (Figure 3.23). However, a previous study reported a strong decrease in 
the cellularity of the thymus at 8 weeks after induction of c-myc deletion (WILSON et al. 
2004). Thus, the normal T cell counts might be based on remaining long-lived T cells 
after induction of c-myc deletion (similar to the long-lived B cells, Figure 3.24). 
Therefore we analyzed the developmental stages of T cells in the thymuses of mice 
upon c-myc and upon del(15-17) deletion. 
4 weeks after induction of c-myc deletion the cellularity of the thymus dropped 
dramatically (Figure 3.29 A). Furthermore, among the remaining thymic cells the 
CD4+/CD8+ DP population was virtually absent (Figure 3.29 B,C). Gating on the DN 
population revealed that basically only DN CD44- CD25- cells (DN4) remained (Figure 
3.29 B,D). However, these could be also non-hematopoietic cells, e.g. epithelial cells, 
since these cells were only defined by negativity for the indicated cell surface 
molecules. Thus indeed the remaining mature T cells, that have been generated before 
the induction of c-myc deletion, accounted for the normal T cell counts in the BM as c-
myc deletion impairs further T cell development. 
In contrast del(15-17) mice displayed a normal thymus cellularity and normal T 
cell frequencies except for a slight, but significant increase in the overall DN population 
size that was due to an increase in DN3 cells. The change in numbers of this T cell 
progenitor cell type did not result in changes of mature T cells, neither in the thymus 
nor the BM. 
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Figure 3.29: T cell development is impaired upon conditional c-myc deletion but not 
del(15-17) deletion 
Comparison of mice with MxCre driven c-myc deletion and mice with del(15-17) deletion 
compared to the respective control mice. A Thymus cellularity 4 weeks after 1st poly(I:C) 
injection. B Representative flow cytometry profiles of thymic cells stained for thymocytes. C 
Quantitative and statistical analysis of numbers of developing and mature T cells in the thymus 
(SP CD4=single positive CD4+ CD8- cells; SP CD8=single positive CD8+ CD4- cells); 
DN=double negative (CD4- CD8-) cells; DP=double positive (CD4+ CD8+) cells; C Quantitative 
and statistical analysis of numbers of developing T cells in the thymus gated on the CD4- CD8- 
double negative population (DN1= CD44+ CD25-; DN2= CD44+ CD25+; DN3= CD44- CD25+; 
DN4= CD44- CD25-). 
Data shown are mean (±SEM) values (n = 5-8). Statistical significance is indicated for the 
comparison between c-mycflox/flox and c-myc∆Mx and between c-myc+/flox and del(15-17); *p≤0.05; 
**p≤0.01; ***p≤0.005; ****p≤0.001. 
In summary deletion of c-myc has a strong effect on basically all mature effector 
cells, leading to life-threatening pancytopenia and thrombocytosis. Differentiated cell 
types in del(15-17) were similarly affected except for only a mild effect on erythrocytes 
and T cells. This was coherent with the rather mild decrease of c-myc expression upon 
deletion of the DHEC in MEPs (Figure 3.17). Altogether, these data indicate that the 
DHEC is active and contributes to c-myc expression in the erythrocyte-megakaryocyte 
lineage, but that one or several additional enhancers, located elsewhere in the locus, can 
maintain c-myc expression in these cells independently of the DHEC. T cell 
development is not impaired upon DHEC deletion and numbers of mature cells and c-
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myc expression within these cells are similar to controls, thus suggesting that c-myc 
expression in T cells is completely driven by other enhancer(s) outside the DHEC. 
3.9 The DHEC region consists of individual modules 
The DHEC, identified by histone marks in hematopoietic tissues (Figure 3.12), 
spans across a 126 kb region and is almost entirely covered by the del(15-17) region, 
which covers a sequence of 259 kb. A closer look at the DHEC revealed the presence of 
multiple sites that are evolutionary conserved as it is visualized in Figure 3.30 (bottom 
panel: Genomic Evolutionary Rate Profiling (GERP), (COOPER et al. 2005)). This 
indicates an enrichment for functional elements at these conserved sites. Interestingly, 
some of these conserved regions correspond to clusters of hematopoietic transcription 
factor binding sites, defined by ChIP-seq in a hematopoietic progenitor cell line (HPC-
7; Figure 3.30) (HANNAH et al. 2011; WILSON et al. 2010). 
 
 
Figure 3.30: The enhancer region consists of individual modules 
Enlarged view on the genomic region of the DHEC in the c-myc/Pvt1 flanking locus. Top lines 
show H3K27 acetylation in BM and BM derived macrophages (BMDM), obtained from SHEN et 
al. (2012). Middle lines show ChIP-seq profiles of transcription factor occupancy performed in 
HPC-7 cells, obtained from Wilson et al. (2010). The bottom line shows the Genomic 
Evolutionary Rate Profiling (GERP) (COOPER et al. 2005). Location of individual modules within 
the DHEC are highlighted and termed with the indicated letters. 
To get further insight into the involvement of the different modules that compose the 
DHEC, we sought to examine the enrichment of the H3K27ac enhancer mark over the 
different modules in different cell types (Figure 3.31). For this experiment we sorted 
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LSK cells, granulocytes, macrophages and B cells from wild type mice and subjected 
them to chromatin immunoprecipitation using an H3K27ac antibody and subsequent 
qRT-PCR. As controls served three independent loci of non enriched regions (according 
to several datasets from ENCODE) at other chromosomes and a locus located within the 
del(15-17) region but outside the DHEC (OUT). The locations of the different modules 
(A-G) as well as some interjacent locations (AB, EF, FG) are indicated in Figure 3.30. 
We found that the extent of H3K27ac enrichment varied greatly depending of the 
cell type: in LSK cells modules D and G were particularly prominent whereas in 
granulocytes modules A, B, C and G showed high enrichment. Macrophages instead 
showed high enrichment for module G only, while B cells completely lacked any 
enrichment for the enhancer mark. Thus these data indicate that the activity of the 
DHEC is dependent on individual modules within the cluster and that the activity in 
individual cell types is driven by distinct modules. 
 
 
Figure 3.31: Relative enrichment for H3K27ac in the individual modules 
Indicated cell types were sorted from wild type mice and subjected to ChIP using an H3K27ac 
antibody. Enrichment was measured by qRT-PCR for the in Figure 3.30 indicated positions 
compared to the input material and normalized to average negative control enrichment. A LSK 
cells, B granulocytes, C macrophages, D B cells. 
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3.10 The DHEC region is highly conserved in humans and 
implicated in leukemia 
The human c-MYC locus is highly syntenic to the mouse orthologous region 
(Figure 1.8). The different modules composing the DHEC are also highly conserved in 
sequence, their locations on the human chromosome 8 are depicted in Figure 3.32. Most 
modules overlap with high enrichment for the enhancer-associated chromatin 
modifications H3K4 monomethylation and H3K27 acetylation in mobilized CD34+ 
HSCs from healthy donors while H3K4 trimethylation is not enriched (BERNSTEIN et al. 
2010). Furthermore, these modules display DNase hypersensitivity, a feature of active 
cis-regulatory sequences (BIRNEY et al. 2007; BOYLE et al. 2008; CRAWFORD et al. 
2006a; CRAWFORD et al. 2006b; SABO et al. 2004a; SABO et al. 2004b; XI et al. 2007). 
Thus, the enhancer region is highly conserved in humans and exhibits enhancer features 
in human HSCs. 
 
Figure 3.32: Evidence for the presence of a HSC specific enhancer cluster in the human 
c-myc/Pvt1 flanking locus 
The positions of the sequences equivalent to the DHEC modules are depicted for the human 
chromosome 8. Chromatin modifications (H3K4me1, H3K27ac, H3K4me3) and DNase 
hypersensitivity sites in mobilized CD34+ hematopoietic stem cells (MCD34) from two healthy 
donors were obtained from the NIH Roadmap Epigenomics Mapping Consortium (BERNSTEIN et 
al. 2010). 
Genome-wide association studies (GWAS) have identified thousands of single-
nucleotide polymorphisms (SNPs) that are linked to human diseases. Many variations 
are located in non-coding regions, thus the evaluation of their direct function is 
complicated. 40% of GWAS SNPs are located in DNase hypersensitivity sites thus 
pointing towards a prevalent location of these disease- and trait associated variants in 
regulatory elements (MAURANO et al. 2012). 
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Five common SNPs are present within the human DHEC region that have been 
associated with human diseases (Figure 3.33). Two of them (rs10098310 and 
rs10956483) refer to hematopoiesis as they reflect changes in monocyte counts (NALLS 
et al. 2011; OKADA et al. 2011). These two GWAS SNPs do not directly overlap with 
any of the modules. However, visual examination of haplotype maps (HapMaps) for 
two populations (CEU=Utah residents of northern and western European ancestry; 
JPT+CHB=Japanese individuals from Tokyo, Japan and Han Chinese individuals from 
Beijing, China) revealed the presence of two blocks (highlighted in yellow and purple) 
spanning the DHEC, which are enriched for high linkage disequilibrium (LD) values 
(Figure 3.33, dark red marks high LD). Thus the two hematopoiesis related SNPs are 
very likely to be linked to their neighbouring areas containing the conserved DHEC 
modules. 
 
Figure 3.33: Implication of the DHEC in human diseases 
The genomic coordinates on chromosome 8 (hg18) are shown at the top and the location of five 
GWAS SNPs with the affected traits is indicated in green. The pattern of linkage disequilibrium 
(LD) in the HapMap of CEU and JPT+CHB populations (HapMap release 22) reveals blocks 
(highlighted in yellow and purple) with high LD. Blue bars indicate the areas found to be focally 
amplified in AML patients (KUHN et al. 2012; RADTKE et al. 2009). The dashed box marks the 
common region. 
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Another more direct link to human disease appeared due to the recurrent 
observation of focal amplifications overlapping the DHEC region in acute myeloid 
leukemia (KUHN et al. 2012; RADTKE et al. 2009). As it is represented in Figure 3.33 
the common region that is focally amplified in these patients encompasses the modules 
C to F, attributing the core function of the enhancer to this area. 
c-MYC expression is found to be elevated in several cancers (DANG 2012; MEYER 
and PENN 2008). Its expression levels in AML however were contrarily reported. A first 
microarray based study on AML samples reported elevated levels (COURT et al. 2004), 
which was supported by further qRT-PCR experiments obtained in an independent 
study (SALVATORI et al. 2011). However, in other studies c-MYC was not detected as 
one of the highly overexpressed genes (ROSS et al. 2004; STIREWALT et al. 2008; VALK 
et al. 2004). 
Since we had access to primary AML samples we sought to determine c-MYC 
expression by qRT-PCR (Figure 3.34). The levels are represented relative to c-MYC 
expression in cord blood (CB) samples. The analysis revealed a high diversity of c-MYC 
expression ranging from very low (light green) and normal (dark green) over modestly 
elevated levels (light red) to samples with more than 5-fold increased c-MYC levels 
(dark red). The underlying karyotype and mutational analysis for each patient sample 
did not reveal a general correlation between cytogenetic aberrations and the c-MYC 
expression pattern (Dr. Simon Raffel, personal communication). 
The analysis of the DHEC region in high expressing compared to low expressing 
samples in respect to enhancer marks could provide a direct link between the enhancer 
region, c-MYC expression and leukemia. This will be addressed in future experiments. 
 
Figure 3.34: c-MYC expression levels in primary samples of AML 
c-myc expression levels in primary samples of AML relative to levels in cord blood (CB, grey). 
Red bars highlight samples with 5 to 10-fold levels, light red bars samples with 1.3 to 5-fold 
levels, green bars samples with 0.7 to 1.3-fold levels and light green bars 0 to 0.7-fold levels. 
Data shown are mean values (with range). 
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For some enhancers it was shown that germline duplications can lead to 
malformations affecting the organ where they are active (DATHE et al. 2009; LOHAN et 
al. 2014). Similarly, it is possible that somatic duplications of the DHEC can constitute 
an alternative way to up- or misregulate c-MYC expression in a tissue-specific manner. 
A first attempt to test this hypothesis in the murine system was done by analyzing mice 
carrying a duplication of the enhancer region (Figure 3.35 A). However, neither mice 
carrying 3 nor 4 copies of the DHEC did display gross alterations in hematopoietic cell 
frequencies (Figure 3.35 B-D). Thus, a variation in the copy number of the DHEC did 
not manifest in a hematopoietic phenotype in these mice. 
 
Figure 3.35: Murine duplication of the DHEC or a 3 Mb large region encompassing c-myc 
and the DHEC does not change cell frequencies 
A Locations of the transposon insertions used to generate mice with duplications of the 
interjacent sequence. B,E Number of BM cells in (B) young dup15-17) mice (10 days old) and 
(E) adult dup(c17-17) mice. B,C,F,G Quantification of major hematopoietic cell types in (C,D) 
dup(15-17) mice and (F,G) dup(c17-17) mice. H,I mRNA expression of c-myc (H) and Ddef1 (I) 
by hematopoietic stem and progenitor cells was measured by qRT-PCR in wild type, 
heterozygous and homozygous dup(c17-17) mice. 
Data shown are mean (±SEM) values (n = 1-4 for dup(15-17) and n = 2-4 for dup(c17-17)). 
RESULTS 
 
 87
Besides we also tested mice having the whole c-myc locus duplicated, spanning a 
3.4 Mb region encompassing Fam84b, A1bg, c-myc, Pvt1 and the DHEC. Also in these 
mice we did not detect significant differences in cell frequencies in the BM (Figure 
3.35 E-F). However, analysis of gene expression levels revealed an increase in c-myc 
expression in multipotent progenitors (LSK CD150-CD48+) according to the copy 
number while the HSC and MPP1 population (LSK CD150+CD48-) showed no change 
in expression. As expected Ddef1 expression was unaltered as this gene was located 
outside of the duplicated region. These results suggest another layer of transcriptional 
regulation of c-myc in hematopoietic stem and early progenitor cells. 
In summary, the DHEC is highly conserved from mice to humans and mobilized 
human HSCs display similar enhancer-associated chromatin marks as murine 
hematopoietic cells. Furthermore, the human DHEC is linked to changes in white blood 
cell counts and AML, thus underscoring a function in human hematopoietic diseases. c-
MYC is differentially expressed in primary AML samples, however a direct association 
between the DHEC and c-MYC in humans needs to be proven. 
 
 4 DISCUSSION 
4.1 c-Myc expression in hematopoietic cells is regulated by a 
distal enhancer cluster 
Hundreds of studies have been carried out to dissect the c-myc promoter region to 
identify the trans-acting factors and molecular mechanisms that may regulate its 
expression (reviewed in (WIERSTRA and ALVES 2008)). However, as the c-myc 
promoter proximal region does not recapitulate its expression and regulation in vivo 
(LAVENU et al. 1994; MAUTNER et al. 1996), regulatory elements have to be located 
outside the 50 kb region surrounding the c-myc gene. Our results demonstrate that in 
vivo, c-myc expression in HSPCs depends critically on the activity provided by a very 
remote enhancer region, located almost 1.7 Mb away from the promoter region. 
Importantly, our analysis of compound alleles showed that the regulatory interaction 
between c-myc and the DHEC are taking place in cis. Homozygous deletion of the 
DHEC critically affected almost all hematopoietic cell types in the BM. Specifically, it 
led to an increase in stem and progenitor cells and megakaryocytes accompanied by a 
decrease in myeloid and B cells. 
This phenotype was already apparent in del(8-17) mice where the deletion 
encompassed in addition to the DHEC a large part located centromerically to this 
cluster. These mice showed a more dramatic phenotype as the homozygous deletion 
was perinatal lethal with only few surviving mice. For this reason we analyzed these 
mice 10 days after birth. The cell cycle status of HSCs in the BM of del(8-17) mice was 
dramatically changed, having less cells in G0 and more in G1. In accordance to the 
decreased body size this observation resembled a developmental retardation. In fact 
fetal HSCs in the mouse liver are actively cycling thereby satisfying the demand of 
expansion of the HSC pool during this developmental phase. Only after transition to the 
DISCUSSION 
 
 89
BM HSCs enter a quiescent state (BOWIE et al. 2007; BOWIE et al. 2006). Analysis of 
the stem and progenitor compartment in the fetal liver at E15.5 showed that regulation 
by the enhancer is already occuring at a very early phase of hematopoiesis, thus it seems 
not to be temporarily restricted. It is possible that this kind of retardation is dependent 
on an increased retention of HSCs in the fetal liver as it was shown for c-Myc 
deficiency in adult HSCs and the BM niche. In this situation adhesion molecules were 
upregulated that are thought to attach the cells more tightly to cells of the surrounding 
niche (WILSON et al. 2004). 
As shown by our collaborators the del(8-17) region possesses enhancer activity 
regulating c-myc in the developing face (USLU et al. 2014). Similarly c-myc expression 
was dramatically downregulated in stem and progenitor cells (LSK), however the 
myeloid committed cells (LS-K) showed 85% c-myc expression on the mRNA level 
(Figure 3.7). c-myc expression in other tissues such as fetal heart and liver at E11.5 was 
not affected (USLU et al. 2014). At this stage, hematopoiesis is just starting to colonize 
the fetal liver, therefore a decrease in c-myc expression is not expected (KUMARAVELU 
et al. 2002; MEDVINSKY and DZIERZAK 1996; MÜLLER et al. 1994). Even at later stages, 
a decreased c-myc expression due to hematopoietic cells would not have become 
apparent in the whole organ as normal c-myc expression in the non-hematopoietic cells 
(e.g. at E15.5 > 95%; Figure 3.6) would have covered it. Overall these results showed 
that the enhancers in the del(8-17) region are acting only in specific tissues. Moreover, 
they suggest a cell-type specific regulation, showing specificity for the stem and 
progenitor cell compartment. Later, the extended analysis of c-myc expression in 
multiple hematopoietic cell types in compound heterozygous mice confirmed that all 
cells of the stem and progenitor compartment were affected by the DHEC deletion 
(Figure 3.17). However, most other cell types, including restricted progenitors as well 
as differentiated cell types were similarly affected. The only exceptions were MEPs 
with partial decrease in c-myc expression and T cells with normal c-myc expression 
levels (see also chapter 4.2), thus the observed partially retained c-myc expression in 
del(8-17) myeloid committed progenitor cell population was most probably due to c-
myc expression in MEPs. 
The genomic integration of the reporter gene enabled us to measure the activity of 
nearby enhancers. Several other methods are generally used to analyze the regulatory 
potential of a candidate sequence. These include classical reporter-gene assays carried 
out by cloning the respective sequence next to an easily accessible reporter gene such as 
green fluorescent protein (GFP), luciferase or  β-galactosidase (LacZ). Activity is then 
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measured in transiently or stably transfected cultured cells. Most importantly the choice 
of a representative cell line is necessary to be able to draw conclusions about the tissue-
specificity of the enhancer sequence. Still, cell lines are transcriptionally very different 
from their original tissues, thus this method has major limitations. Another possibility is 
to inject reporter constructs into embryos, which then allows following of the gene 
expression throughout development (PENNACCHIO et al. 2006). However, the in vivo 
activity might still not reflect the endogenous expression due to differences in the 
chromatin structure (MASTON et al. 2006). Furthermore, the cloned construct only 
allows the isolated view on the selected sequence but does not take into account 
cooperative activity with other regulatory sequences and not the respective distance 
between enhancer and target promoter. Usage of bacterial artifical chromosomes 
(BACs) to generate transgenic animals circumvented these latter limitations since this 
assay measures enhancer activity in its native position to the target promoter (VAN 
KEUREN et al. 2009). However, distance is limited to the maximum size (~500 kb) that 
can be cloned into the BAC, which is not sufficient for large, complex landscapes. 
Therefore the generation of transgenic mice with genomic integration of the reporter 
construct overcomes those limitations mentioned above and provides an integrated and 
non-gene-centric view of cis-regulatory activity (RUF et al. 2011). 
LacZ activity of insertions tested across the c-myc/Pvt1 flanking locus revealed 
that enhancer activity was present in hematopoietic stem, progenitor and committed 
progenitor cells, but almost absent in differentiated cells. Importantly, this assay 
restricted enhancer activity towards the telomeric end of the c-myc/Pvt1 flanking locus. 
This is in contrast to the facial enhancer function which spreads much further to the 
telomeric side (USLU et al. 2014). The restriction towards the telomeric side became 
also apparent by RNA-seq results of cells from the medial faces of del(8–17) 
homozygous embryos (USLU et al. 2014). This analysis showed downregulation of 
several hematopoietic-related genes that arose from cells in small blood vessels in the 
dissected tissue. However, this observation was only made for the del(8-17) deletion but 
not the del(8-14) deletion, suggesting that the blood phenotype is mediated by an 
enhancer region in the latter region. Overall enhancer activity detected from the 17a 
insertion correlated well with c-myc expression detected by qRT-PCR. Although 
deletion of the several tested regions retained the reporter gene at the breakpoint, no 
lacZ expression could be detected in any tested cell type. This implicates that no 
regulatory input is acting on the reporter gene promoter, which means in turn that the 
regulatory input acting on 17a has been deleted by the minimum deletion of del(15-17). 
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Combined analysis of this enhancer activity assay and publicly available chromatin 
modifications as well as 3D organizational studies allowed the localization of a cluster 
of enhancer peaks in hematopoietic tissues that we termed DHEC (distal hematopoietic 
enhancer cluster). 
We carried out a series of experiments with DHEC deleted mice to define the 
function of the DHEC. In contrast to the del(8-17) deletion del(15-17) deletion was not 
lethal. Instead, mice appeared with normal body size and no apparent defect. However, 
in the hematopoietic system these mice displayed with an accumulation of stem and 
progenitor cells (LSK) and a disturbed pattern within the differentiated lineages. Thus 
they closely resembled the phenotype of the MxCre mediated conditionally deleted c-
myc mice which we proved by direct side-by-side comparison. Most important was the 
observation that compound heterozygous mice do exhibit the same phenotype as mice 
with DHEC deletion alone. This experiment nicely demonstrated genetic allelism 
between the c-myc knockout and the enhancer deletion alleles, thus providing genetic 
evidence for the hypothesis that the c-myc downregulation is a direct consequence of 
the DHEC deletion and not mediated by an indirect mechanism. Furthermore, this 
experiment proved the function of the enhancer in cis as expression could not be driven 
from the intact c-myc gene despite the presence of the intact enhancer region on the 
other chromosome. 
An observation that was apparent throughout all experiments in DHEC and c-myc 
deleted mice was the accumulation of CD48+ multipotent progenitor cells whereas HSC 
and MPP1 numbers remained unchanged. This is in contrast to the previous assumption 
that c-Myc deficiency leads to the accumulation of the most potent hematopoietic cells, 
the HSCs (GUO et al. 2009; WILSON et al. 2004). This former observation was based on 
a limited marker combination for the identification of HSCs. Reevaluation of the results 
confirmed that previous definition of HSCs as LSK CD135- (Flk2-/Flt3R-) cells 
comprises the populations HSC, MPP1, MPP2 and MPP3. Since MPP3 account for the 
largest amount of cells within the LSK CD135- population the drawn conclusion of an 
HSC accumulation was instead an increase in multipotent progenitor cells. 
Previous analysis of the cell cycle, proliferation and apoptosis revealed that there 
was no difference in c-myc deleted LSK cells, thus the accumulation of these cells was 
thought not to occur due to increased proliferation or survival (WILSON et al. 2004). Our 
results comparing the cell cycle of c-myc deleted and del(15-17) deleted stem and 
progenitor cells to cells of the respective control mice at 4 weeks after poly(I:C) 
induction showed a different cell cycle profile (Figure 3.24). Although these data 
DISCUSSION 
 
 92
showed a higher proliferation for c-myc deleted HSCs and MPP1 cells these cells did 
not accumulate in the BM. Moreover c-Myc deficient mice showed a similar 
distribution in the stem and multipotent progenitor compartment as del(15-17) mice, 
which did not show increased proliferation in the HSC and MPP1 population. This 
stronger cycling behavior might be a feedback mechanism to the more severe loss of 
committed progenitors (Figure 3.20 E) and mature effector cells (chapter 3.8.2). Further 
experiments such as BrdU incorporation assays and terminal deoxynucleotide 
transferase dUTP nick end labeling (TUNEL) assays will help to discriminate between 
apoptosis and self-renewal changes in these more defined cell populations. 
Transplantation experiments of both del(8-17) and del(15-17) BM cells revealed 
reconstitution in the HSC compartment but hardly any contribution to differentiated 
cells in the periphery (Figure 3.8 and Figure 3.14). This phenotype closely resembled 
the published transplantation effect of c-myc deleted HSCs, however del(15-17) HSCs 
did not accumulate as dramatically as reported for c-Myc deficient HSCs (WILSON et al. 
2004). Strikingly, donor derived cells showed a different distribution of hematopoietic 
cells in reconstituted mice compared to homeostatic del(15-17) mice, as the most 
primitive HSCs accumulated most with a concomitant decrease along the hierarchy. 
This in turn means that in the transplantation setting, deletion of the DHEC did not 
result in an increase in multipotent progenitor populations. Also, transplanted del(15-
17) HSCs did not contribute to T cells or megakaryocytes although they were able to 
give rise to these cell types in del(15-17) mice. This difference may be due to the stress 
situation that occurs in the transplantation setting or may be caused by differences of 
Myc requirement for lineage differentiation in fetal and adult HSCs (mutant adult HSCs 
were transplanted but the enhancer deletion was present already during ontogeny in the 
mutant mice). Another possibility is that DHEC deletion leads in addition to 
hematopoietic changes also to changes in the BM niche that promotes the phenotype 
observed under homeostatic conditions. Upon transplantation this niche-dependent 
effect would be missing and could contribute to the described phenotype. We do not 
have any further evidence for a function of the DHEC in niche cells yet, but this will be 
investigated in future experiments for example by reverse chimera analysis. Notably, 
macrophages, T cells and megakaryocytes were at least reconstituted by del(15-17) 
HSCs in a range from 3 to 6.6% of total BM chimerism, while the other del(15-17) HSC 
derived mature effector cells were virtually absent (<1%). Since these transplantations 
were performed in a competitive setting, the differentiation potential towards these 
lineages might be covered by efficient hematopoiesis derived from competitor HSCs. 
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To investigate this further, three types of transplantations could be set up. Straight 
transplantation of del(15-17) BM into lethally irradiated recipient mice would 
circumvent the influence of competitor BM. This transplantation might lead to early 
lethality as observed in transplantation of c-myc deleted BM (WILSON et al. 2004). 
Furthermore, we would not be able to easily discriminate the origin of long-lived cells 
such as T cells, if they are either transplanted or newly derived from engrafted HSCs. 
Therefore as an alternative we would sort LSK cells and transplant them along with 
Sca-1 depleted competitor BM. The latter population ensures quick generation of 
effector cells for a limited in time. Meanwhile engrafted del(15-17) LSK cells have the 
possibility to re-establish the blood system and lack competition long-term. Third, we 
could generate del(15-17) compound heterozyogus mice carrying a floxed c-myc allele 
together with the MxCre transgene. After transplantation and establishment of a stable 
hematopoietic system by the donor HSCs, deletion of the floxed c-myc allele allows the 
evaluation of del(15-17) derived cells in blood and BM. In a similar experiment, GUO et 
al. (2009) showed that the thrombocytosis phenotype upon c-Myc deficiency is an HSC 
cell-intrinsic defect. It will be interesting to see if this holds true for deletion of the 
DHEC and especially the formation of other cells such as macrophages, T cells and red 
blood cells. 
In summary, DHEC deletion generally resembled c-Myc deficiency, but in some 
instances it manifested to a slightly milder extend. This could likely be due to residual 
c-myc expression at a very low level. 
4.2 Deletion of the enhancer affects some hematopoietic cell 
types differently than conditional c-myc deletion 
Our experiments demonstrate that DHEC has a primordial role in controlling c-
myc expression in most hematopoietic lineages, most prominently in HSCs and MPPs. 
Its regulatory input is particularly essential for the formation of granulocytes and B 
lymphocytes, which recalls the phenotype of MxCre driven c-myc deletion. However, 
not all hematopoietic cell types were similarly affected by deletion of the DHEC, which 
will be discussed in this chapter. 
On the protein level immature thymocytes of the double negative compartment do 
express high levels of c-Myc, however only a very small subset of the maturing double 
positive thymocytes show c-Myc expression at a low level. Single positive thymocytes 
have an overall low but detectable expression of c-Myc whereas mature T cells in the 
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periphery do not express c-Myc anymore (HUANG et al. 2008; ZIMMERMAN and ALT 
1990). Generation of chimeras using c-myc deficient ES cells and RAG-1-/- recipient 
blastocyts showed that c-Myc is necessary for populating the thymus in adult mice 
(DOUGLAS et al. 2001). Apparently N-Myc could not complement c-Myc deficiency to 
drive proper T cell development which is in accordance to its co-expression with c-Myc 
only in early stages of T cell development. Furthermore, deletion of c-myc induced by 
Lck promoter driven Cre recombinase, which ablates expression starting at the DN3 
stage, suggests that c-Myc is required for the proliferation at that stage, however 
thymocytes are able to differentiate further to the DP stage. The adult thymus however 
contained a 10 times lower number of cells (DOSE et al. 2006). 
A reduced thymic cellularity 8 weeks after induction of MxCre driven c-myc 
deletion has already been shown (WILSON et al. 2004) and is confirmed by our results 4 
weeks after induction. The DP compartment was almost completely depleted, single 
positive thymocytes most probably were remaining long-lived thymocytes derived from 
c-Myc expressing cells prior to induction, which could easily be tested by PCR. 
However, the deletion of the DHEC resulted in almost normal T cell development with 
the only change of an increased DN3 population. Later stages were not affected as 
thymocytes further developed through the DP and SP stages to finally generate mature 
CD4+ and CD8+ lymphocytes in the periphery. Indeed c-myc expression in these mature 
T cells was not changed in compound heterozygous mice. Thus further enhancer 
elements located outside the del(15-17) region seem to be present that account for 
sufficient c-Myc expression during T cell development. 
Recently, this T cell enhancer for c-myc expression has been identified and 
characterized (HERRANZ et al. 2014). The authors located the human T cell enhancer 
1.4 Mb downstream of the c-MYC TSS and showed that it exhibits enhancer-associated 
chromatin marks in a human T-ALL cell line and physically interacts with the c-MYC 
promoter region. Furthermore, this enhancer contains a recognition site for NOTCH1, a 
ligand-activated transcription factor oncogene associated with T-ALL (TZONEVA and 
FERRANDO 2012; WENG et al. 2004). The equivalent region in mice is located 1.3 Mb 
downstream of the c-myc TSS thus 355 kb centromeric to the DHEC region. 
Homozygous deletion of the T cell enhancer showed that it is specifically required for 
thymocyte development beyond the DN3/DN4 stage, whereas many other 
hematopoietic cell types including the stem cell compartment were not affected. 
Moreover the enhancer was shown to be required for NOTCH1-induced T cell 
leukemogenesis. 
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Although our results support the presence of a T cell enhancer outside of the 
DHEC, part of our results are, on first sight, contradictory to the T cell enhancer 
described above. The del(8-17) region covers this enhancer thus one would expect 
similar defects in T cell development in mice with a homozygous deletion for this 
region. However, both control and homozygous mice, analyzed 10 days after birth, have 
comparable, albeit low numbers of mature CD4+ and CD8+ T lymphocytes in the BM. 
Although we did not look at T cell development in the thymus yet, an overall defect at 
this developmental stage would be expected to result in reduced numbers of mature 
cells in the periphery as it is the case for the study of the T cell enhancer by HERRANZ et 
al.. This issue requires further analyses for multiple reasons. First, with the available 
data we compare the lymphocyte populations at different developmental stages, and 
second, the comparison so far allows only an indirect observation since different tissues 
are evaluated (BM compared to thymus, spleen and lymph nodes). Del(8-17) mice were 
analyzed at 10 days age whereas T cell enhancer deleted mice were analyzed at 6 weeks 
age. T cell development at early stages is regulated differently compared to the adult 
situation (DOUAGI et al. 2002). In favor of a differential age-dependent requirement of 
c-Myc for T cell development are results from DOUGLAS et al., which show that thymic 
colonization in the absence of c-Myc occurs more frequently at fetal stages than at 
postnatal stages. However, analysis of the fetal stage revealed a block at the late stage 
of DN cell maturation, thus c-Myc deficient thymocytes did not contribute to the 
periphery. Enhancers regulate target gene expression in a tissue- and stage specific 
manner (VISEL et al. 2009). Therefore it is possible that T cell development in the 
embryo and the newborn mouse gets different regulatory input than in the adult mouse. 
If another enhancer not deleted by del(8-17) exists that drives T cell development at 
least until 10 days after birth, T cell enhancer deleted mice present with mature T cells 
at wild type levels. 
Notably, although null deletion of the T cell enhancer resulted in dramatically 
reduced thymic cellularity and reduced T cell numbers in the periphery as shown for 
spleen and lymph nodes this latter decrease was only modest to approximately 40% of 
wild type levels (HERRANZ et al. 2014). To test if this rather mild effect on mature T 
cells is equivalent to full c-Myc deficiency, mature T cells in c-myc∆Mx mice have to be 
analyzed for the presence of c-myc deleted cells. This can be done e.g. either by 
genotyping of sorted cells or by introducing a reporter construct such as the 
Rosa26EYFPflox/flox allele into the mouse that marks c-Myc deficient cells. Finally, 
although being performed with only a single mouse per group, the del(8-14) mouse 
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displayed normal T cell numbers. This deletion also encompasses the T cell enhancer 
but not the DHEC and since these mice were analyzed at an adult stage, the argument of 
regulation due to different requirement of c-Myc at the fetal stage is not valid for the 
observed phenotype. Therefore this issue needs to be addressed in more detail in future 
experiments. 
Similar as for T lymphocytes c-Myc is also necessary for B lymphocyte 
development. Deletion of c-myc exclusively in B cells beginning at the very early pro-B 
cell stage via a Cre recombinase driven by the mb1 promoter led to a developmental 
defect at the pro- to pre-B cell transition in the BM (HOBEIKA et al. 2006; VALLESPINOS 
et al. 2011). Our experiments showed that deletion of the DHEC led to significantly 
downregulated c-myc expression in B cells and a similar effect on the immature B cell 
population as achieved directly by c-myc deletion via MxCre recombinase. Thus in 
contrast to T lymphocytes c-myc expression in early B cells is driven by the DHEC. 
MEP progenitor cells are restricted to the megakaryocyte/erythrocyte lineage 
(AKASHI et al. 2000). In wild type mice mRNA expression levels of c-myc were similar 
to HSC, MPP and committed progenitor populations (Figure 3.17), however on the 
protein level this population showed highest expression among all hematopoietic cell 
types, which was a 7-fold increase compared to HSCs (EHNINGER et al. 2014). This 
discrepancy between the transcript and the protein level suggests posttranscriptional 
regulation mechanisms, as it was shown e.g. by the E3 ubiquitin ligase Fbw7 (REAVIE et 
al. 2010). Thus MEPs in particular seem to depend on high levels of c-Myc. Upon 
deletion of the DHEC c-myc expression was mildly reduced in these cells, suggesting 
that its expression depends only partially on this enhancer region (Figure 3.17). 
Moreover erythrocytes, progeny of the MEP population, barely showed a phenotype as 
opposed to c-Myc deficient erythrocytes. 
Among the mature cell types, only red blood cells were shown to have detectable 
c-Myc at the protein level (EHNINGER et al. 2014), suggesting a functional role for c-
Myc in this cell type. Indeed the deletion of c-myc led to a dramatic phenotype in the 
erythroid lineage as it was shown upon MxCre driven deletion in the BM (WILSON et al. 
2004, GUO et al. 2009 and our results) and Sox2Cre driven deletion in the epiblast 
(DUBOIS et al. 2008). In the latter case apoptosis in the erythroblast population has been 
observed and was considered to contribute to or even cause the death of the embryos. 
Hemavet and peripheral blood smear analyses revealed a strong anemia with 
anisocytosis, hypochromasia and polychromatosia of the red blood cells upon c-Myc 
deficiency. Erythroblasts, the immediate progeny of erythrocytes in the BM, were 
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decreased. This could either cause the defect observed in the periphery and/or be the 
consequence of a feedback mechanism, that tries to replenish functional red blood cells 
in the periphery and leads to exhaustion of erythroid progenitors. The latter situation is 
supported by the finding of a high number of polychromatic cells, a sign of premature 
release. Conversely, the number of proerythroblasts was slightly increased, thus 
suggesting that c-Myc deficiency leads to a differentation block at that stage. Therefore 
both scenarios seem to cooperatively lead to the anemic phenotype. In sharp contrast 
deletion of the DHEC caused only a mild anemia with a normochromatic macrocytosis. 
It was not accompanied by a significant change in (pro-) erythroblast populations in the 
BM, thus the mild defect could be sufficiently compensated. Of note, LacZ profiles of 
the proerythroblast population revealed a small subpopulation that showed strong, 
DHEC-dependent, expression from insertion 17a (Figure 3.10). The activity of the 
enhancer in this subpopulation could account for the reduction of c-myc expression in 
erythroblasts in DHEC deleted mice (Figure 3.17). Most importantly DHEC deletion 
did not cause lethality. The only differences in the hematopoietic system between both 
mouse models manifested in T cell development and the erythroid phenotype. The 
former is dispensable for laboratory mice (e.g. in Prkdcscid mice), therefore our results 
strengthen the hypothesis that lethality upon c-Myc deficiency is caused by the strong 
defect in erythroid development and function (DUBOIS et al. 2008; TRUMPP et al. 2001; 
WILSON et al. 2004). Altogether, these data indicated that the DHEC is active and 
contributes to c-myc expression in the erythrocyte-megakaryocyte lineage, but that one 
or several additional enhancers, located elsewhere in the locus, can maintain c-myc 
expression in these progenitors, independently of the DHEC. 
A broad analysis of enhancer-associated marks across the respective cell types 
could assist in identification of such an enhancer. A global analysis of chromatin 
modifications across different stages of hematopoietic differentiation has recently been 
published (LARA-ASTIASO et al. 2014). A short description of these data as well as 
visualization of chromatin modifications in the DHEC and c-myc region can be found in 
the Appendix section 6.1.1 with Figure 6.1 and Figure 6.2. Overall these data are in 
accordance with our ChIP-PCR results, showing highest enrichment for the H3K27ac 
enhancer mark at the D and G module in stem and progenitor cells (compare Figure 
3.31 to Figure 6.1), while granulocytes show higher enrichment at modules A, B and G. 
In our results B cells gave no specific enrichment for H3K27ac, which stands in 
contrast to the data shown in Figure 6.1. However, in these data combined analysis for 
H3K27ac and H3K4me1 also revealed an overall lower enhancer mark signal for all 
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lymphocytes compared to stem and progenitor cells. Most interestingly LARA-ASTIASO 
et al. provide data for enhancer-associated marks in MEPs and erythroblast cells. 
Strikingly, these profiles appear to be different to other progenitor or differentiated cell 
types. The modules A to G were less prominent, in contrast, a peak located next to 
module G and a peak at module H show highest signals. Thus this region might possess 
enhancer potential specific for regulation of c-myc expression in the erythroid lineage. 
Since the transposon 17a is located at position 63.550.550 on chromosome 15 and this 
insertion served as the breakpoint for del(15-17) deletion, module H was not deleted in 
all experiments performed throughout this thesis. This module could have caused the 
partially retained expression of c-myc in MEPs. However, if module H indeed would 
possess enhancer activity, one could have expected detection of LacZ expression in 
these cells upon deletion of del(15-17) as it keeps the reporter gene located close to 
module H. This was not the case (Figure 3.9), therefore other not yet defined regions are 
likely to be responsible for c-myc enhancer function in the erythroid lineage. 
4.3 Thrombocytosis caused by c-myc downregulation 
Platelets are critical elements in the blood system. They are not only important 
during homeostasis and thrombosis but also for tissue regeneration after injury and 
inflammation (GAWAZ et al. 2005; SEMPLE et al. 2011). Often patients suffering from 
critical thrombocytopenia, for example, as a result of a hematopoietic disease or 
chemotherapy, require platelet transfusions (LIEBERMAN et al. 2014). Platelets are 
derived from giant multinucleated cells in the BM, the megakaryocytes (PATEL et al. 
2005; THON and ITALIANO 2010). Both, megakaryocyte and platelet numbers, were 
highly increased upon c-myc deficiency (GUO et al. 2009). Thus the megakaryocytic 
lineage is the only lineage in the hematopoietic system not being downregulated by the 
lack of c-myc. GUO et al. showed that c-Myc is required for polyploidy formation 
resulting in smaller megakaryocytes upon c-Myc deficiency. However, cytoplasmic 
maturation is not impaired, thus functional platelets are produced from these smaller 
megakaryocytes. Similar to c-Myc deficiency our results proved that deficiency of the 
DHEC also leads to an increase in the megakaryocytic lineage mediated by c-myc 
downregulation. 
In situations of acute blood loss or other stress situations that lead to loss of cells 
of the megakaryocytic lineage these have to be rapidly and efficiently replenished to 
ensure survival of the organism. Although subsequently challenged by another study a 
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model has been suggested in 2005 favoring a direct shortcut within the hematopoietic 
hierarchy that connects the stem cell compartment with megakaryocytic progenitors 
(ADOLFSSON et al. 2005). Data from others but also our lab suggest the presence of 
megakaryocytic lineage primed HSCs or progenitors (HAAS et al. 2014; SANJUAN-PLA 
et al. 2013). More detailed, work from HAAS et al. allows a respective identification of 
megakaryocytic primed progenitors by analysing the primed transcriptome state on 
single cell level. Thus already at an very early stage of the hierarchy some cells carry 
determinants for their latter megakaryocytic identity. To gain a first insight into 
megakaryocytic differentiation potential at the stem and progenitor level upon c-Myc 
downregulation we determined the amount of CD41 expressing cells in these 
compartments. These results suggested that megakaryocytic progenitors are pushed 
from the HSC compartment further down the hierarchy, which is in accordance with the 
ultimately increased megakaryocyte numbers in the BM. It would be interesting to 
further track the megakaryocytic populations along the hierarchy using more defined 
markers (PRONK et al. 2007). Furthermore, transcriptome analysis on the single cell 
level could identify the proportion of megakaryocytic primed HSCs. 
Concomitant deletion of c-myc and N-myc leads to the loss of all major BM cell 
types including megakaryocytes (LAURENTI et al. 2008). Furthermore, expression of N-
myc is restricted to the very early HSC compartment. These observations argue for the 
requirement of functional Myc expression (either c-Myc or N-Myc) for the 
megakaryocytic differentiation potential, which could happen on the level of 
megakaryocytic priming on the HSC/progenitor level. To test this latter hypothesis, one 
could check for N-myc levels in the above mentioned single cell transcriptome analysis 
to see if megakaryocytic priming coincides with higher Myc levels. Also, N-Myc 
deficient mice should be analyzed for a potential defect in megakaryopoiesis, which 
was not addressed in the original paper (LAURENTI et al. 2008). 
4.4 Mechanisms of DHEC function 
The DHEC region has recently been described in murine leukemia cells to exert 
enhancer function (SHI et al. 2013). 3C and 4C experiments in this study showed long-
range interaction between the enhancer region and c-myc in a murine and a human 
leukemia cell line but not in HEK293T cells. Due to the limitation in cell numbers we 
could not analyze the long-range interaction in mouse stem and progenitor cells by 3C 
techniques. Instead, we decided to show interaction indirectly by DNA-FISH 
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experiments. First analyses revealed that c-myc and enhancer probe signals nicely 
overlapped whereas combination with a probe located at the same distance telomeric to 
the enhancer showed distinct foci (data not shown). These results suggest that not only 
in leukemic cells but also under homeostatic conditions the DHEC physically contacts 
the c-myc gene locus and therefore enables transcriptional regulation (chapter 1.1.3.3). 
As outlined in the introduction, the expression of enhancer RNAs (eRNAs) has 
been described only a few years ago (KIM et al. 2010; KOCH et al. 2011). Global 
analysis of transcription in human cells using cap analysis of gene expression (CAGE) 
showed that the majority of eRNAs are non-polyadenylated and only 10% to 20% of 
eRNAs exist in the polyadenylated state (ANDERSSON et al. 2014; DJEBALI et al. 2012). 
The polyadenylation status further correlates with the directionality of transcription and 
the size of the transcript. Non-polyadenylated eRNAs are transcribed bidrectional and 
are usually 500-2000 bp in size whereas polyadenylated eRNAs reach sizes greater than 
3000 bp and are generated by unidirectional transcription (NATOLI and ANDRAU 2012). 
Since polyadenylation confers among other functions mRNA stability, non-
polyadenylated eRNAs are thought to be quite unstable and sensitive to degradation. 
Enhancer transcription correlates well with enhancer activity as shown by co-
expression of nearby genes (HAH et al. 2011; HAH et al. 2013; KIM et al. 2010; WANG 
et al. 2011). Therefore enhancer transcription might be a useful indicator of enhancer 
activity (MELGAR et al. 2011). The concrete function and mechanism of eRNAs in 
enhancer activity is not yet clarified, however there is evidence for RNA-dependent 
(LAM et al. 2013; LI et al. 2013; MELO et al. 2013; MOUSAVI et al. 2013) and RNA-
independent roles of eRNA transcription (KAIKKONEN et al. 2013). 
The del(15-17) region so far contains no annotated gene except of a putative, 
unclassified sequence (AK040104), which gets disrupted by the deletion del(15-17) as 
the centromeric breakpoint lies within this sequence. Interestingly, analysis of recently 
published transcriptome data of murine HSCs (CHALLEN et al. 2014) revealed the 
presence of a transcript between module F and G (Figure 6.3). This transcript showed 
expression at a very low but significant level (signal range <35 units compared to 
>1000 units for c-myc; Figure 6.4) and displayed a size of  ~5 kb without any intronic 
sequences. Therefore, since these RNA-seq data were derived after enrichment for 
polyadenylated transcripts, this transcript can be classified to the group of 
polyadenylated eRNAs. RNA-seq data for B cells and granulocytes from the same study 
revealed that this transcript is not expressed in these differentiated cell types and thus 
correlates with DHEC enhancer activity measured by LacZ expression. If this eRNA is 
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involved in mediating the phenotype observed upon DHEC deletion remains to be 
investigated. Similarly the presence of further eRNAs encoded within the DHEC could 
be examined by transcript analysis without polyA-enrichment. 
The latter finding also prompted us to look further into the data of CHALLEN et al. 
(2012, 2014) who investigated the role of DNA methylation in HSCs. DNA methylation 
is an epigenetic mechanism involved in modulating many biological activities such as 
transcription (chapter 1.1.2.2.3), genomic imprinting and genome stability (CHEN and LI 
2006). Among the different types of DNA methyltransferases Dnmt3a and Dnmt3b are 
responsible for modifying unmethylated DNA, thus they are called de novo 
methyltransferases (HATA et al. 2002; OKANO et al. 1999). Serial transplantation of 
Dnmt3a deleted HSCs led to an increased contribution of these donor cells to the 
peripheral blood while HSCs accumulated in the BM (CHALLEN et al. 2012). Combined 
deficiency of Dnmt3a and Dnmt3b (dKO) in HSCs led to further increase in HSC self-
renewal while differentiation capacity declined after secondary transplantation 
(CHALLEN et al. 2014). Overall Dnmt3 deficiency resembled the c-myc KO phenotype 
on the long run. Therefore we asked for c-myc and N-myc expression levels after these 
serial transplantations. Indeed Dnmt3a KO and Dnmt3a/b dKO HSCs showed a strong 
downregulation of both genes compared to HSCs from age matched control mice 
(Figure 6.4). Thus Myc might be a key factor in mediating the phenotype upon Dnmt3 
deficiency in HSCs. 
Previous DNA methylation studies revealed an association of low methylated 
regions with cell-specific regulatory regions or transcription factor binding sites 
(HODGES et al. 2011; STADLER et al. 2011; ZILLER et al. 2013). In line with these 
studies analysis of DNA methylation in the DHEC region revealed some narrow valleys 
at the individual enhancer modules (Figure 6.3), while the surrounding sequences were 
highly methylated. Most interestingly, deletion of Dnmt3a and more prominently of 
Dnmt3a/b in HSCs from tertiary transplanted mice showed some differences in DNA 
methylation compared to the wild type control. Of note, a site of significant 
hypomethylation partially overlapped with the eRNA sequence mentioned above 
(Figure 6.3, dashed box). However, this hypomethylation was not accompanied by a 
decreased eRNA expression, instead it was slightly increased, which is contradictory to 
a direct connection between DNA methylation and c-myc regulation via enhancer 
function of this eRNA. A potential implication of regulation by the human homologues 
DNMT3A/c-MYC for leukemia development will be discussed at the end of the 
following chapter. 
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4.5 Function of the MYC enhancer region in leukemia 
The identification of the murine c-myc enhancer region and the characterization of 
its physiological role for hematopoiesis have important implications for human health. 
Firstly, the human MYC locus is highly syntenic to the mouse orthologous region. The 
different blocks composing the DHEC are also highly conserved in sequence. Both 
myeloid/erythroid and lymphoblastoid cell lines show enhancer-associated chromatin 
modifications over some of the DHEC modules (ERNST et al. 2011) and more 
importantly most of the modules are covered by enhancer-associated chromatin marks 
in mobilized CD34+ HSCs (Figure 3.32) (BERNSTEIN et al. 2010). Common SNPs 
present within the DHEC have been associated with different human traits linked to 
hematopoietic defects, including changes in monocyte counts (NALLS et al. 2011; 
OKADA et al. 2011). Also, focal amplifications overlapping the DHEC have been 
recurrently observed in acute myeloid leukemia (Kuhn et al. 2012; Radtke et al. 2009). 
Interestingly, also duplications of the T cell enhancer region are implicated specifically 
with T-cell acute lymphoblastic leukemia (HERRANZ et al. 2014). Both regions were not 
focally amplified, for example in chronic lymphocytic leukemia (EDELMANN et al. 
2012), suggesting that duplications of specific enhancer modules may contribute to 
cancer in some but not all cell types. It is likely that these disease-associated patterns 
can be used to identify further enhancer modules active in hematopoiesis. For other 
enhancers it has been shown that their germline duplications can lead to malformations 
affecting the organ where they are active (DATHE et al. 2009; LOHAN et al. 2014). Our 
results showed that neither duplication of the DHEC nor of the whole c-myc/Pvt1 
flanking locus resulted in a misregulation of the hematopoietic system. It is likely that 
transcriptional and posttranscriptional regulatory mechanisms are involved in dosage 
compensation and keep Myc expression at physiological levels. Evidence for the former 
is e.g. shown in HSC/MPP1 cells that show no difference in c-myc expression upon 
duplication of the whole c-myc/Pvt1 flanking locus. The importance for 
posttranscriptional regulation mechanisms have been discussed already in chapter 4.2. 
However, we looked at dup(15-17) mice at a very early time point soon after birth as 
this experiment was carried out along with a del(8-17) experiment. Detection of a 
potential contribution of the murine DHEC duplication to leukemia formation should be 
followed up in aged mice or can be addressed by breeding these mice to a mouse strain 
with a high susceptibility to leukemia formation. Similarly it was recently shown that 
duplication of the whole locus (c-myc/Pvt1/Gsdmc) promoted cancer development in 
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predisposed mice for mammary tumors (GUY et al. 1992; TSENG et al. 2014). In this 
context, cancer susceptibility by c-myc copy number increase was dependent on Pvt1 as 
duplication of c-myc alone or Pvt1/Gsdmc without c-myc did not show a reduced tumor-
free survival rate. 
Recent works have underlined that in cancerous cells MYC becomes regulated by 
so-called super-enhancers (LOVEN et al. 2013). This misregulation can occur due to 
translocations that juxtapose MYC to other enhancers (BERGSAGEL and KUEHL 2001; 
DALLA-FAVERA et al. 1982; TAUB et al. 1982). In the above mentioned study an altered 
in cis regulation due to juxtaposition of the c-myc gene close to a potential regulatory 
element could be ruled out since mice with a duplicated allele on one chromosome but a 
null allele on the other did not show pre-cancerous characteristics (TSENG et al. 2014). 
In murine leukemia cells the DHEC region has recently been exposed as a super-
enhancer, since it shows prominent and widespread deposition of H3K27ac, Mediator, 
and BET bromo-domain proteins (SHI et al. 2013). Our data suggest that in normal 
hematopoiesis, the DHEC is not acting as a super-enhancer, but instead coincides with a 
series of spatially close, but nonetheless separately acting modules that exert distinct 
activities. The conversion of enhancers into regions with higher enrichment of H3K27ac 
chromatin marks, a feature of super-enhancers, appeared common in cancers (HNISZ et 
al. 2013). This suggests that epigenetic alterations may contribute to this “super-
enhancer transformation”, either through chromatin changes or due to misregulated 
expression of transcription factors or epigenetic remodelers that may superimpose 
transcriptional programs normally separated in distinct cell types. The examination of 
enhancer-associated chromatin marks in the DHEC of primary AML samples and their 
association with c-MYC expression levels will help to shed more light on this process as 
data published so far rely mostly on cell lines. 
As already mentioned above, MYC might not only be deregulated in established 
AML, but also be implicated together with DNMT3A in leukemia development. In 
2010 DNMT3A has been first identified as a somatic mutation in AML patients (LEY et 
al. 2010). This study revealed a mutation frequency of 22% that frequently occured 
together with mutations in nucleophosmin (NPM1), FMS-related tyrosine kinase 3 
(FLT3) and isocitrate dehydrogenase 1 (IDH1). Cancer is thought to be a clonal disease, 
meaning that all cancer cells descend from a single cell (GREAVES and MALEY 2012; 
YATES and CAMPBELL 2012). Somatic mutations accumulate in a stepwise manner until 
disease manifestation and upon diagnosis cancer cells consist of several clones bearing 
different mutations. Their dominance varies over time, also in response to cancer 
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treatment. A recent study tried to shed light on the clonal evolution of AML and found 
that HSCs acquire pre-leukemic mutations, which allow clonal expansion and 
subsequent acquisition of mutations leading to cancer (SHLUSH et al. 2014). Since these 
pre-leukemic cells can survive chemotherapy they then serve as a reservoir for new 
clones leading to relapse. DNMT3A mutations have been identified as such an early 
event in leukemogenesis. Transferring our observations from data of Dnmt3a KO mice 
to this model, DNMT3A mutations might lead to downregulation of MYC in HSCs. 
This in turn could account for the accumulation of these pre-leukemic HSCs, which 
upon acquisition of further mutations, lead to development of AML. Such further 
mutations might also account for deregulated c-MYC expression in the established 
leukemia, possibly by transforming the MYC enhancer. 
4.6 Regulation of stem cells by Myc 
In the hematopoietic system combined deficiency for c-Myc and N-Myc led to a 
rapid hematopoietic failure associated with impaired proliferation, differentiation and 
increased apoptosis (LAURENTI et al. 2008). Interestingly, under homeostatic conditions 
Myc deficiency in the dormant HSCs failed to proliferate but were maintained in the 
bone marrow and these Myc deficient dormant HSCs could even be transplanted. Since 
Myc function is closely associated with proliferative potential and we detected a 
dramatic downregulation of c-myc upon enhancer deletion, our observation of increased 
MPP cell numbers instead of HSCs was surprising at first sight. However, c-myc 
downregulation was accompanied by an upregulation of N-myc transcripts in all 
progenitor cells, which accounts for their proliferative potential up to the stage of 
MPPs. The wide loss of differentiation potential most likely is associated with retention 
of HSPCs in the niche as it was shown for the conditional c-myc deletion (WILSON et al. 
2004). WILSON et al. observed an upregulation of N-cadherin and a number of adhesion 
receptors in c-myc deficient LSK cells, suggesting that c-Myc controls the balance 
between differentiation and HSPC accumulation by regulating HSPC interaction with 
the microenvironment. The fact that enhancer deleted mice were still able to generate T 
cells and red blood cells to an almost normal extent suggests that at least some cells can 
overcome this differentiation block, likely due to fluctuations in basal c-myc expression 
in HSCs/progenitors. Such escaping cells are either already committed to the distinct 
lineages or, in case they are still multi- or oligopotent, their expansion and 
differentiation within the respective lineage is driven by regulatory elements outside the 
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identified enhancer region (as it is the case for the T cell enhancer (HERRANZ et al. 
2014)). 
Interestingly, similar roles of Myc regulation as in hematopoietic cells have been 
observed in our laboratory in ES cells (SCOGNAMIGLIO AND TRUMPP, personal 
communication). ES cells grown under conventional culture conditions in medium 
containing serum have been shown to rapidly differentiate upon deletion of c-myc and 
N-myc (SMITH et al. 2010; VARLAKHANOVA et al. 2010). These culture conditions keep 
ES cells not in a stable pluripotent but a primed state that is sustained by Myc proteins. 
However, serum-free culture together with 2 inhibitors (“2i”) targeting the mitogen-
activated protein kinase kinase (Mek) and the glycogen synthase kinase-3 (Gsk3) can 
establish a naïve ground state of pluripotency (YING et al. 2008). Work by 
SCOGNAMIGLIO AND TRUMPP showed that under these culture conditions ES cells 
lacking c-Myc and N-Myc form only very small colonies that lack proliferation activity. 
They remain undifferentiated and retain their pluripotency network (unpublished). This 
observation highly resembles the situation in the most primitive HSC population 
lacking both c-Myc and N-Myc (LAURENTI et al. 2008). 
In summary, Myc activity is dispensible for the most potent dormant stem cells at 
the top of their hierarchy which harbor the highest self-renewal capacitiy (naïve ESCs 
and HSCs). Myc is not only essential for proliferation of stem and progenitor cells but 
simultaneously also promotes stem cell differentiation. In contrast terminal 
differentiation is blocked by overexpression of Myc leading to an expansion of late 
progenitor cells. 
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4.7 Outlook 
The characterization of the distal c-myc enhancer adds a valuable contribution to 
the understanding of c-myc transcription regulation in hematopoietic cells. However, 
thus far we only characterized the function regarding deletion of the whole cluster. By 
using the CRISPR/Cas-mediated genome engineering tool (YANG et al. 2014) mice 
have been generated by our collaborators that harbor deletion of single modules within 
the DHEC. Analysis of these mice will add further understanding in the differential 
usage of these single enhancer elements in hematopoiesis. Also, these experiments will 
elucidate the potential role of the eRNA, which can then be addressed further by 
overexpression or shRNA-mediated knockdown. 
Furthermore, we want to extend our studies on the implication on leukemia 
initiation and maintenance. Forced c-Myc expression in transgenic mice results in a 
variety of malignancies (ADAMS et al. 1985; CHESI et al. 2008; LEDER et al. 1986). In 
most mouse models, however, secondary events are required for malignancy, as mice 
present with disease after a long latency (BEER et al. 2004; ELLWOOD-YEN et al. 2003; 
FELSHER and BISHOP 1999). Retrovirus-mediated expression of c-myc in BM cells leads 
to rapid development of acute myeloid leukemia (LUO et al. 2005). On one hand, we 
plan to use the mouse line with duplication of the DHEC (dup(15-17)) and see if the 
latency period of leukemia is shortened in theses mice. For this experiment a leukemia 
model with a long latency period is anticipated, as shown in leukemia induction by 
HoxA9 (KROON et al. 1998). On the other hand, we would like to assess whether this 
enhancer region is important for AML maintenance. Therefore we are currently 
breeding mice to gain compound heterozygous mice with a del(15-17) allele, a floxed c-
myc allele and the inducible MxCre transgene. LSK cells will be transduced by 
retroviral overexpression of MLL-AF9 and transplanted into recipient mice. The impact 
of the enhancer region on leukemia maintenance will be determined by Cre-mediated c-
myc deletion after first signs of leukemia onset. 
 
  
5 MATERIAL & METHODS 
5.1 Material 
5.1.1 Reagents 
Reagent Company 
Acetone Sigma-Aldrich (St. Louis, USA) 
ACK lysis buffer Lonza (Walkersville, USA) 
Agarose Sigma-Aldrich (St. Louis, USA) 
Ammonium sulfate ((NH4)2SO4) Roth (Karlsruhe, Germany) 
BD Cytofix/Cytoperm™ Becton Dickinson (Franklin Lakes, USA) 
BD Perm/Wash™ buffer Becton Dickinson (Franklin Lakes, USA) 
Boric acid Sigma-Aldrich (St. Louis, USA) 
Bromphenol blue Sigma-Aldrich (St. Louis, USA) 
bovine serum albumin (BSA) PAA Laboratories, Pasching, Austria 
Deoxyribonucleotide triphosphate (dNTP) Thermo Fisher Scientific (Waltham, USA) 
Dimethylsulfoxid (DMSO)  Sigma-Aldrich (St. Louis, USA) 
Direct PCR Tail Lysis Reagent Peqlab (Erlangen, Germany) 
DNA Gene Ruler 100 bp Thermo Fisher Scientific (Waltham, USA) 
DNA oligonucleotides (primers) Sigma-Aldrich (St. Louis, USA) 
Entellan Merck (Darmstadt, Germany) 
Ethanol (EtOH) Merck (Darmstadt, Germany) 
Ethidium bromide Roth (Karlsruhe, Germany) 
Ethylenediamine tetra-acetic acid-disodium 
salt (EDTA) Sigma-Aldrich (St. Louis, USA) 
Fetal calf serum (FCS) PAA Laboratories, Pasching, Austria 
fluorescein di-(β-D-galactopyranoside) (FDG) Sigma-Aldrich (St. Louis, USA) 
Glacial acetic acid Sigma-Aldrich (St. Louis, USA) 
Giemsa Sigma-Aldrich (St. Louis, USA) 
Glycerol Applichem (Darmstadt, Germany) 
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Hanks’ Balanced Salt Solution (HBSS) Thermo Fisher Scientific (Waltham, USA) 
Hoechst33342 Thermo Fisher Scientific (Waltham, USA) 
4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES buffer) Thermo Fisher Scientific (Waltham, USA) 
Hydrochloric acid (HCl) Roth (Karlsruhe, Germany) 
Isopropanol Sigma-Aldrich (St. Louis, USA) 
May-Grünwald Sigma-Aldrich (St. Louis, USA) 
Methanol (MeOH) Sigma-Aldrich (St. Louis, USA) 
Magnesium chloride (MgCl2) VWR International (Radnor, USA) 
MethoCult M3434 medium StemCell Technology (Vancouver, Canada) 
One Comp eBeads eBioscience (San Diego, USA) 
Paraformaldehyde (PFA) Sigma-Aldrich (St. Louis, USA) 
Penicillin-Streptomycin (10000 units/ml) Thermo Fisher Scientific (Waltham, USA) 
Phosphate buffered saline (PBS) Sigma-Aldrich (St. Louis, USA) 
Polyinosinic-polycytidylic acid (poly(I:C)) InvivoGen (Toulouse, France) 
Potassium chloride (KCl) Roth (Karlsruhe, Germany) 
Potassium dihydrogen phosphate (KH2PO4) Roth (Karlsruhe, Germany) 
Power SYBR Green Master Mix Thermo Fisher Scientific (Waltham, USA) 
Rnase-free water Thermo Fisher Scientific (Waltham, USA) 
Rnase Zap Thermo Fisher Scientific (Waltham, USA) 
RPMI 1640 Sigma-Aldrich (St. Louis, USA) 
Sodium chloride (NaCl) Sigma-Aldrich (St. Louis, USA) 
Sodium hydroxide (NaOH) Sigma-Aldrich (St. Louis, USA) 
Sodium dihydrogen phosphate (Na2HPO4) Sigma-Aldrich (St. Louis, USA) 
Trimethoprim/sulfamethoxazole Ratiopharm (Ulm, Germany) 
Sucrose Sigma-Aldrich (St. Louis, USA) 
Trisodium citrate Sigma-Aldrich (St. Louis, USA) 
tris(hydroxymethyl)aminomethane (Tris) Sigma-Aldrich (St. Louis, USA) 
Triton X-100 Applichem (Darmstadt, Germany) 
Xylol Sigma-Aldrich (St. Louis, USA) 
Table 5.1: Reagents 
 
5.1.2 Enzymes 
Enzyme Company 
Dnase I Qiagen (Hilden, Germany) 
Proteinase K Peqlab (Erlangen, Germany) 
DreamTaq DNA polymerase Thermo Fisher Scientific (Waltham, USA) 
SuperScript Reverse Transcriptase Thermo Fisher Scientific (Waltham, USA) 
Table 5.2: Enzymes 
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5.1.3 Buffers 
Buffers provided with the kits were used in the case of RNA isolation and reverse 
transcription. All other buffers used are listed in Table 5.3. 
Buffer Composition 
10x TBE 
890 mM Tris 
890 mM boric acid 
20 mM EDTA pH 8.0 
pH 8.0 
10x PCR buffer 
670 mM TrisHCl, pH 8.8 
67 mM MgCl2 
1.7 mg/ml BSA 
166 mM (NH4)2SO4 
Decalcification buffer 
0.4 M EDTA 
pH 7.2 adjusted with sodium hydroxide 
DNase I stock solution Lyophilized Dnase I (1500 Kunitz units) dissolved in 550 µl Rnase-free H2O aliquoted and stored at -20°C 
Dnase treatment 
µl Dnase solution 
35 µl buffer RDD (provided in the Rnase-free Dnase Set) 
DNA gel loading buffer 
0.25 % bromophenol blue 
0.25 % xylencyanol 
15 % glycerol 
in 10 ml dH2O 
Giemsa solution 14.3% Giemsa in modified Sörensen buffer 
HBSS+ Hanks’ Balanced Salt Solution supplemented with 2% fetal calf serum and a final concentration of 10 mM HEPES 
May-Grünwald solution 50% May-Grünwald in modified Sörensen buffer 
modified Sörensen buffer 
8 mM Na2HPO4 
3.6 mM KH2PO4 
pH 6.8 
Table 5.3: Buffers 
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5.1.4 Antibodies for flow cytometry 
Antigen Label Clone Company 
B220 PE-Cy5, PE-Cy7, APCeFluor®780 RA3-6B2 eBioscience 
B220 biotin RA3-6B2 BioLegend 
CD4 FITC, PE-Cy7, Pacific Blue GK1.5 eBioscience 
CD4 biotin GK1.5 BioLegend 
CD8a PE-Cy5, PE-Cy7 53-6.7 eBioscience 
CD8a biotin 53-6.7 BioLegend 
CD11b AlexaFluor®700, PE-Cy7 M1/70 eBioscience 
CD11b biotin M1/70 BioLegend 
CD16/32 (FcγR) Pacific Blue 93 eBioscience 
CD25 PE PC61.5 eBioscience 
CD34 AlexaFluor®700, FITC RAM34 eBioscience 
CD41 eFluor®450, FITC, PE-Cy7 MWReg30 eBioscience 
CD44 Pacific Blue IM7 BioLegend 
CD45 AlexaFluor®700 30-F11 eBioscience 
CD45.1 FITC, PE, PE-Cy7 A20.1 eBioscience 
CD45.2 Pacific Blue 104 BioLegend 
CD45.2 AlexaFluor®700 104 BD Pharmingen 
CD48 Pacific Blue HM48-1 BioLegend 
CD48 PE, PE-Cy7 HM48-1 eBioscience 
CD71 PE OKT9 eBioscience 
CD117 (c-Kit) APC-eFluor®780 2B8 eBioscience 
CD127 (IL7Rα) PE A7R34 eBioscience 
CD135 PE A2F10  eBioscience 
CD150 PE-Cy5 TC15-12F12.2 BioLegend 
Ki67 FITC B56 BD Pharmingen 
Gr-1 (Ly6-G) APC, PE-Cy7 RB6-8C5 eBioscience 
Gr-1 (Ly6-G) biotin RB6-8C5 BioLegend 
Sca-1 APC D7 eBioscience 
Streptavidin PE-TexasRed - BD Pharmingen 
Ter119 APC-eFluor®780, PE-Cy7 TER-119 eBioscience 
Ter119 biotin TER-119 BioLegend 
Table 5.4: Antibodies for flow cytometry 
Abbreviations: APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin; PE-
Cy5, phycoerythrin-Cyanine 5; PE-Cy7, phycoerythrin-Cyanine 7; PE-TxRed, phycoerythrin-
Texas Red. 
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5.1.5 Kits 
Name Company 
SuperScript® VILO™ cDNA Synthesis Kit Thermo Fisher Scientific (Waltham, USA) 
Arcturus® PicoPure® RNA Isolation Kit Thermo Fisher Scientific (Waltham, USA) 
DNeasy Blood & Tissue Kit Qiagen (Hilden, Germany) 
Table 5.5: Kits 
5.1.6 Consumables 
Item Company 
384-well PCR plates Thermo Fisher Scientific (Waltham, USA) 
BD Micro-Fine (1 ml, 29 Gx8 mm) Becton Dickinson (Franklin Lakes, USA) 
Cell strainer (40 µm nylon) Becton Dickinson (Franklin Lakes, USA) 
Cover Slips (24x60 mm) Thermo Fisher Scientific (Waltham, USA) 
Disposable scalpel (20) Feather Safety Razor (Osaka, Japan) 
Eppendorf tubes (1.5 and 2 ml safe-lock) Eppendorf (Hamburg, Germany) 
FACS-tubes (5 ml) Becton Dickinson (Franklin Lakes, USA) 
Falcon tubes (sterile, 15 ml) Sarstedt (Nümbrecht, Germany) 
Falcon tubes (sterile, 50 ml) Greiner (Frickenhausen, Germany) 
Folded Filters Munktell (Falun, Sweden) 
Microscope slides Thermo Fisher Scientific (Waltham, USA) 
Microvette 200K3E Sarstedt (Nümbrecht, Germany) 
Mortar and pestle Sigma-Aldrich (St. Louis, USA) 
Multiwell culture plate (6-well, 12-well) Corning Inc. (Corning, USA) 
paper towels tissue WEPA Hygieneprodukte (Arnsberg, Germany) 
Pasteur pipettes WU Mainz (Bamberg, Germany) 
Petri dishes (sterile, 35 mm) Becton Dickinson (Franklin Lakes, USA) 
Petri dishes (sterile, 100 mm) TPP Techno Plastic Products AG (Trasadingen Switzerland) 
PCR-Reaction tubes (0.2 ml SingleCap 8-er 
SoftStripes) 
Biozym Scientific (Hessisch Oldendorf, 
Germany) 
Rnase-free microtubes Axygen (Union City, USA) 
Serological Pipettes (5 ml, 10 ml, 25 ml, 50 ml) Becton Dickinson (Franklin Lakes, USA) 
Sterile filtered and not filtered tips (10 µl, 20 µl, 
200 µl, 1000 µl) Starlab (Milton Keynes, UK) 
Syringe without needle (5 ml) Terumo (Leuven, Germany) 
Table 5.6: Consumables 
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5.1.7 Equipment 
Equipment Company 
Analytical Balance ALC-1100.2 Acculab (Göttingen, Germany) 
Bench centrifuge Eppendorf 5810r centrifuge Eppendorf (Hamburg, Germany) 
Cell culture hood Safe2020 Thermo Fisher Scientific (Waltham, USA) 
DynaMag™ magnets Thermo Fisher Scientific (Waltham, USA) 
Electronic pipette Eppendorf Research Pro 
(5-100 µl) Eppendorf (Hamburg, Germany) 
Electrophoresis power supply (PowerPac 
Basic Power Supply) Bio-Rad Laboratories (Hercules, USA) 
Electrophoresis unit (Sub-Cell GT) Bio-Rad Laboratories (Hercules, USA) 
FACS AriaI, FACS Aria II, FACS Aria III Becton Dickinson (Franklin Lakes, USA) 
Heating block (MHR23) Ditabis (Pforzheim, Germany) 
Hemavet HV 950 Hematology System ERBA Diagnostics (Miami, USA) 
Cs-137  γ-irradiator (1990) Buchler GmbH (Braunschweig, Germany) 
LSR II Becton Dickinson (Franklin Lakes, USA) 
LSR Fortessa Becton Dickinson (Franklin Lakes, USA) 
Microwave oven Sharp (Osaka, Japan) 
Millipore H2O-production unit Milli-Q plus Millipore (Eschborn, Germany) 
Neubauer counting chamber Braun (Melsungen, Germany) 
pH211 Microprocessor pH-Meter Hanna Instruments (Woonsocket, USA) 
Pipettes (p-2, p-20, p-200, p-1000) Gilson (Bad Camberg, Germany) 
Pipetboy acu Integra Biosciences (Fernwald, Germany) 
Precision weighing balance ALC-110.4 Acculab (Göttingen, Germany) 
Refrigerator 4°C Liebherr (Biberach an der Riß, Germany) 
Refrigerator -20°C Liebherr (Biberach an der Riß, Germany) 
Refrigerator -80°C SANYO Electric Co. (Wood Dale, USA) 
Staining dish for microscope slides Roth (Karlsruhe, Germany) 
Stuart roller mixer SRT2 Sigma-Aldrich (St. Louis, USA) 
Thermocycler (T3000) Biometra (Göttingen, Germany) 
UV-Transluminator and video system Intas (Göttingen, Germany) 
ViiA™ 7 Real-Time PCR System with 384-
well block Thermo Fisher Scientific (Waltham, USA) 
Vi-CELL Series Cell Viability Analyzer Beckman Coulter, Brea, USA 
Vortex-Genie 2 Scientific Industries (Bohemia, USA) 
Zeiss Axioplan microscope equipped with a 
AxioCam Icc 3 colour camera Zeiss (Jena, Germany) 
Zeiss Primo Vert inverted microscope 
equipped with an AxioCam Erc 5s Zeiss (Jena, Germany) 
Table 5.7: Equipment 
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5.1.8 Computer, printer and software 
Computer, printer or software Company 
Adobe Illustrator CS6 Adobe (San Jose, USA) 
Adobe Photoshop CS5 Adobe (San Jose, USA) 
AxioVs40 V4.8.2.0 Carl Zeiss MicroImaging (Jena, Germany) 
BD FACSDiva software Becton Dickinson (Franklin Lakes, USA) 
CloneManager 9 Scientific & Educational Software (Cary, USA) 
DataAssist software 3.01 Thermo Fisher Scientific (Waltham, USA) 
EndNote X3 Thompson Reuters (New York, USA) 
FACSDiva Software Becton Dickinson (Franklin Lakes, USA) 
Fiji (SCHINDELIN et al. 2012) Open Source image processing package 
FlowJo 9.6.4 Software TreeStar (Ashland, USA) 
GraphPad Software Prism GraphPad (La Jolla, USA) 
Intas GDS Intas (Göttingen, Germany) 
MacBookPro notebook Apple (Cupertino, USA) 
Microsoft Office 2008 for Mac Microsoft Corporation (Redmond, USA) 
Microsoft Windows 7 Microsoft Corporation (Redmond, USA) 
Parallels Desktop 6 for Mac Parallels Holdings (Renton, USA) 
ViiA7 software v 1.1 Thermo Fisher Scientific (Waltham, USA) 
Printer HP Colour Laserjet CP2025 Hewlett-Packard (Palo Alto, USA) 
Printer HP Laserjet P2035 Hewlett-Packard (Palo Alto, USA) 
Printer Lexmark C544dn Lexmark (Lexington, USA) 
Printer Lexmark E460dn Lexmark (Lexington, USA) 
Printer Mitsubishi P93D Mitsubishi Electric (Tokio, Japan) 
Zen 2011 lite Carl Zeiss Microscopy (Jena, Germany) 
Table 5.8: Computer, printer and software 
 
5.1.9 Internet resources 
Tool Internet address 
Epigenome Browser http://www.epigenomebrowser.org/ 
NCBI databases and tools http://ncbi.nlm.nih.gov 
TAD Data visualization http://yuelab.org/hi-c/database.php 
TRACER database http://www.ebi.ac.uk/panda-srv/tracer/index.php 
UCSC Genome Browser http://genome.ucsc.edu 
VISTA Browser http://genome.lbl.gov/vista 
Table 5.9: Internet resources 
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5.2 Methods 
5.2.1 Animals 
Mice were maintained in the animal facility of the German Cancer Research Center 
(DKFZ, Heidelberg) or at the European Molecular Biology Laboratory (EMBL, 
Heidelberg) under specific pathogen-free conditions (SPF) and housed in individually 
ventilated cages (IVC). If not indicated differently, the mice were on a C57Bl/6 
background. Adult mice used for experiments were between 6 and 12 weeks old at the 
beginning of the respective experiment if not specified differently. The age of embryos 
or newborn mice is specified. 
 
Mouse strains 
C57Bl/6 J. C57Bl/6 J mice are referred to as (CD45.2+) wild type (Wt) mice. These 
mice were either purchased from Harlan Laboratories or were bred at the DKFZ or 
EMBL. 
 
B6.SJL-Ptprca-Pep3b-/BoyJ. B6.SJL-Ptprca-Pep3b-/BoyJ mice are referred to as 
CD45.1+ wt mice. These mice were purchased from Charles River Laboratories, Italy or 
were bred at the DKFZ. 
 
Myctm2.1Atp/Myctm1Atp. Myctm2.1Atp/Myctm1Atp mice are referred to as c-mycflox/KO mice. 
The knockout allele (c-mycKO) has been generated by replacing the entire c-myc open 
reading frame (ORF) with a Pgk-Hprt cassette (TRUMPP et al. 2001). These mice were 
on a mixed background and bred at DKFZ. 
 
Tg(Mx1-cre)1Cgn Myctm2.1Atp/Myctm2.1Atp. Tg(Mx1-cre)1Cgn Myctm2.1Atp/Myctm2.1Atp 
mice are referred to as MxCre c-mycflox/flox mice. The c-myc allele is flanked by loxP 
recognition sites (TRUMPP et al. 2001), therefore expression of Cre recombinase causes 
the flanked gene to be removed. The Cre recombinase is under the control of the 
myxovirus resistance (Mx1) promoter, which can be induced by administration of the 
synthetic double-stranded RNA polymer polyinosinic-polycytidylic acid (polyI:C) 
(KÜHN et al. 1995). This leads to efficient deletion of c-myc in several tissues, e.g. the 
hematopoietic system, the liver and the BM stroma. 
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To induce deletion of loxP-flanked alleles, mice were injected intraperitoneally (i.p.) 
with 100 µg polyI:C in 200 µl PBS 5 times every other day. Control mice were injected 
with an equal volume of PBS. These mice were bred at DKFZ. 
 
Transgenic mouse lines with transposon insertions and deletions/duplications 
Mice carrying a transgenic insertion generated by the Sleeping Beauty transposon-based 
system were established in the laboratory of Dr. François Spitz (RUF et al. 2011). In 
Table 5.10 the respective position of the transposons as well as their direction and the 
parental transposon is indicated. These data are also available in the TRACER 
Database. In Table 5.11 the transgenic mouse lines are listed that were generated using 
targeted meiotic recombination as explained in chapter 3.1. Short names are used 
throughout the thesis. Most of these animals were maintained at EMBL and genotyping 
was performed by Dr. Veli V. Uslu. Only the lines del(14-17) and del(15-17) were also 
bred at DKFZ on a mixed background (derived from breedings below). 
Line name Short name Chr Position (mm9) LoxP Transposon parent 
196231 c17 15 60133316 minus 179039 
205880 c8a 15 61051281 minus 196231 or 194578 
194578 3a 15 62168343 plus 179039 
184347 8a 15 62668548 plus 179039 
193058 14b 15 63185343 plus 179039 
193637 14c 15 63196469 plus 179039 
192339 15a 15 63291835 plus 179039 
193315 16a 15 63461422 minus 179039 
179039 17a 15 63550550 plus 176598 
192857 17b 15 63550550 minus 179039 
Table 5.10: Transgenic mouse lines with transposon insertions 
Table specifies position of insertions, direction of loxP (strand) and parental transposon. 
 
Line name Centromeric breakpoint 
Telomeric 
breakpoint Region spanned (mm9) Length (bp) 
del(8-17) 184347 179039 chr15:62668548-63550550 882002 
del(14-15) 193058 192339 chr15:63185343-63291835 106492 
del(14-17) 193637 179039 chr15:63196469-63550550 354081 
del(15-17) 192339 179039 chr15:63291835-63550550 258715 
dup(15-17) 192339 179039 chr15:63291835-63550550 258715 
dup(c17-17) 196231 192857 chr15:60133316-63550550 3417234 
Table 5.11: Transgenic mouse lines carrying deletions or duplications 
Table specifies breakpoints, spanned regions and length of deleted/duplicated region. 
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del(14-17)/c-mycflox or del(14-17)/c-mycKO. Del(14-17) mice were crossed with 
Myctm2.1Atp/Myctm1Atp mice to generate compound heterozygous mice. These were on a 
mixed background and were bred at DKFZ. 
del(15-17)/c-mycflox or del(15-17)/c-mycKO. Del(15-17) mice were crossed with 
Myctm2.1Atp/Myctm1Atp mice to generate compound heterozygous mice. These were on a 
mixed background and were bred at DKFZ. 
5.2.2 Genotyping 
5.2.2.1 Genomic DNA extraction 
Mice maintained at the German Cancer Research Center were marked using numbered 
ear tags or ear punches. Approximately 3 mm of the tail was cut and subsequently 
incubated with 100 µl Direct PCR Tail Lysis Reagent containing 0.2 mg/ml proteinase 
K at 55°C for 3 to 16 hours until the tissue was completely enzymatically digested. 
Inactivation of proteinase K was achieved by incubation at 85°C for 45 min. Samples 
were stored at 4°C and 1 µl used for genotyping by polymerase chain reaction. 
Genomic DNA from lineage depleted cells (5.2.3.4) of MxCre c-mycflox/flox mice was 
extracted using the DNeasy Blood & Tissue Kit according to the manufacturers 
instructions. 
5.2.2.2 Polymerase chain reaction 
The polymerase chain reaction (PCR) was used to amplify specfic DNA fragments 
(MULLIS 1990). Usage of two oligonucleotide pairs (primers) allows amplification of a 
particular DNA sequence. Primers used for genotyping are listed Table 5.12. 
All PCR amplifications were performed in an end volume of 30 µl according to the 
standard protocol shown in Table 5.13. Specific PCRs required addition of either 10% 
DMSO (c-mycKO) or 0.13% Triton (c-mycflox and c-mycdel ORF). 
PCRs were performed according to the standard program shown in Table 5.14 on a 
T3000 thermocycler. Genotyping for the MxCre transgene was performed with 62°C 
annealing temperature. Finally, the PCR product was loaded onto an agarose gel. 
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Genotype Primer name Sequence (5’-3’) Amplicon 
KOF 2432 GGT TCT CTC TCA TGG AGT GTA TCA GG del(14-17) / 
del(15-17) KOR 426 AAG TAG ATG TCC TAA CTG ACT TTGC 
KO: 285 bp 
WTF 2646 GAT GGG ACT TCC CAC ATA ACA GC del(14-17) / 
del(15-17) WTR 2647 AAT GCC AAA GAC AAG GAC TCC AG 
WT: 850 bp 
KOF 193637 CCT CCT GGG ATT TCC ATG ACT C 
del(14-17) 
KOR 429 TCC TAA CTG ACC TAA GAC AGG 
KO: 294 bp 
KOF 2646 GAT GGG ACT TCC CAC ATA ACA GC 
del(15-17) 
KOR 429 TCC TAA CTG ACC TAA GAC AGG 
KO: 548 bp 
5’floxB ACA ACG TCT TGG AAC GTC AGA GG 
c-mycflox 
3’floxB GCA TTT TAA TTC CAG CGC ATC AG 
WT: 350 bp 
Flox: 500 bp 
cmyc KOA2F GTA ATT CCA GCG AGA GAC AGA GG 
c-mycKO 
cmyc KOA2R AAC CTG GTT CAT CAT CGC TAA TC 
KO: 850 bp 
MxU121 GGC AGG GCT CCT CAG TGA TTC 
MxCre 
Cre21L CTG GCG ATC CCT GAA CAT GTC 
tg: 550 bp 
cmyc del1 AAA TAG TGA TCG TAG TAA AAT TTA GCC TG 
c-mycdel ORF 
cmyc del2 ACC GTT CTC CTT AGC TCT CAC G 
del: 200 bp 
Table 5.12: Genotyping primers 
 
 
reagent volume 
1/10 10x PCR buffer 3,0 µl 
dNTP mix (10 mM) 2.1 µl 
forward primer (10 µM) 0.6 µl 
reverse primer (10 µM) 0.6 µl 
DreamTaq DNA Polymerase (5 U/µl) 0.2 µl 
DNA 1,0 µl 
dH2O fill up to 30 µl 
Table 5.13: PCR reaction conditions 
 
 
Step Temperature Time Number of cycles 
Denaturation       95°C 2 min                1 
Denaturation       94°C 45 s 
Annealing       60°C 45 s 
Elongation       72°C 45 s 
              35 
Final elongation       72°C 5 min                1 
Table 5.14: PCR thermal cycling program 
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5.2.2.3 Electrophoresis of DNA 
In order to separate the DNA fragments amplified by PCR according to their molecular 
weight, PCR products were subjected to gel electrophoresis. The gel composed of 1-2% 
agarose diluted in 1x TBE buffer was boiled using a microwave oven. Ethidium 
bromide solution at a concentration of 30 µg/100 ml gel was added before the solution 
was filled into a gel tray that contained a comb at one side. After polymerization the gel 
was transferred into a chamber filled with 1x TBE and the comb was removed. The 
PCR-products were mixed with a loading buffer containing bromophenol blue and then 
loaded onto the gel along with a DNA ladder. The gel was run at a voltage of 120 V 
until fragments were separated. DNA fragments were visualized with an UV 
transilluminator and documented with a camera system. 
5.2.3 Cell preparation 
5.2.3.1 Isolation of cells from bone marrow 
After sacrificing the mice by cervical dislocation, hematopoietic organs were removed 
and kept in PBS on ice. Bones from hind legs (femur, tibia), hips (ilium) and/or 
vertebrae (columna vertebralis) were isolated and muscle and connective tissue was 
removed using a scalpel and tissue. Bones were crushed with mortar and pestle in 
RPMI-1640 medium supplemented with 2% fetal calf serum (FCS). Cell suspensions 
were filtered through a 40 µm cell strainer. Viable cell numbers were determined with a 
Vi-CELL cell counter or manually using a Neubauer chamber. 
5.2.3.2 Isolation of cells from liver and thymus 
Liver and thymus were passed through a 40 µm cell strainer into RPMI-1640 medium 
supplemented with 2% FCS. Viable cell numbers were determined with a Vi-CELL cell 
counter. 
5.2.3.3 Peripheral blood isolation 
For isolation of peripheral blood (PB), 4-5 drops of blood were collected from the vena 
facialis into an EDTA containing tube. A blood cell count was performed using the 
automated Hemavet counter. For flow cytometric analysis erythrocytes were lysed 
twice with 1 ml of ACK lysing buffer at room temperature for 5 min. All centrifugation 
steps were conducted at 1,600 rpm for 5 min at 4°C with an Eppendorf 5810r 
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centrifuge. All wash steps were performed with ice-cold PBS supplemented with 2% 
FCS. 
5.2.3.4 Lineage depletion 
BM cells depleted for lineage positive cells were prepared by staining with a cocktail of 
rat anti-mouse monoclonal antibodies (mAbs) against the following lineage markers: 
CD4 (GK1.5), CD8a (53.6.7), B220 (RA3-6B2), Gr1 (RB6.8C5), Ter119 (Ter119) and 
CD11b (M1/70). These antibodies were purified and conjugated in our laboratory 
according to standard protocols. Labeled cells were then removed by incubation with 
sheep anti-rat IgG coated Dynabeads® (4.5 µm diameter superparamagnetic polystyrene 
beads) at a 2:1 bead-to-target cell ratio and subsequent magnetic separation. All 
centrifugation steps were conducted at 1,600 rpm for 5 min at 4°C with an Eppendorf 
5810r centrifuge. All wash steps were performed with ice-cold PBS supplemented with 
2% FCS. 
5.2.3.5 Cell surface staining 
All antibody cell surface stainings were performed in a solution of 50% RPMI-1640 
supplemented with 2% FCS and 50% cultured supernatant from the 24G2 hybridoma 
cell line, which produces a rat monoclonal antibody directed against the CD16/32 or 
FcγR antigen. Cell surface stainings that aimed to identify committed progenitor cells 
by CD16/32 (FcγR) expression were performed in RPMI-1640 supplemented with 2% 
FCS only. All antibodies used in the experiments were titrated before usage. 
For hematopoietic stem and progenitor cell identification, total or lineage depleted cells 
were stained using lineage antibodies (CD4, CD8, CD11b, Gr-1, B220 and TER119) 
and antibodies against c-Kit, Sca-1, CD150, CD48, CD135, CD34 and in part also 
CD41. All experiments with the del(8-17) mouse line did not include the CD135 
marker, therefore MPP3 and MPP4 are combined as MPP3/4. 
For staining of progenitor cells, cells were stained using lineage antibodies (CD4, CD8, 
CD11b, Gr-1, B220 and TER119) and antibodies against c-Kit, Sca-1, CD16/32, CD34, 
CD127 and CD135. 
For staining of mature hematopoietic cells antibodies against CD4, CD8, CD11b, 
CD41, CD71, B220, Gr-1 and TER119 were used. 
Mean fluorescence intensities for lacZ stainings and CD41 expression in HSCs were 
determined as geometric mean of the respective fluorescence signal. 
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Abbreviation Population name Cell surface phenotype 
Lin lineage (adult mice) CD11b
+ Gr-1+ B220+ CD4+ CD8a+ 
Ter119+ 
Lin lineage (fetuses) Gr-1+ B220+ CD4+ CD8a+ Ter119+ 
LSK hematopoietic stem and progenitor cells Lin
- Sca-1+ c-Kit+ 
HSC hematopoietic stem cell LSK CD150+ CD48- CD34- (CD135-) 
MPP1 multipotent progenitor 1 LSK CD150+ CD48- CD34+ (CD135-) 
MPP2 multipotent progenitor 2 LSK CD150+ CD48+ CD34+ (CD135-) 
MPP3 multipotent progenitor 3 LSK CD150- CD48+ CD34+ CD135- 
MPP4 multipotent progenitor 4 LSK CD150- CD48+ CD34+ CD135+ 
MPP3/4 multipotent progenitors 3 and 4 LSK CD150- CD48+ CD34+ 
LS-K myeloid committed progenitors Lin- Sca-1- c-Kit+ 
CMP common myeloid progenitor Lin- Sca-1- c-Kit+ IL7Rα- CD34+ FcγRlow 
GMP granulocyte macrophage progenitor Lin
- Sca-1- c-Kit+ IL7Rα- CD34+ FcγRhigh 
MEP megakaryocyte erythrocyte progenitor Lin
- Sca-1- c-Kit+ IL7Rα- CD34- FcγRlow 
CLP common lymphoid progenitor Lin- Sca-1int c-Kitint IL7Rα+ 
gran / My granulocytes CD11b+ Gr-1+ 
mac macrophages CD11b+ Gr-1- 
B B lymphocytes B220+ 
T T lymphocytes CD4+ cells and CD8a+ cells 
CD4+ T CD4+ T lymphocytes CD4+ 
CD8+ T CD8+ T lymphocytes CD8a+ 
DP double positive thymocytes CD4+ CD8a+ 
SP CD4 single positive CD4 thymocytes CD4+ 
SP CD8 single positive CD8 thymocytes CD8a+ 
DN double negative thymocytes CD4- CD8a- 
DN1 DN1 thymocytes CD4- CD8a- CD44+ CD25- 
DN2 DN2 thymocytes CD4- CD8a- CD44+ CD25+ 
DN3 DN3 thymocytes CD4- CD8a- CD44- CD25+ 
DN4 DN4 thymocytes CD4- CD8a- CD44- CD25- 
ProE proerythroblasts CD71+ Ter119- 
EB erythroblasts CD71+ Ter119+ 
EP erythrocyte progenitors CD71+ 
RBC red blood cells Ter119+ 
Mgk megakaryocytes CD41+ 
Table 5.15: Hematopoietic populations and corresponding cell surface markers 
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Detection of chimerism in BM and peripheral blood cells was achieved by using 
CD45.1 and CD45.2 antibodies. 
For staining of developing T cells thymocytes were stained with antibodies against 
CD4, CD8, CD44, CD25, c-Kit, Ter119. 
To calculate the number of a cell type, the absolute frequency of the population 
determined by flow cytometry was multiplied by the number of cells in the tissue 
determined by the Vi-CELL cell counter. 
All monoclonal antibody conjugates were purchased from companies indicated in Table 
5.4. The cell surface phenotypes used to identify and purify each population are listed in 
Table 5.15. 
5.2.3.6 Cell cycle staining 
For cell cycle analysis, cell surface stained cells were fixed and permeabilized with 
Cytofix/Cytoperm according to manufacturers instructions. Cells were then stained with 
anti-Ki67 antibody for at least one hour on ice followed by addition of Hoechst33342 
for 5 min. After washing cells were immediately acquired at the flow cytometer. 
5.2.3.7 LacZ staining 
Cell surface stained BM cells were pelleted, resuspended in 200 µl (differentiated cell 
and progenitor cell staining) or 500 µl (HSC staining) of HBSS+ buffer and warmed for 
10 min to 37°C. Hypotonic loading was accomplished by diluting the cells in a 2:1 ratio 
with warmed 2 mM fluorescein di-(β-D-galactopyranoside) (FDG) containing 1% 
DMSO and 1% ethanol and incubation at 37°C for exactly 1 min. Loading was stopped 
by adding 2 ml of ice-cold HBSS+ solution and intracellular hydrolysis of FDG to 
fluorescein catalyzed by β-galactosidase was allowed to proceed on ice for 1 h. Cells 
were immediately acquired at the flow cytometer. 
5.2.4 Flow cytometry 
5.2.4.1 Flow cytometry for cell analysis 
Cells were analyzed by flow cytometry on either a LSRII or LSR Fortessa cell analyzer 
equipped with a 350 nm, 405 nm, 488 nm, 561 nm, and 640 nm laser. Prior to analysis 
of multicolor samples, compensation was manually adjusted according to signals from 
OneComp eBeads stained with single antibodies. 
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5.2.4.2 Fluorescence-activated cell sorting (FACS) 
Fluorescence-activated cell sorting (FACS) was performed on a FACSAria I, a 
FACSAria II or a FACSAria III cell sorter at the DKFZ Flow Cytometry Service Unit. 
5.2.4.3 Analysis of flow cytometric data 
Analysis of flow cytometric data was performed using the FlowJo software version 
9.6.4. Analysis was performed on live cells gated according to forward and side scatter 
characteristics. 
5.2.5 Competitive transplantation 
BM cells were isolated as described in 5.2.3.1. Cells were mixed in a 80:20 ratio with 
BM cells of CD45.1+/CD45.2+ mice and an aliquot of this cell suspension was cell 
surface stained for differentiated cells and hematopoietic stem and progenitor cells to 
determine the input ratio by flow cytometry. A volume of 100 µl containing 3x106 cells 
was intravenously injected into the tail vein of lethally irradiated (2x4.5 Gy using a Cs 
137 γ-irradiator on the day before) CD45.1+ mice. Mice were kept on antibiotic 
(trimethoprim/sulfamethoxazole) containing water for 3 weeks post transplantation. 
Peripheral blood chimerism was assessed by flow cytometry at 4, 8 and 12 weeks after 
transplantation. Mice were sacrificed after 16 weeks for peripheral blood and BM 
analysis by flow cytometry. 
5.2.6 Colony forming unit assay 
10,000 freshly prepared BM cells were mixed with 1 ml of semi-solid MethoCult 
M3434 medium and plated on a 35 mm culture plate. Colonies were counted after ten 
days using an Zeiss Primo Vert inverted microscope (4x and 10x objective) and images 
were captured using an AxioCam Erc 5s. 
5.2.7 mRNA expression analysis 
5.2.7.1 RNA isolation 
500-50,000 cells were sorted in Extraction Buffer and RNA isolation was performed as 
described in the manual of the PicoPure RNA Isolation Kit including Rnase-free Dnase 
digestion to avoid unwanted contamination of genomic. 
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5.2.7.2 Reverse transcription 
RNA samples were transcribed using the SuperScript VILO cDNA synthesis kit 
according to the manufacturer’s instructions. cDNA was diluted in Rnase-free water. 
5.2.7.3 Quantitative real-time polymerase chain reaction 
Quantitative real-time PCR (qRT-PCR) reactions were performed on a ViiA 7 Real-
Time PCR System using the Power SYBR Green Master Mix (at DKFZ). PCR reactions 
were performed in 384-well plates in a reaction volume of 10 µl with primer 
concentrations of 0.5 µM. The initial denaturation step of 95°C for 10 min was followed 
by 40 cycles of 15 seconds denaturation step at 95°C and 45 s annealing and extension 
step at 60°C. To confirm the specificity of the reaction a melting curve analysis was 
performed after the amplification cycles (denaturation at 95°C followed by continuous 
melting steps (0.5°C/s) starting from 65°C to 95°C). The fluorescent signal was 
monitored at the end of the extension step for each cycle as well as during the 
temperature ramp. Results were analyzed using the supplied ViiA 7 Software. The cycle 
number at which the fluorescence exceeds the background signal (cycle threshold; Ct) 
for each sample was determined with the baseline threshold algorithm that subtracts a 
baseline component and sets a fluorescent threshold in the exponential region for gene 
quantification. 
Genotype Direction Sequence (5’-3’) Product size 
forward CCC TAG TGC TGC ATG AGG AGA CAC 
c-myc 
reverse CCA CAG ACA CCA CAT CAA TTT CTT CC 
93 bp 
forward CTC CGG AGA GGA TAC CTT GA 
N-myc 
reverse TCT CTA CGG TGA CCA CAT CG 
89 bp 
forward AAG AAC GGG ATC CTG ACC ATC TCC 
Ddef1 
reverse TGG CAG GTG AGG AGG TTT AAC TTA GC 
74 bp 
forward CCA GGG AAA GGA TTC AAT TAA GG 
Fam84b 
reverse CAC AAC AGC AGG CCA AAA ACA 
61 bp 
forward TGG CCA CGA AAT ACG AGA G 
Fam49b 
reverse CGC CTT CTC TTG CAA CTT CT 
81 bp 
forward TTT CAG CTA GCA TCC TGT ACT CC 
OAZ1 
reverse GAC CCT GGT CTT GTC GTT AGA  
77 bp 
Table 5.16: qRT-PCR primer 
Lyophilized oligonucleotides were resuspended with dH2O and stored at 4°C overnight. Primers 
were diluted to a final concentration of 10 pM/µl and stored at -20 °C. 
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Primers used in this study are listed in Table 5.16. Efficiency of all primers was 
validated for the relevant Ct range. Expression levels were normalized to the levels of 
OAZ1 expression, which were previously identified by Dr. Armin Ehninger as being 
stably expressed in BM cells. Relative gene expression was calculated by the 2(-∆∆Ct)-
method (LIVAK and SCHMITTGEN 2001). 
5.2.8 Histology 
5.2.8.1 Peripheral blood smears 
2 µl of peripheral blood was placed close to the end of a glass slide. A second spreader 
slide was hold at an angle of approximately 30° and slowly moved backwards towards 
the blood drop. After the blood was spread along the edge of the spreader slide, the 
blood smear was produced moving the spreader slide forward. Air-dried smears were 
fixed with 100% of methanol for 5 min and then kept at room temperature until further 
processing. 
5.2.8.2 May-Grünwald-Giemsa staining 
Peripheral blood smears were stained for 7 min in May-Grünwald solution mixed 1:1 
with modified Sörensen buffer. Slides were 10 s air-dried and then immersed for 20 min 
into freshly prepared Giemsa solution. Stainings were allowed to differentiate in three 
wash steps in modified Sörensen buffer solution (one time for 10 s and two times for 
4 min), then air-dried and mounted with in Entellan after immersing in Xylol for 
15 min. Slides were analyzed on an Zeiss Axioplan widefield microscope (20, 40 and 
63x objective) and images were captured using an AxioCam Icc3. 
5.2.8.3 Image analysis of peripheral blood smears 
Image analysis was done using FIJI, employing the automated macro shown below. 
Correct encircling of red blood cells was always verified and corrected by visual 
inspection of the processed image. 
 
run(“Set Measurements...”, “area perimeter fit shape feret’s 
skewness kurtosis redirect=None decimal=3”); 
run(“Set Scale...”, “distance=0 known=0 pixel=1 unit=pixel 
global”); 
run(“Clear Results”); 
roiManager(“Reset”); 
run(“Duplicate...”, “title=dupl.czi duplicate”); 
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run(“Split Channels”); 
close(); 
run(“Invert”); 
run(“Grays”); 
run(“Subtract Background...”, “rolling=50 sliding”); 
run(“Median...”, “radius=2”); 
run(“Unsharp Mask...”, “radius=4 mask=0.90”); 
//run(“Threshold...”); 
setAutoThreshold(“Default dark”); 
setThreshold(9, 255); 
run(“Convert to Mask”); 
run(“Fill Holes”); 
run(“Watershed”); 
setAutoThreshold(“Default dark”); 
run(“Analyze Particles...”, “size=200-1000 circularity=0.85-1.00 
show=Nothing display exclude summarize add”); 
close(); 
close(); 
roiManager(“Show None”); 
roiManager(“Show All”); 
5.2.9 Chromatin Immunoprecipitation (ChIP) 
Cell suspensions of BM cells were crosslinked directly after isolation by adding PFA to 
a final concentration of 1%. After 10 min shaking at room temperature, PFA was 
quenched by adding 10% volume of a 1 M glycine solution. After centrifugation for 
5 min and 500 g at room temperature, cell surface staining was performed as described 
in chapter 5.2.3.5. 
Chromatin immunoprecipitation (ChIP) experiments were carried out according to 
protocols from the group of François Spitz at EMBL. 
5.2.10 Statistics 
For statistical analysis and graphical representation of data the GraphPad Prism 
software version 6.0b was used. If not specified differently graphs show the mean value 
and error bars indicate standard error of the mean (SEM). Significance of differences 
between samples was determined using unpaired two-tailed t-tests. Significance was 
plotted with *** (p < 0.001; extremely significant), ** (0.001 > p < 0.01; very signifi-
cant), * (0.01 > p < 0.05; significant), ns (p > 0.05; not significant). 
 
  
6 APPENDIX 
6.1 Supplementary Figures 
6.1.1 Chromatin modifications in hematopoietic cell types 
Global chromatin modifications were published in August 2014 for several murine 
hematopoietic cell types (LARA-ASTIASO et al. 2014). Cells were isolated by FACS 
from wild type mice using cell surface staining as indicated in Table 6.1. ChIP pro-
files for H3K4me1, H3K27ac and H3K4me3 chromatin modifications in the DHEC 
region are shown in Figure 6.1 and 6.2 together with the position of the enhancer 
modules and ChIP profiles of several transcription factors (WILSON et al. 2010). 
cell type tissue/organ cell surface staining 
LT-HSC BM Lin- c-Kit+ Sca-1+ Flk2- CD34- 
ST-HSC BM Lin- c-Kit+ Sca-1+ Flk2- CD34+ 
MPP BM Lin- c-Kit+ Sca-1+ Flk2+ CD34+ 
CMP BM Lin- c-Kit- Sca-1+ FcgRIIlow CD34+ 
GMP BM Lin- c-Kit- Sca-1+ FcgRIIhigh CD34+ 
MEP BM Lin- c-Kit- Sca-1+ FcgRIIlow CD34- 
CLP BM Lin- c-Kit+ Sca-1+ Flk2+ IL7R+ 
granulocytes (gran) BM CD3- B220- Nk1.1- CD11b+ Gr-1+ High SSC 
macrophages (mac) BM CD3- B220- F4/80+ CD115- Low SSC 
B cells (B) spleen CD3- B220+ CD19+ 
CD4+ T cells (CD4 T) spleen CD3+ B220- CD4+ CD8- 
CD8+ T cells (CD8 T) spleen CD3+ B220- CD4- CD8+ 
EryA spleen Ter119+ CD71+ high FSC 
EryB spleen Ter119+ CD71+ low FSC 
Table 6.1: Cell surface marker for hematopoietic cell isolation used by LARA-ASTIASO et 
al. 2014. 
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Figure 6.1: Enhancer-associated chromatin modifications in the DHEC region 
Positions of enhancer modules are indicated at the top. Below the ChIP data for transcription 
factors in the HP-7 hematopoietic cell line are shown in black (WILSON et al. 2010). Enhancer-
associated chromatin marks are shown in blue (H3K4me1) and green (H3K427ac) for 
different murine hematopoietic cell types (Table 6.1) (LARA-ASTIASO et al. 2014). Dashed 
boxes highlight erythroid lineage related prominent marks at module H. 
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Figure 6.2: Active promoter-associated chromatin marks in the DHEC region 
A Positions of enhancer modules are indicated at the top. H3K4me3 in different murine 
hematopoietic populations in the DHEC region reveals non-coding gene desert. B Same 
modification as in A for the c-myc locus showing high signal for active promoter mark 
H3K4me3 for c-myc and Pvt1 using the same signal range (LARA-ASTIASO et al. 2014). 
6.1.2 DNA methylation and RNA transcript in the DHEC region 
RNA-seq results from HSCs, defined as side population LSK CD150+ cells, showed a 
low expressed, not yet annotated transcript in the DHEC region (CHALLEN et al. 2014; 
SUN et al. 2014) and decreased expression of c-myc and N-myc in Dnmt3a knockout 
and Dnmt3ab double knockout mice (CHALLEN et al. 2014). 
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Figure 6.3: Presence of a transcript within the DHEC region in HSCs 
On the top the positions of enhancer modules are indicated. Results from whole-genome 
bisulfite sequencing (WGBS) and RNA-seq results (RNA) of age-matched control (ctrl) versus 
tertiary-transplanted Dnmt3a knockout (KO) and Dnmt3ab double knockout (dKO) HSCs are 
depicted in the first 6 lanes. RNA-seq results for granulocytes (gran) and B cells reveal no 
transcript in the DHEC region. The dashed box highlights a differentially methylated region 
that coincides with a low level of transcription (CHALLEN et al. 2012; CHALLEN et al. 2014). 
 
Figure 6.4: c-myc and N-myc transcripts are decreased upon Dnmt3a and Dnmt3ab 
knockout 
Data as in Figure 6.3 for the c-myc (A) and the N-myc (B) locus (CHALLEN et al. 2012; 
CHALLEN et al. 2014). Range for RNA-seq signals is adjusted (compare to Figure 6.3). 
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6.2 Abbreviations 
 
% percent 
°C degree Celsius 
< inferior 
> superior 
2i 2 inhibitor 
3C chromosome conformation capture 
3D three-dimensional 
4C circularized 3C 
5C 3C carbon copy 
ac acetylation 
ACK ammonium-chloride-potassium 
ADP adenosine diphosphate 
AF9 ALL1 fused gene from chromosome 9 
AGM aorta-gonad-mesonephros 
AML acute myeloid leukemia 
APC allophycocyanin 
ATP adenosine triphosphate 
B B cells 
BAC bacterial artifical chromosome 
BAT brown adipose tissue 
BL-CFC blast colony-forming cell 
bp base pair(s) 
bHLH-Zip basic-helix-loop-helix leucine zipper 
BL-CSC blast colony-forming cell 
BM bone marrow 
BMDM bone marrow derived macrophages 
BrdU 5-Bromo-2-deoxyuridine 
BRE TFIIB-recognition site 
BSA bovine serum albumin 
CAFC cobblestone area-forming cell 
CB cord blood 
CD cluster of differentiation 
CDK cycline-dependent kinase 
CEU Utah residents of northern and western European ancestry 
CFU colony forming unit 
CFU-S spleen colony forming unit 
CHB Han Chinese individuals from Beijing, China 
CHD chromo-ATPase-helicase-DNA-binding protein 
ChIA-PET 
chromosome interaction 
analysis by paired-end tag 
sequencing 
ChIP chromatin immunoprecipitation 
chr chromosome 
c-Kit 
v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene 
homolog 
CLP common lymphoid progenitor 
CMP common myeloid progenitor 
c-Myc cellular myelocytomatosis homologue 
CP committed progenitor 
CpG cytosine phosphodiester bond guanine 
Cs cesium 
Ct cycle threshold 
CTCF CCCTC-binding factor 
CTD carboxy-terminal domain 
CRC chromatin remodeling complex 
CRU competitive repopulating unit 
Cy5 cyanine 5 
Cy7 cyanine 7 
DC dendritic cell 
DCE downstream core element 
Ddef1 development and differen–tiation enhancing factor 1 
del deletion 
dH2O distilled water 
DHEC distal hematopoietic enhancer cluster 
DHS Dnase hypersensitivity site 
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DKFZ German Cancer Research Center 
dKO double knock-out 
dl deciliter 
DMSO dimethylsulfoxid 
dMyc Drosophila Myc 
DN double negative 
DNA deoxyribonucleic acid 
Dnase deoxyribonuclease 
DNMT DNA methyl transferase 
dNTP deoxyribonucleotide triphosphate 
DP double positive 
dpc days postcoitus 
DPE downstream promoter element 
dup duplication 
dUTP deoxyuridine triphosphate 
E embryonic day 
E-box enhancer box 
EB proerythroblast population 
EDTA ethylenediamine tetra-acetic acid 
EMBL European Molecular Biology Laboratory 
ENCODE Encyclopedia of DNA elements 
EP/E-P erythrocyte progenitors 
EPCR Endothelial protein C receptor 
eRNA enhancer RNA 
ESAM endothelial cell adhesion molecule 
EtOH ethanol 
EryA erythroblast population A 
EryB erythroblast population B 
EryC erythroblast population C 
ESC/ES 
cells embryonic stem cells 
EYFP enhanced yellow fluorescent protein 
FACS fluorescence activated cell sorting 
Fbw7 F-box and WD-40 domain protein 7 
FCS fetal calf serum 
FDG fluorescein di-(β-D-galactopyranoside) 
FIJI Fiji is just imageJ 
FISH fluorescent in situ hybridization 
FITC fluorescein isothiocyanate 
fl femtoliter 
Flk2 fetal liver kinase-2 
FLT3 FMS-related tyrosine kinase 3 
g gram or G-force 
G0 resting phase 
G1 Gap1 phase 
GCN5 general control of amino-acid synthesis 5 
GERP genomic evolutionary rate profiling 
GFP green fluorescent protein 
GMP granulocyte/macrophage progenitor 
GO gene ontology 
gran granulocytes 
GROMIT 
genome regulatory 
organization mapping with 
itegrated transposons 
GSK-3β Glycogen synthase kinase-3 β 
GTF general transcription factor 
GWAS genome-wide association studies 
Gy Gray 
h hour 
H2A histone 2A 
H2A.Z H2A family, member Z 
H2B histone 2B 
H3 histone 3 
H4 histone 4 
HapMap haplotype map 
HAT histone acetyltransferase 
Hb hemoglobin 
HBB hemoglobin subunit beta 
HBSS Hanks’ Balanced Salt Solution 
HCl hydrochloric acid 
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HCT hematocrit 
HDAC histone deacetylase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
hg18 human Mar. 2006 (NCBI36/ hg18) browser sequences 
hg19 human Feb. 2009 (GRCh37/ hg19) browser sequences 
Hi-C a genome-wide 3C analysis method 
hox genes homeotic genes 
HS hypersensitivity site 
HSC hematopoietic stem cell 
Hsp heat shock protein 
HSZ hämatopoetische Stammzelle 
IDH1 isocitrate dehydrogenase 1 
IFN Interferon 
IgG immunoglobulin G 
INO80 inositol requiring mutant 80 
ISWI Imitation Switch 
IVC individually ventilated cages 
JPT Japanese individuals from Tokyo, Japan 
Inr initiator element 
K lysine or 1000 
kb kilobase(s) 
KH2PO4 
potassium dihydrogen 
phosphate  
KO knock-out 
LacZ  β-galactosidase 
LCR locus control region 
LD linkage disequilibrium 
LIF leukemia inhibitory factor 
Lin lineage 
LMPP lymphoid-primed multipotent progenitor 
L-Myc Lung cancer amplified myelocytomatosis homologue 
lncRNA long non-coding RNA 
LSK Lin- Sca-1+ c-kit+ 
LS-K Lin- Sca-1- c-kit+ 
LTC-IC long-term culture-initiating cell 
M molar or million 
mac macrophages 
Mad mitotic arrest deficient 
Max Myc-associated factor X 
Mb megabase(s) 
MBD methyl-binding domain 
MC29 myelocytoma virus 29 
MCD34 mobilized CD34+ HSCs 
m(e)1 monomethylation 
m(e)2 dimethylation 
m(e)3 trimethylation 
MEF mouse embryonic fibroblast 
Mek mitogen-activated protein kinase kinase 
MEP megakaryocyte/erythroid-progenitor 
MeOH methanol 
MkEP megakaryocyte/erythrocyte progenitor 
MFI mean fluorescence intensity 
µg microgram 
mg milligram 
MgCl2 magnesium chloride 
Mgk megakaryocytes 
Mgk-P megakaryocyte progenitor 
min minute(s) 
Miz1 Myc-interacting Zinc finger protein 1 
MkEP megakaryocyte/erythrocyte progenitor 
µl microliter 
ml milliliter 
MLL mixed lineage leukemia 
µm micrometer 
µM micromolar 
mm millimeter 
mM millimolar 
mm9 mouse July 2007 (NCBI37/ mm9) browser sequences 
Mnt MAX network transcriptional repressor 
MPP multipotent progenitor 
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MPV mean platelet volume 
mRNA messenger RNA 
MTE motif ten element 
My myeloid cells 
Myc myelocytomatosis viral oncogene homolog 
NaCl sodium chloride 
NaOH sodium hydroxide 
Na2HPO4 sodium dihydrogen phosphate 
(NH4)2SO4 ammonium sulfate 
NK natural killer 
N-Myc Neuroblastoma amplified myelocytomatosis homologue 
nm nanometer 
NPM nucleophosmin 
Olfact olfactory bulb 
PB peripheral blood 
PBS phosphate buffered saline 
PcG polycomb group 
PCR polymerase chain reaction 
PFA paraformaldehyde 
pH power of hydrogen 
PIC pre-initiation complex 
pM picomolar 
polyA poly adenosine tail 
poly(I:C) Polyinosinic-polycytidylic acid 
PRC polycomb repressive complex 
PRE polycomb response element 
P1 promoter 1 
P2 promoter 2 
P3 promoter 3 
PE phycoerythrin 
PLT platelet count 
pM picomolar 
Pol2 RNA polymerase II 
Pvt1 plasmacytoma variant translocation 1 
qRT-PCR quantitative real-time polymerase chain reaction 
R arginine 
RBC red blood cells 
RET rearranged during transfection 
RNA ribonucleic acid 
RNAPII RNA polymerase II 
Rnase ribonuclease 
RNA-seq RNA sequencing 
Rnf32 Ring finger protein 32 
RPMI Roswell Park Memorial Institute 
rRNA ribosomal RNA 
RU repopulating unit 
s seconds 
Sca-1 stem cell antigen-1 
SD standard deviation 
SEM standard error of the mean 
Seq sequencing 
S/G2/M synthesis/gap2/mitotic phase 
Shh sonic hedgehog 
shRNA small hairpin RNA 
Sin3 Swi-independent 3 
SLAM signaling lymphocytic activation molecule 
Smint small intestine 
SNP single-nucleotide polymorphism 
snRNA small nuclear ribonucleic acid 
SP single positive 
SPF specific pathogen-free conditions 
SV40 Simian virus 40 
SWI/SNF SWItch/Sucrose NonFermentable 
SWR1 Swi2/Snf2 related 1 
T T cells 
TAD topological associating domain 
T-ALL T-cell acute lymphoblastic leukemia 
TBE TRIS-borat-EDTA buffer 
TBP TATA-binding protein 
TF transcription factor 
TSS transcriptional start site 
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TRACER 
transposase and recombi–
nase-associated chromosomal 
engineering resource 
TRIS tris(hydroxymethyl)amino-methane 
tRNA transfer RNA 
TRRAP Transformation/transcription domain-associated protein 
TUNEL 
terminal deoxynucleotide 
transferase dUTP nick end 
labeling 
TxRed Texas Red 
UCSC University of California, Santa Cruz 
UV ultraviolet 
V volt 
WBC white blood cell count 
WGBS whole-genome bisulfite sequencing 
Wt wild type 
APPENDIX 
 
 135
6.3 List of figures 
Figure 1.1: Distal regulatory elements ............................................................................. 5?
Figure 1.2: Histone modifications used for functional annotation of the mammalian 
genome ........................................................................................................ 14?
Figure 1.3: Timeline of hematopoietic events in the developing mouse........................ 23?
Figure 1.4: Hierarchical organization of the hematopoietic system............................... 24?
Figure 1.5: Gene regulation by Myc .............................................................................. 27?
Figure 1.6: Gene ontology analysis of Myc target genes ............................................... 28?
Figure 1.7: c-Myc controls the balance between HSC self-renewal and differentiation 33?
Figure 1.8: Conservation of the c-myc/Pvt1-flanking locus in humans ......................... 35?
Figure 3.1: The c-myc/Pvt1 gene locus is flanked by a large non-coding region .......... 40?
Figure 3.2: The deletion del(8-17) disturbs the differentiated cells ............................... 41?
Figure 3.3: The deletion del(8-17) leads to an increase of the hematopoietic stem and 
progenitor cell population............................................................................ 42?
Figure 3.4: The deletion del(8-17) leads to a more active cell cycle state of 
hematopoietic stem and progenitor cells ..................................................... 44?
Figure 3.5: Accumulation of hematopoietic stem and progenitor cells in the liver of 
newborn del(8-17) mice .............................................................................. 45?
Figure 3.6: Accumulation of hematopoietic stem and progenitor cells in the fetal liver of 
del(8-17) mice ............................................................................................. 46?
Figure 3.7: Analysis of gene expression in the c-myc/Pvt1 flanking locus upon del(8-17)
..................................................................................................................... 47?
Figure 3.8: Competitive transplantation shows an impaired differentiation potential but 
retained self-renewal of del(8-17) HSCs..................................................... 49?
Figure 3.9: Enhancer activity at the distal end of the c-myc/Pvt1 flanking locus .......... 51?
Figure 3.10: Enhancer activity across the c-myc gene desert......................................... 52?
Figure 3.11: The c-myc/Pvt1 flanking locus is located in a large TAD domain ............ 54?
Figure 3.12: Regulatory elements in the c-myc gene desert........................................... 55?
Figure 3.13: Deletion of the del(15-17) region leads to an accumulation of multipotent 
progenitor cells and a disturbed appearance of mature effector cells ......... 57?
Figure 3.14: Competitive transplantation shows an impaired differentiation potential but 
retained self-renewal of del(15-17) HSCs................................................... 59?
APPENDIX 
 
 136
Figure 3.15: Compound heterozygous mice display a similar phenotype as homozygous 
del(15-17) mice ........................................................................................... 61?
Figure 3.16: Compound heterozygous mice display reduced colony formation ability 62?
Figure 3.17: Relative gene expression in compound heterozygous mice ...................... 64?
Figure 3.18: A reduced distance between the DHEC and c-myc does not change 
hematopoietic cell frequencies .................................................................... 66?
Figure 3.19: The BM cellularity is equally reduced upon c-myc and del(15-17) deletion
..................................................................................................................... 67?
Figure 3.20: The distribution of stem, multipotent progenitor and committed progenitor 
cells is equally affected by c-myc and del(15-17) deletion except for CMPs 
and MEPs..................................................................................................... 69?
Figure 3.21: The effect of c-myc and del(15-17) deletion on the cell cycle profiles of 
hematopoietic stem and progenitor cell populations ................................... 70?
Figure 3.22: Expression of CD41 in HSCs and multipotent progenitor cells is changed 
upon deletion of c-myc and del(15-17)........................................................ 71?
Figure 3.23: The distribution of differentiated cell types is equally affected by c-myc 
and del(15-17) deletion except for erythrocytes.......................................... 72?
Figure 3.24: The effect of c-myc and del(15-17) deletion on the cell cycle profiles of B 
cells.............................................................................................................. 73?
Figure 3.25: Peripheral blood analysis by an automated cell count reveals differences in 
the erythrocyte phenotype upon c-myc or del(15-17) deletion.................... 75?
Figure 3.26: Peripheral blood smears show anemia in c-myc∆Mx mice which is not 
apparent in del(15-17) mice......................................................................... 76?
Figure 3.27: The size of erythrocytes in c-myc∆Mx mice is decreased and shows a higher 
variability..................................................................................................... 77?
Figure 3.28: BM erythroid progenitor numbers are decreased upon c-myc deletion ..... 78?
Figure 3.29: T cell development is impaired upon conditional c-myc deletion but not 
del(15-17) deletion ...................................................................................... 80?
Figure 3.30: The enhancer region consists of individual modules................................. 81?
Figure 3.31: Relative enrichment for H3K27ac in the individual modules ................... 82?
Figure 3.32: Evidence for the presence of a HSC specific enhancer cluster in the human 
c-myc/Pvt1 flanking locus ........................................................................... 83?
Figure 3.33: Implication of the DHEC in human diseases............................................. 84?
Figure 3.34: c-MYC expression levels in primary samples of AML.............................. 85?
APPENDIX 
 
 137
Figure 3.35: Murine duplication of the DHEC or a 3 Mb large region encompassing c-
myc and the DHEC does not change cell frequencies ................................. 86?
Figure 6.1: Enhancer-associated chromatin modifications in the DHEC region ......... 127?
Figure 6.2: Active promoter-associated chromatin marks in the DHEC region .......... 128?
Figure 6.3: Presence of a transcript within the DHEC region in HSCs ....................... 129?
Figure 6.4: c-myc and N-myc transcripts are decreased upon Dnmt3a and Dnmt3ab 
knockout .................................................................................................... 129?
 
6.4 List of tables 
Table 5.1: Reagents ...................................................................................................... 108?
Table 5.2: Enzymes ...................................................................................................... 108?
Table 5.3: Buffers......................................................................................................... 109?
Table 5.4: Antibodies for flow cytometry .................................................................... 110?
Table 5.5: Kits .............................................................................................................. 111?
Table 5.6: Consumables ............................................................................................... 111?
Table 5.7: Equipment ................................................................................................... 112?
Table 5.8: Computer, printer and software................................................................... 113?
Table 5.9: Internet resources ........................................................................................ 113?
Table 5.10: Transgenic mouse lines with transposon insertions .................................. 115?
Table 5.11: Transgenic mouse lines carrying deletions or duplications ...................... 115?
Table 5.12: Genotyping primers................................................................................... 117?
Table 5.13: PCR reaction conditions............................................................................ 117?
Table 5.14: PCR thermal cycling program................................................................... 117?
Table 5.15: Hematopoietic populations and corresponding cell surface markers........ 120?
Table 5.16: qRT-PCR primer ....................................................................................... 123?
Table 6.1: Cell surface marker for hematopoietic cell isolation used by LARA-ASTIASO 
et al. 2014. ................................................................................................. 126?
 
APPENDIX 
 
 138
6.5 Publications 
VON PALESKE, L., USLU, V.U., PETRETICH, M. SPITZ, F., TRUMPP, A. A novel enhancer 
region 1.7 Mb downstream of the c-myc gene drives its expression in 
hematopoietic stem and progenitor cells. Abstract chosen for oral presentation at 
the 56th ASH Annual Meeting in San Francisco, Dec. 2014. 
KLIMMECK, D., CABEZAS-WALLSCHEID, N., REYES, A., VON PALESKE, L., RENDERS, 
HANSSON, J., KRIJGSVELD, J., HUBER, W., TRUMPP, 2014. Transcriptome-wide 
Profiling and Posttranscriptional Analysis of Hematopoietic Stem/Progenitor Cell 
Differentiation toward Myeloid Commitment. Stem Cell Reports 3: 1-18. 
CABEZAS-WALLSCHEID, N., KLIMMECK, D., HANSSON, J., LIPKA, D. B., REYES, A., 
WANG, Q., WEICHENHAN, D., LIER, A., VON PALESKE, L., RENDERS, S., 
WÜNSCHE, P., ZEISBERGER, P., BROCKS, D., GU, L., HERRMANN, C., HAAS, S., 
ESSERS, M. A., BRORS, B., EILS, R., HUBER, W., MILSOM, M. D., PLASS, C., 
KRIJGSVELD, J., TRUMPP, A., 2014. Identification of Regulatory Networks in 
HSCs and Their Immediate Progeny via Integrated Proteome, Transcriptome, and 
DNA Methylome Analysis. Cell Stem Cell 15(4):507-22. 
DOHRN L., SALLES D., SIEHLER S.Y., KAUFMANN J., WIESMÜLLER L., 2012. BRCA1-
mediated repression of mutagenic end-joining of DNA double-strand breaks 
requires complex formation with BACH1. Biochem J. 441(3):919-26. 
 
  139
7 CONTRIBUTIONS 
The completion of this thesis would not have been possible without the help of many 
people ranging from technical support to the contributions of ideas. 
 
All experiments were performed in collaboration with Dr. Veli V. Uslu and Massimo 
Petretich from the lab of Dr. François Spitz at EMBL therefore I clarify their respective 
contributions to the project. Dr. Veli V. Uslu generated the transposon-mediated 
transgenic mouse strains and performed the genotyping of the mice housed at EMBL 
(mouse strains used for lacZ stainings, del(8-17), dup(15-17), dup(c17-17) and del(15-
17) mice used for transplantation). He dissected mice from EMBL and assisted in bone 
marrow cell isolation. He provided sequences for primers for genotyping of the 
transgenic mouse strains as well as the primers for qRT-PCR. qRT-PCR analysis of 
del(8-17) and dup(c17-17) were performed by him. Massimo Petretich performed ChIP 
experiments with FACS-sorted cells provided by me. The results were evaluated and 
visualized by a joint effort of Dr. Veli V. Uslu, Dr. François Spitz, Prof. Dr. Andreas 
Trumpp and me. 
 
At DKFZ great technical support, including bleeding, cell preparation and injections of 
mice, was provided by Petra Zeisberger, Katja Müdder, Adriana Przybylla and Daniel 
Baumgärtner. 
 
CONTRIBUTIONS 
 
 140
Genotyping of mice housed at DKFZ was done in part by Melanie Neubauer and 
Adriana Przybylla. The animal care takers under supervision of Anja Rathgeb 
contributed to the maintenance of the mouse facility as well as the irradiation of mice. 
 
The FACS sorts were performed together with Steffen Schmitt, Klaus Hexel, Jens 
Hartwig, Ann Atzberger and Tobias Rubner of the DKFZ FACS Core Facility. 
 
Dr. Damir Krunic helped in writing the Fiji macro for analysis of microscope images. 
 
Dr. Simon Raffel provided me with the qRT-PCR data for c-MYC expression in human 
AML samples. 
 
  
8 ACKNOWLEDGEMENTS 
ACKNOWLEDGEMENTS 
 
 142
 
  
9 BIBLIOGRAPHY 
ABRAMSON, S., MILLER, R. G. and PHILLIPS, R. A., 1977. The identification in adult 
bone marrow of pluripotent and restricted stem cells of the myeloid and lymphoid 
systems. J Exp Med 145: 1567-1579. 
ADAMS, J. M., HARRIS, A. W., PINKERT, C. A., CORCORAN, L. M., ALEXANDER, W. S., 
CORY, S., PALMITER, R. D. and BRINSTER, R. L., 1985. The c-myc oncogene 
driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic 
mice. Nature 318: 533-538. 
ADELMAN, K., and LIS, J. T., 2012. Promoter-proximal pausing of RNA polymerase II: 
emerging roles in metazoans. Nat Rev Genet 13: 720-731. 
ADHIKARY, S., and EILERS, M., 2005. Transcriptional regulation and transformation by 
Myc proteins. Nat Rev Mol Cell Biol 6: 635-645. 
ADOLFSSON, J., BORGE, O. J., BRYDER, D., THEILGAARD-MONCH, K., ASTRAND-
GRUNDSTROM, I., SITNICKA, E., SASAKI, Y. and JACOBSEN, S. E., 2001. 
Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) 
stem cell compartment is accompanied by loss of self-renewal capacity. Immunity 
15: 659-669. 
ADOLFSSON, J., MANSSON, R., BUZA-VIDAS, N., HULTQUIST, A., LIUBA, K. et al., 2005. 
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-
megakaryocytic potential a revised road map for adult blood lineage commitment. 
Cell 121: 295-306. 
AHMADIYEH, N., POMERANTZ, M. M., GRISANZIO, C., HERMAN, P., JIA, L. et al., 2010. 
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range 
interaction with MYC. Proc Natl Acad Sci U S A 107: 9742-9746. 
AKASHI, K., TRAVER, D., MIYAMOTO, T. and WEISSMAN, I. L., 2000. A clonogenic 
common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 
193-197. 
BIBLIOGRAPHY 
 
 144
ALBERTS, B., JOHNSON, A., LEWSI, J., RAFF, M., ROBERTS, K. and WALTER, P., 2008 
Molecular Biology of the Cell. Garland Science, New York. 
AMATI, B., BROOKS, M. W., LEVY, N., LITTLEWOOD, T. D., EVAN, G. I. and LAND, H., 
1993. Oncogenic activity of the c-Myc protein requires dimerization with Max. 
Cell 72: 233-245. 
AMERICO, J., WHITELEY, M., BROWN, J. L., FUJIOKA, M., JAYNES, J. B. and KASSIS, J. 
A., 2002. A complex array of DNA-binding proteins required for pairing-sensitive 
silencing by a polycomb group response element from the Drosophila engrailed 
gene. Genetics 160: 1561-1571. 
ANDERSSON, R., GEBHARD, C., MIGUEL-ESCALADA, I., HOOF, I., BORNHOLDT, J. et al., 
2014. An atlas of active enhancers across human cell types and tissues. Nature 
507: 455-461. 
ARA, T., TOKOYODA, K., SUGIYAMA, T., EGAWA, T., KAWABATA, K. and NAGASAWA, 
T., 2003. Long-term hematopoietic stem cells require stromal cell-derived factor-
1 for colonizing bone marrow during ontogeny. Immunity 19: 257-267. 
ARNOSTI, D. N., and KULKARNI, M. M., 2005. Transcriptional enhancers: Intelligent 
enhanceosomes or flexible billboards? J Cell Biochem 94: 890-898. 
ATCHLEY, W. R., and FITCH, W. M., 1995. Myc and Max: molecular evolution of a 
family of proto-oncogene products and their dimerization partner. Proc Natl Acad 
Sci U S A 92: 10217-10221. 
AYER, D. E., KRETZNER, L. and EISENMAN, R. N., 1993. Mad: a heterodimeric partner 
for Max that antagonizes Myc transcriptional activity. Cell 72: 211-222. 
AYER, D. E., LAWRENCE, Q. A. and EISENMAN, R. N., 1995. Mad-Max transcriptional 
repression is mediated by ternary complex formation with mammalian homologs 
of yeast repressor Sin3. Cell 80: 767-776. 
BAENA, E., GANDARILLAS, A., VALLESPINOS, M., ZANET, J., BACHS, O., REDONDO, C., 
FABREGAT, I., MARTINEZ, A. C. and DE ALBORAN, I. M., 2005. c-Myc regulates 
cell size and ploidy but is not essential for postnatal proliferation in liver. Proc 
Natl Acad Sci U S A 102: 7286-7291. 
BAENA, E., ORTIZ, M., MARTINEZ, A. C. and DE ALBORAN, I. M., 2007. c-Myc is 
essential for hematopoietic stem cell differentiation and regulates Lin(-)Sca-
1(+)c-Kit(-) cell generation through p21. Exp Hematol 35: 1333-1343. 
BAINES, P., and VISSER, J. W., 1983. Analysis and separation of murine bone marrow 
stem cells by H33342 fluorescence-activated cell sorting. Exp Hematol 11: 701-
708. 
BALAZS, A. B., FABIAN, A. J., ESMON, C. T. and MULLIGAN, R. C., 2006. Endothelial 
protein C receptor (CD201) explicitly identifies hematopoietic stem cells in 
murine bone marrow. Blood 107: 2317-2321. 
BIBLIOGRAPHY 
 
 145
BALDRIDGE, M. T., KING, K. Y., BOLES, N. C., WEKSBERG, D. C. and GOODELL, M. A., 
2010. Quiescent haematopoietic stem cells are activated by IFN-gamma in 
response to chronic infection. Nature 465: 793-797. 
BANERJI, J., RUSCONI, S. and SCHAFFNER, W., 1981. Expression of a beta-globin gene is 
enhanced by remote SV40 DNA sequences. Cell 27: 299-308. 
BANNISTER, A. J., and KOUZARIDES, T., 2011. Regulation of chromatin by histone 
modifications. Cell Res 21: 381-395. 
BARON, M. H., 2013. Concise Review: early embryonic erythropoiesis: not so primitive 
after all. Stem Cells 31: 849-856. 
BARSKI, A., CUDDAPAH, S., CUI, K., ROH, T. Y., SCHONES, D. E., WANG, Z., WEI, G., 
CHEPELEV, I. and ZHAO, K., 2007. High-resolution profiling of histone 
methylations in the human genome. Cell 129: 823-837. 
BAUS, J., LIU, L., HEGGESTAD, A. D., SANZ, S. and FLETCHER, B. S., 2005. Hyperactive 
transposase mutants of the Sleeping Beauty transposon. Mol Ther 12: 1148-1156. 
BECKER, A. J., MC, C. E. and TILL, J. E., 1963. Cytological demonstration of the clonal 
nature of spleen colonies derived from transplanted mouse marrow cells. Nature 
197: 452-454. 
BEER, S., ZETTERBERG, A., IHRIE, R. A., MCTAGGART, R. A., YANG, Q. et al., 2004. 
Developmental context determines latency of MYC-induced tumorigenesis. PLoS 
Biol 2: e332. 
BEISEL, C., and PARO, R., 2011. Silencing chromatin: comparing modes and 
mechanisms. Nat Rev Genet 12: 123-135. 
BENZ, C., COPLEY, M. R., KENT, D. G., WOHRER, S., CORTES, A. et al., 2012. 
Hematopoietic stem cell subtypes expand differentially during development and 
display distinct lymphopoietic programs. Cell Stem Cell 10: 273-283. 
BERGSAGEL, P. L., and KUEHL, W. M., 2001. Chromosome translocations in multiple 
myeloma. Oncogene 20: 5611-5622. 
BERNSTEIN, B. E., MIKKELSEN, T. S., XIE, X., KAMAL, M., HUEBERT, D. J. et al., 2006. 
A bivalent chromatin structure marks key developmental genes in embryonic stem 
cells. Cell 125: 315-326. 
BERNSTEIN, B. E., STAMATOYANNOPOULOS, J. A., COSTELLO, J. F., REN, B., 
MILOSAVLJEVIC, A. et al., 2010. The NIH Roadmap Epigenomics Mapping 
Consortium. Nat Biotechnol 28: 1045-1048. 
BERTA, M. A., BAKER, C. M., COTTLE, D. L. and WATT, F. M., 2010. Dose and context 
dependent effects of Myc on epidermal stem cell proliferation and differentiation. 
EMBO Mol Med 2: 16-25. 
BIBLIOGRAPHY 
 
 146
BERTONCELLO, I., HODGSON, G. S. and BRADLEY, T. R., 1985. Multiparameter analysis 
of transplantable hemopoietic stem cells: I. The separation and enrichment of 
stem cells homing to marrow and spleen on the basis of rhodamine-123 
fluorescence. Exp Hematol 13: 999-1006. 
BETTESS, M. D., DUBOIS, N., MURPHY, M. J., DUBEY, C., ROGER, C., ROBINE, S. and 
TRUMPP, A., 2005. c-Myc is required for the formation of intestinal crypts but 
dispensable for homeostasis of the adult intestinal epithelium. Mol Cell Biol 25: 
7868-7878. 
BIEDA, M., XU, X., SINGER, M. A., GREEN, R. and FARNHAM, P. J., 2006. Unbiased 
location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the 
human genome. Genome Res 16: 595-605. 
BIRNEY, E., STAMATOYANNOPOULOS, J. A., DUTTA, A., GUIGO, R., GINGERAS, T. R. et 
al., 2007. Identification and analysis of functional elements in 1% of the human 
genome by the ENCODE pilot project. Nature 447: 799-816. 
BLACKWELL, T. K., HUANG, J., MA, A., KRETZNER, L., ALT, F. W., EISENMAN, R. N. and 
WEINTRAUB, H., 1993. Binding of myc proteins to canonical and noncanonical 
DNA sequences. Mol Cell Biol 13: 5216-5224. 
BLACKWELL, T. K., KRETZNER, L., BLACKWOOD, E. M., EISENMAN, R. N. and 
WEINTRAUB, H., 1990. Sequence-specific DNA binding by the c-Myc protein. 
Science 250: 1149-1151. 
BLACKWOOD, E. M., and EISENMAN, R. N., 1991. Max: a helix-loop-helix zipper protein 
that forms a sequence-specific DNA-binding complex with Myc. Science 251: 
1211-1217. 
BLACKWOOD, E. M., LUSCHER, B. and EISENMAN, R. N., 1992. Myc and Max associate 
in vivo. Genes Dev 6: 71-80. 
BLANCO-BOSE, W. E., MURPHY, M. J., EHNINGER, A., OFFNER, S., DUBEY, C., HUANG, 
W., MOORE, D. D. and TRUMPP, A., 2008. C-Myc and its target FoxM1 are critical 
downstream effectors of constitutive androstane receptor (CAR) mediated direct 
liver hyperplasia. Hepatology 48: 1302-1311. 
BLOW, M. J., MCCULLEY, D. J., LI, Z., ZHANG, T., AKIYAMA, J. A. et al., 2010. ChIP-
Seq identification of weakly conserved heart enhancers. Nat Genet 42: 806-810. 
BONAL, C., THOREL, F., AIT-LOUNIS, A., REITH, W., TRUMPP, A. and HERRERA, P. L., 
2009. Pancreatic inactivation of c-Myc decreases acinar mass and 
transdifferentiates acinar cells into adipocytes in mice. Gastroenterology 136: 
309-319 e309. 
BOUCHARD, C., DITTRICH, O., KIERMAIER, A., DOHMANN, K., MENKEL, A., EILERS, M. 
and LUSCHER, B., 2001. Regulation of cyclin D2 gene expression by the 
BIBLIOGRAPHY 
 
 147
Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone 
acetylation at the cyclin D2 promoter. Genes Dev 15: 2042-2047. 
BOWIE, M. B., KENT, D. G., DYKSTRA, B., MCKNIGHT, K. D., MCCAFFREY, L., 
HOODLESS, P. A. and EAVES, C. J., 2007. Identification of a new intrinsically 
timed developmental checkpoint that reprograms key hematopoietic stem cell 
properties. Proc Natl Acad Sci U S A 104: 5878-5882. 
BOWIE, M. B., MCKNIGHT, K. D., KENT, D. G., MCCAFFREY, L., HOODLESS, P. A. and 
EAVES, C. J., 2006. Hematopoietic stem cells proliferate until after birth and show 
a reversible phase-specific engraftment defect. J Clin Invest 116: 2808-2816. 
BOYER, L. A., PLATH, K., ZEITLINGER, J., BRAMBRINK, T., MEDEIROS, L. A. et al., 2006. 
Polycomb complexes repress developmental regulators in murine embryonic stem 
cells. Nature 441: 349-353. 
BOYLE, A. P., DAVIS, S., SHULHA, H. P., MELTZER, P., MARGULIES, E. H., WENG, Z., 
FUREY, T. S. and CRAWFORD, G. E., 2008. High-resolution mapping and 
characterization of open chromatin across the genome. Cell 132: 311-322. 
BRENNER, C., DEPLUS, R., DIDELOT, C., LORIOT, A., VIRE, E. et al., 2005. Myc represses 
transcription through recruitment of DNA methyltransferase corepressor. EMBO J 
24: 336-346. 
BRYDER, D., ROSSI, D. J. and WEISSMAN, I. L., 2006. Hematopoietic stem cells: the 
paradigmatic tissue-specific stem cell. Am J Pathol 169: 338-346. 
BULGER, M., and GROUDINE, M., 2011. Functional and mechanistic diversity of distal 
transcription enhancers. Cell 144: 327-339. 
BUSHEY, A. M., DORMAN, E. R. and CORCES, V. G., 2008. Chromatin insulators: 
regulatory mechanisms and epigenetic inheritance. Mol Cell 32: 1-9. 
CABEZAS-WALLSCHEID, N., KLIMMECK, D., HANSSON, J., LIPKA, D. B., REYES, A. et al., 
2014. Identification of Regulatory Networks in HSCs and Their Immediate 
Progeny via Integrated Proteome, Transcriptome, and DNA Methylome Analysis. 
Cell Stem Cell. 
CAI, H. N., and SHEN, P., 2001. Effects of cis arrangement of chromatin insulators on 
enhancer-blocking activity. Science 291: 493-495. 
CAMPOS, E. I., and REINBERG, D., 2009. Histones: annotating chromatin. Annu Rev 
Genet 43: 559-599. 
CAO, R., WANG, L., WANG, H., XIA, L., ERDJUMENT-BROMAGE, H., TEMPST, P., JONES, 
R. S. and ZHANG, Y., 2002. Role of histone H3 lysine 27 methylation in 
Polycomb-group silencing. Science 298: 1039-1043. 
BIBLIOGRAPHY 
 
 148
CARRAMUSA, L., CONTINO, F., FERRO, A., MINAFRA, L., PERCONTI, G., GIALLONGO, A. 
and FEO, S., 2007. The PVT-1 oncogene is a Myc protein target that is 
overexpressed in transformed cells. J Cell Physiol 213: 511-518. 
CARTWRIGHT, P., MCLEAN, C., SHEPPARD, A., RIVETT, D., JONES, K. and DALTON, S., 
2005. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-
dependent mechanism. Development 132: 885-896. 
CASHMAN, J., HENKELMAN, D., HUMPHRIES, K., EAVES, C. and EAVES, A., 1983. 
Individual BFU-E in polycythemia vera produce both erythropoietin dependent 
and independent progeny. Blood 61: 876-884. 
CAWLEY, S., BEKIRANOV, S., NG, H. H., KAPRANOV, P., SEKINGER, E. A. et al., 2004. 
Unbiased mapping of transcription factor binding sites along human 
chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. 
Cell 116: 499-509. 
CHALLEN, G. A., SUN, D., JEONG, M., LUO, M., JELINEK, J. et al., 2012. Dnmt3a is 
essential for hematopoietic stem cell differentiation. Nat Genet 44: 23-31. 
CHALLEN, G. A., SUN, D., MAYLE, A., JEONG, M., LUO, M. et al., 2014. Dnmt3a and 
dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell 
Stem Cell 15: 350-364. 
CHANG, T. C., YU, D., LEE, Y. S., WENTZEL, E. A., ARKING, D. E., WEST, K. M., DANG, 
C. V., THOMAS-TIKHONENKO, A. and MENDELL, J. T., 2008. Widespread 
microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43-50. 
CHANG, T. C., ZEITELS, L. R., HWANG, H. W., CHIVUKULA, R. R., WENTZEL, E. A. et al., 
2009. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and 
proliferation. Proc Natl Acad Sci U S A 106: 3384-3389. 
CHARRON, J., MALYNN, B. A., FISHER, P., STEWART, V., JEANNOTTE, L., GOFF, S. P., 
ROBERTSON, E. J. and ALT, F. W., 1992. Embryonic lethality in mice homozygous 
for a targeted disruption of the N-myc gene. Genes Dev 6: 2248-2257. 
CHEN, C. Z., LI, M., DE GRAAF, D., MONTI, S., GOTTGENS, B. et al., 2002. Identification 
of endoglin as a functional marker that defines long-term repopulating 
hematopoietic stem cells. Proc Natl Acad Sci U S A 99: 15468-15473. 
CHEN, T., and LI, E., 2006. Establishment and maintenance of DNA methylation 
patterns in mammals. Curr Top Microbiol Immunol 301: 179-201. 
CHESI, M., ROBBIANI, D. F., SEBAG, M., CHNG, W. J., AFFER, M. et al., 2008. AID-
dependent activation of a MYC transgene induces multiple myeloma in a 
conditional mouse model of post-germinal center malignancies. Cancer Cell 13: 
167-180. 
BIBLIOGRAPHY 
 
 149
CHOI, K., KENNEDY, M., KAZAROV, A., PAPADIMITRIOU, J. C. and KELLER, G., 1998. A 
common precursor for hematopoietic and endothelial cells. Development 125: 
725-732. 
CHRISTENSEN, J. L., and WEISSMAN, I. L., 2001. Flk-2 is a marker in hematopoietic stem 
cell differentiation: a simple method to isolate long-term stem cells. Proc Natl 
Acad Sci U S A 98: 14541-14546. 
CHRISTENSEN, J. L., WRIGHT, D. E., WAGERS, A. J. and WEISSMAN, I. L., 2004. 
Circulation and chemotaxis of fetal hematopoietic stem cells. PLoS Biol 2: E75. 
CLAASSEN, G. F., and HANN, S. R., 2000. A role for transcriptional repression of 
p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-
cycle arrest. Proc Natl Acad Sci U S A 97: 9498-9503. 
CLAMP, M., FRY, B., KAMAL, M., XIE, X., CUFF, J., LIN, M. F., KELLIS, M., LINDBLAD-
TOH, K. and LANDER, E. S., 2007. Distinguishing protein-coding and noncoding 
genes in the human genome. Proc Natl Acad Sci U S A 104: 19428-19433. 
COLE, M. D., and COWLING, V. H., 2008. Transcription-independent functions of MYC: 
regulation of translation and DNA replication. Nat Rev Mol Cell Biol 9: 810-815. 
COOPER, G. M., STONE, E. A., ASIMENOS, G., GREEN, E. D., BATZOGLOU, S. and SIDOW, 
A., 2005. Distribution and intensity of constraint in mammalian genomic 
sequence. Genome Res 15: 901-913. 
COUILLARD, M., and TRUDEL, M., 2009. C-myc as a modulator of renal stem/progenitor 
cell population. Dev Dyn 238: 405-414. 
COURT, E. L., SMITH, M. A., AVENT, N. D., HANCOCK, J. T., MORGAN, L. M., GRAY, A. 
G. and SMITH, J. G., 2004. DNA microarray screening of differential gene 
expression in bone marrow samples from AML, non-AML patients and AML cell 
lines. Leuk Res 28: 743-753. 
COWLING, V. H., and COLE, M. D., 2007. The Myc transactivation domain promotes 
global phosphorylation of the RNA polymerase II carboxy-terminal domain 
independently of direct DNA binding. Mol Cell Biol 27: 2059-2073. 
CRAWFORD, G. E., DAVIS, S., SCACHERI, P. C., RENAUD, G., HALAWI, M. J. et al., 
2006a. DNase-chip: a high-resolution method to identify DNase I hypersensitive 
sites using tiled microarrays. Nat Methods 3: 503-509. 
CRAWFORD, G. E., HOLT, I. E., WHITTLE, J., WEBB, B. D., TAI, D. et al., 2006b. 
Genome-wide mapping of DNase hypersensitive sites using massively parallel 
signature sequencing (MPSS). Genome Res 16: 123-131. 
CREYGHTON, M. P., CHENG, A. W., WELSTEAD, G. G., KOOISTRA, T., CAREY, B. W. et 
al., 2010. Histone H3K27ac separates active from poised enhancers and predicts 
developmental state. Proc Natl Acad Sci U S A 107: 21931-21936. 
BIBLIOGRAPHY 
 
 150
CUMANO, A., DIETERLEN-LIEVRE, F. and GODIN, I., 1996. Lymphoid potential, probed 
before circulation in mouse, is restricted to caudal intraembryonic 
splanchnopleura. Cell 86: 907-916. 
CUMANO, A., FERRAZ, J. C., KLAINE, M., DI SANTO, J. P. and GODIN, I., 2001. 
Intraembryonic, but not yolk sac hematopoietic precursors, isolated before 
circulation, provide long-term multilineage reconstitution. Immunity 15: 477-485. 
CZERMIN, B., MELFI, R., MCCABE, D., SEITZ, V., IMHOF, A. and PIRROTTA, V., 2002. 
Drosophila enhancer of Zeste/ESC complexes have a histone H3 
methyltransferase activity that marks chromosomal Polycomb sites. Cell 111: 
185-196. 
DALLA-FAVERA, R., BREGNI, M., ERIKSON, J., PATTERSON, D., GALLO, R. C. and 
CROCE, C. M., 1982. Human c-myc onc gene is located on the region of 
chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci 
U S A 79: 7824-7827. 
DANG, C. V., 2012. MYC on the path to cancer. Cell 149: 22-35. 
DANG, C. V., O'DONNELL, K. A., ZELLER, K. I., NGUYEN, T., OSTHUS, R. C. and LI, F., 
2006. The c-Myc target gene network. Semin Cancer Biol 16: 253-264. 
DARZYNKIEWICZ, Z., ROBINSON, J. P. and MARIO ROEDERER, M., 2009 Essential 
Cytometry Methods. Academic Press. 
DATHE, K., KJAER, K. W., BREHM, A., MEINECKE, P., NURNBERG, P. et al., 2009. 
Duplications involving a conserved regulatory element downstream of BMP2 are 
associated with brachydactyly type A2. Am J Hum Genet 84: 483-492. 
DAVIS, A. C., WIMS, M., SPOTTS, G. D., HANN, S. R. and BRADLEY, A., 1993. A null c-
myc mutation causes lethality before 10.5 days of gestation in homozygotes and 
reduced fertility in heterozygous female mice. Genes Dev 7: 671-682. 
DE BRUIJN, M. F., SPECK, N. A., PEETERS, M. C. and DZIERZAK, E., 2000. Definitive 
hematopoietic stem cells first develop within the major arterial regions of the 
mouse embryo. EMBO J 19: 2465-2474. 
DE WIT, E., and DE LAAT, W., 2012. A decade of 3C technologies: insights into nuclear 
organization. Genes Dev 26: 11-24. 
DEATON, A. M., and BIRD, A., 2011. CpG islands and the regulation of transcription. 
Genes Dev 25: 1010-1022. 
DEVIDO, S. K., KWON, D., BROWN, J. L. and KASSIS, J. A., 2008. The role of Polycomb-
group response elements in regulation of engrailed transcription in Drosophila. 
Development 135: 669-676. 
BIBLIOGRAPHY 
 
 151
DIXON, J. R., SELVARAJ, S., YUE, F., KIM, A., LI, Y., SHEN, Y., HU, M., LIU, J. S. and 
REN, B., 2012. Topological domains in mammalian genomes identified by 
analysis of chromatin interactions. Nature 485: 376-380. 
DJEBALI, S., DAVIS, C. A., MERKEL, A., DOBIN, A., LASSMANN, T. et al., 2012. 
Landscape of transcription in human cells. Nature 489: 101-108. 
DOMINGUEZ-SOLA, D., YING, C. Y., GRANDORI, C., RUGGIERO, L., CHEN, B. et al., 
2007. Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-
451. 
DOSE, M., KHAN, I., GUO, Z., KOVALOVSKY, D., KRUEGER, A., VON BOEHMER, H., 
KHAZAIE, K. and GOUNARI, F., 2006. c-Myc mediates pre-TCR-induced 
proliferation but not developmental progression. Blood 108: 2669-2677. 
DOUAGI, I., VIEIRA, P. and CUMANO, A., 2002. Lymphocyte commitment during 
embryonic development, in the mouse. Semin Immunol 14: 361-369. 
DOUGLAS, N. C., JACOBS, H., BOTHWELL, A. L. and HAYDAY, A. C., 2001. Defining the 
specific physiological requirements for c-Myc in T cell development. Nat 
Immunol 2: 307-315. 
DUBOIS, N. C., ADOLPHE, C., EHNINGER, A., WANG, R. A., ROBERTSON, E. J. and 
TRUMPP, A., 2008. Placental rescue reveals a sole requirement for c-Myc in 
embryonic erythroblast survival and hematopoietic stem cell function. 
Development 135: 2455-2465. 
DYKSTRA, B., KENT, D., BOWIE, M., MCCAFFREY, L., HAMILTON, M., LYONS, K., LEE, 
S. J., BRINKMAN, R. and EAVES, C., 2007. Long-term propagation of distinct 
hematopoietic differentiation programs in vivo. Cell Stem Cell 1: 218-229. 
DZIERZAK, E., and SPECK, N. A., 2008. Of lineage and legacy: the development of 
mammalian hematopoietic stem cells. Nat Immunol 9: 129-136. 
EDELMANN, J., HOLZMANN, K., MILLER, F., WINKLER, D., BUHLER, A. et al., 2012. 
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new 
recurrent genomic alterations. Blood 120: 4783-4794. 
EHNINGER, A., BOCH, T., UCKELMANN, H., ESSERS, M. A., MUDDER, K., SLECKMAN, B. 
P. and TRUMPP, A., 2014. Posttranscriptional regulation of c-Myc expression in 
adult murine HSCs during homeostasis and interferon-alpha-induced stress 
response. Blood 123: 3909-3913. 
ELLWOOD-YEN, K., GRAEBER, T. G., WONGVIPAT, J., IRUELA-ARISPE, M. L., ZHANG, J., 
MATUSIK, R., THOMAS, G. V. and SAWYERS, C. L., 2003. Myc-driven murine 
prostate cancer shares molecular features with human prostate tumors. Cancer 
Cell 4: 223-238. 
BIBLIOGRAPHY 
 
 152
EMA, H., MORITA, Y., YAMAZAKI, S., MATSUBARA, A., SEITA, J., TADOKORO, Y., 
KONDO, H., TAKANO, H. and NAKAUCHI, H., 2006. Adult mouse hematopoietic 
stem cells: purification and single-cell assays. Nat Protoc 1: 2979-2987. 
EMA, H., and NAKAUCHI, H., 2000. Expansion of hematopoietic stem cells in the 
developing liver of a mouse embryo. Blood 95: 2284-2288. 
ERNST, J., KHERADPOUR, P., MIKKELSEN, T. S., SHORESH, N., WARD, L. D. et al., 2011. 
Mapping and analysis of chromatin state dynamics in nine human cell types. 
Nature 473: 43-49. 
ESSERS, M. A., OFFNER, S., BLANCO-BOSE, W. E., WAIBLER, Z., KALINKE, U., 
DUCHOSAL, M. A. and TRUMPP, A., 2009. IFNalpha activates dormant 
haematopoietic stem cells in vivo. Nature 458: 904-908. 
FELSHER, D. W., and BISHOP, J. M., 1999. Reversible tumorigenesis by MYC in 
hematopoietic lineages. Mol Cell 4: 199-207. 
FERNANDEZ, P. C., FRANK, S. R., WANG, L., SCHROEDER, M., LIU, S., GREENE, J., 
COCITO, A. and AMATI, B., 2003. Genomic targets of the human c-Myc protein. 
Genes Dev 17: 1115-1129. 
FISCHLE, W., WANG, Y., JACOBS, S. A., KIM, Y., ALLIS, C. D. and KHORASANIZADEH, 
S., 2003. Molecular basis for the discrimination of repressive methyl-lysine marks 
in histone H3 by Polycomb and HP1 chromodomains. Genes Dev 17: 1870-1881. 
FISHER, S., GRICE, E. A., VINTON, R. M., BESSLING, S. L. and MCCALLION, A. S., 2006. 
Conservation of RET regulatory function from human to zebrafish without 
sequence similarity. Science 312: 276-279. 
FLANAGAN, J. F., MI, L. Z., CHRUSZCZ, M., CYMBOROWSKI, M., CLINES, K. L., KIM, Y., 
MINOR, W., RASTINEJAD, F. and KHORASANIZADEH, S., 2005. Double 
chromodomains cooperate to recognize the methylated histone H3 tail. Nature 
438: 1181-1185. 
FORD, C. E., HAMERTON, J. L., BARNES, D. W. and LOUTIT, J. F., 1956. Cytological 
identification of radiation-chimaeras. Nature 177: 452-454. 
FORRESTER, W. C., EPNER, E., DRISCOLL, M. C., ENVER, T., BRICE, M., 
PAPAYANNOPOULOU, T. and GROUDINE, M., 1990. A deletion of the human beta-
globin locus activation region causes a major alteration in chromatin structure and 
replication across the entire beta-globin locus. Genes Dev 4: 1637-1649. 
FORSBERG, E. C., SERWOLD, T., KOGAN, S., WEISSMAN, I. L. and PASSEGUE, E., 2006. 
New evidence supporting megakaryocyte-erythrocyte potential of flk2/flt3+ 
multipotent hematopoietic progenitors. Cell 126: 415-426. 
FRANK, S. R., PARISI, T., TAUBERT, S., FERNANDEZ, P., FUCHS, M., CHAN, H. M., 
LIVINGSTON, D. M. and AMATI, B., 2003. MYC recruits the TIP60 histone 
acetyltransferase complex to chromatin. EMBO Rep 4: 575-580. 
BIBLIOGRAPHY 
 
 153
FRANK, S. R., SCHROEDER, M., FERNANDEZ, P., TAUBERT, S. and AMATI, B., 2001. 
Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone 
H4 and gene activation. Genes Dev 15: 2069-2082. 
FULCHER, D. A., and BASTEN, A., 1997. B cell life span: a review. Immunol Cell Biol 
75: 446-455. 
GARTEL, A. L., YE, X., GOUFMAN, E., SHIANOV, P., HAY, N., NAJMABADI, F. and 
TYNER, A. L., 2001. Myc represses the p21(WAF1/CIP1) promoter and interacts 
with Sp1/Sp3. Proc Natl Acad Sci U S A 98: 4510-4515. 
GAWAZ, M., LANGER, H. and MAY, A. E., 2005. Platelets in inflammation and 
atherogenesis. J Clin Invest 115: 3378-3384. 
GEKAS, C., DIETERLEN-LIEVRE, F., ORKIN, S. H. and MIKKOLA, H. K., 2005. The 
placenta is a niche for hematopoietic stem cells. Dev Cell 8: 365-375. 
GERSHENZON, N. I., and IOSHIKHES, I. P., 2005. Synergy of human Pol II core promoter 
elements revealed by statistical sequence analysis. Bioinformatics 21: 1295-1300. 
GEYER, P. K., 1997. The role of insulator elements in defining domains of gene 
expression. Curr Opin Genet Dev 7: 242-248. 
GEYER, P. K., and CORCES, V. G., 1992. DNA position-specific repression of 
transcription by a Drosophila zinc finger protein. Genes Dev 6: 1865-1873. 
GOHL, D., AOKI, T., BLANTON, J., SHANOWER, G., KAPPES, G. and SCHEDL, P., 2011. 
Mechanism of chromosomal boundary action: roadblock, sink, or loop? Genetics 
187: 731-748. 
GOLL, M. G., and BESTOR, T. H., 2005. Eukaryotic cytosine methyltransferases. Annu 
Rev Biochem 74: 481-514. 
GOMEZ-ROMAN, N., GRANDORI, C., EISENMAN, R. N. and WHITE, R. J., 2003. Direct 
activation of RNA polymerase III transcription by c-Myc. Nature 421: 290-294. 
GOODELL, M. A., BROSE, K., PARADIS, G., CONNER, A. S. and MULLIGAN, R. C., 1996. 
Isolation and functional properties of murine hematopoietic stem cells that are 
replicating in vivo. J Exp Med 183: 1797-1806. 
GREAVES, M., and MALEY, C. C., 2012. Clonal evolution in cancer. Nature 481: 306-
313. 
GROSVELD, F., VAN ASSENDELFT, G. B., GREAVES, D. R. and KOLLIAS, G., 1987. 
Position-independent, high-level expression of the human beta-globin gene in 
transgenic mice. Cell 51: 975-985. 
GRUNSTEIN, M., 1997. Histone acetylation in chromatin structure and transcription. 
Nature 389: 349-352. 
GUO, W., and WU, H., 2008. Detection of LacZ expression by FACS-Gal analysis. 
BIBLIOGRAPHY 
 
 154
GUO, Y., NIU, C., BRESLIN, P., TANG, M., ZHANG, S. et al., 2009. c-Myc-mediated 
control of cell fate in megakaryocyte-erythrocyte progenitors. Blood 114: 2097-
2106. 
GUY, C. T., WEBSTER, M. A., SCHALLER, M., PARSONS, T. J., CARDIFF, R. D. and 
MULLER, W. J., 1992. Expression of the neu protooncogene in the mammary 
epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S 
A 89: 10578-10582. 
HAAS, S., HANSSON, J., KLIMMECK, D., LÖFFLER, D., VELTEN, L. et al., 2014. 
Inflammation-driven fast-track differentiation of HSCs into the megakaryocytic 
lineage. Experimental Hematology 42: S14. 
HAH, N., DANKO, C. G., CORE, L., WATERFALL, J. J., SIEPEL, A., LIS, J. T. and KRAUS, 
W. L., 2011. A rapid, extensive, and transient transcriptional response to estrogen 
signaling in breast cancer cells. Cell 145: 622-634. 
HAH, N., MURAKAMI, S., NAGARI, A., DANKO, C. G. and KRAUS, W. L., 2013. Enhancer 
transcripts mark active estrogen receptor binding sites. Genome Res 23: 1210-
1223. 
HAHN, S., 2004. Structure and mechanism of the RNA polymerase II transcription 
machinery. Nat Struct Mol Biol 11: 394-403. 
HALLIKAS, O., PALIN, K., SINJUSHINA, N., RAUTIAINEN, R., PARTANEN, J., UKKONEN, E. 
and TAIPALE, J., 2006. Genome-wide prediction of mammalian enhancers based 
on analysis of transcription-factor binding affinity. Cell 124: 47-59. 
HANDOKO, L., XU, H., LI, G., NGAN, C. Y., CHEW, E. et al., 2011. CTCF-mediated 
functional chromatin interactome in pluripotent cells. Nat Genet 43: 630-638. 
HANNAH, R., JOSHI, A., WILSON, N. K., KINSTON, S. and GOTTGENS, B., 2011. A 
compendium of genome-wide hematopoietic transcription factor maps supports 
the identification of gene regulatory control mechanisms. Exp Hematol 39: 531-
541. 
HARDISON, R., SLIGHTOM, J. L., GUMUCIO, D. L., GOODMAN, M., STOJANOVIC, N. and 
MILLER, W., 1997. Locus control regions of mammalian beta-globin gene 
clusters: combining phylogenetic analyses and experimental results to gain 
functional insights. Gene 205: 73-94. 
HARE, E. E., PETERSON, B. K., IYER, V. N., MEIER, R. and EISEN, M. B., 2008. Sepsid 
even-skipped enhancers are functionally conserved in Drosophila despite lack of 
sequence conservation. PLoS Genet 4: e1000106. 
HARRISON, D. E., JORDAN, C. T., ZHONG, R. K. and ASTLE, C. M., 1993. Primitive 
hemopoietic stem cells: direct assay of most productive populations by 
competitive repopulation with simple binomial, correlation and covariance 
calculations. Exp Hematol 21: 206-219. 
BIBLIOGRAPHY 
 
 155
HASSAN, A. H., PROCHASSON, P., NEELY, K. E., GALASINSKI, S. C., CHANDY, M., 
CARROZZA, M. J. and WORKMAN, J. L., 2002. Function and selectivity of 
bromodomains in anchoring chromatin-modifying complexes to promoter 
nucleosomes. Cell 111: 369-379. 
HASSIG, C. A., FLEISCHER, T. C., BILLIN, A. N., SCHREIBER, S. L. and AYER, D. E., 1997. 
Histone deacetylase activity is required for full transcriptional repression by 
mSin3A. Cell 89: 341-347. 
HATA, K., OKANO, M., LEI, H. and LI, E., 2002. Dnmt3L cooperates with the Dnmt3 
family of de novo DNA methyltransferases to establish maternal imprints in mice. 
Development 129: 1983-1993. 
HATTON, B. A., KNOEPFLER, P. S., KENNEY, A. M., ROWITCH, D. H., DE ALBORAN, I. M., 
OLSON, J. M. and EISENMAN, R. N., 2006. N-myc is an essential downstream 
effector of Shh signaling during both normal and neoplastic cerebellar growth. 
Cancer Res 66: 8655-8661. 
HATTON, K. S., MAHON, K., CHIN, L., CHIU, F. C., LEE, H. W., PENG, D., 
MORGENBESSER, S. D., HORNER, J. and DEPINHO, R. A., 1996. Expression and 
activity of L-Myc in normal mouse development. Mol Cell Biol 16: 1794-1804. 
HEINTZMAN, N. D., HON, G. C., HAWKINS, R. D., KHERADPOUR, P., STARK, A. et al., 
2009. Histone modifications at human enhancers reflect global cell-type-specific 
gene expression. Nature 459: 108-112. 
HEINTZMAN, N. D., STUART, R. K., HON, G., FU, Y., CHING, C. W. et al., 2007. Distinct 
and predictive chromatin signatures of transcriptional promoters and enhancers in 
the human genome. Nat Genet 39: 311-318. 
HERAULT, Y., RASSOULZADEGAN, M., CUZIN, F. and DUBOULE, D., 1998. Engineering 
chromosomes in mice through targeted meiotic recombination (TAMERE). Nat 
Genet 20: 381-384. 
HERMEKING, H., RAGO, C., SCHUHMACHER, M., LI, Q., BARRETT, J. F. et al., 2000. 
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A 97: 
2229-2234. 
HERRANZ, D., AMBESI-IMPIOMBATO, A., PALOMERO, T., SCHNELL, S. A., BELVER, L. et 
al., 2014. A NOTCH1-driven MYC enhancer promotes T cell development, 
transformation and acute lymphoblastic leukemia. Nat Med. 
HNISZ, D., ABRAHAM, B. J., LEE, T. I., LAU, A., SAINT-ANDRE, V., SIGOVA, A. A., 
HOKE, H. A. and YOUNG, R. A., 2013. Super-enhancers in the control of cell 
identity and disease. Cell 155: 934-947. 
HOBEIKA, E., THIEMANN, S., STORCH, B., JUMAA, H., NIELSEN, P. J., PELANDA, R. and 
RETH, M., 2006. Testing gene function early in the B cell lineage in mb1-cre 
mice. Proc Natl Acad Sci U S A 103: 13789-13794. 
BIBLIOGRAPHY 
 
 156
HODGES, E., MOLARO, A., DOS SANTOS, C. O., THEKKAT, P., SONG, Q. et al., 2011. 
Directional DNA methylation changes and complex intermediate states 
accompany lineage specificity in the adult hematopoietic compartment. Mol Cell 
44: 17-28. 
HORIE, K., YUSA, K., YAE, K., ODAJIMA, J., FISCHER, S. E. et al., 2003. Characterization 
of Sleeping Beauty transposition and its application to genetic screening in mice. 
Mol Cell Biol 23: 9189-9207. 
HUANG, C. Y., BREDEMEYER, A. L., WALKER, L. M., BASSING, C. H. and SLECKMAN, B. 
P., 2008. Dynamic regulation of c-Myc proto-oncogene expression during 
lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J 
Immunol 38: 342-349. 
HUANG, S., LI, X., YUSUFZAI, T. M., QIU, Y. and FELSENFELD, G., 2007. USF1 recruits 
histone modification complexes and is critical for maintenance of a chromatin 
barrier. Mol Cell Biol 27: 7991-8002. 
HUBER, T. L., KOUSKOFF, V., FEHLING, H. J., PALIS, J. and KELLER, G., 2004. 
Haemangioblast commitment is initiated in the primitive streak of the mouse 
embryo. Nature 432: 625-630. 
HURLIN, P. J., QUEVA, C. and EISENMAN, R. N., 1997. Mnt, a novel Max-interacting 
protein is coexpressed with Myc in proliferating cells and mediates repression at 
Myc binding sites. Genes Dev 11: 44-58. 
HURLIN, P. J., QUEVA, C., KOSKINEN, P. J., STEINGRIMSSON, E., AYER, D. E., 
COPELAND, N. G., JENKINS, N. A. and EISENMAN, R. N., 1996. Mad3 and Mad4: 
novel Max-interacting transcriptional repressors that suppress c-myc dependent 
transformation and are expressed during neural and epidermal differentiation. 
EMBO J 15: 2030. 
IKUTA, K., and WEISSMAN, I. L., 1992. Evidence that hematopoietic stem cells express 
mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad 
Sci U S A 89: 1502-1506. 
IOSHIKHES, I. P., and ZHANG, M. Q., 2000. Large-scale human promoter mapping using 
CpG islands. Nat Genet 26: 61-63. 
JABBARI, K., and BERNARDI, G., 2004. Cytosine methylation and CpG, TpG (CpA) and 
TpA frequencies. Gene 333: 143-149. 
JOHNSON, G. R., and MOORE, M. A., 1975. Role of stem cell migration in initiation of 
mouse foetal liver haemopoiesis. Nature 258: 726-728. 
JOHNSTON, L. A., PROBER, D. A., EDGAR, B. A., EISENMAN, R. N. and GALLANT, P., 
1999. Drosophila myc regulates cellular growth during development. Cell 98: 
779-790. 
BIBLIOGRAPHY 
 
 157
JONES, P. A., 2012. Functions of DNA methylation: islands, start sites, gene bodies and 
beyond. Nat Rev Genet 13: 484-492. 
JUVEN-GERSHON, T., and KADONAGA, J. T., 2010. Regulation of gene expression via the 
core promoter and the basal transcriptional machinery. Dev Biol 339: 225-229. 
KAIKKONEN, M. U., SPANN, N. J., HEINZ, S., ROMANOSKI, C. E., ALLISON, K. A. et al., 
2013. Remodeling of the enhancer landscape during macrophage activation is 
coupled to enhancer transcription. Mol Cell 51: 310-325. 
KASSIS, J. A., 1994. Unusual properties of regulatory DNA from the Drosophila 
engrailed gene: three "pairing-sensitive" sites within a 1.6-kb region. Genetics 
136: 1025-1038. 
KASSIS, J. A., VANSICKLE, E. P. and SENSABAUGH, S. M., 1991. A fragment of engrailed 
regulatory DNA can mediate transvection of the white gene in Drosophila. 
Genetics 128: 751-761. 
KASTEN, M., SZERLONG, H., ERDJUMENT-BROMAGE, H., TEMPST, P., WERNER, M. and 
CAIRNS, B. R., 2004. Tandem bromodomains in the chromatin remodeler RSC 
recognize acetylated histone H3 Lys14. EMBO J 23: 1348-1359. 
KENG, V. W., YAE, K., HAYAKAWA, T., MIZUNO, S., UNO, Y. et al., 2005. Region-
specific saturation germline mutagenesis in mice using the Sleeping Beauty 
transposon system. Nat Methods 2: 763-769. 
KIEL, M. J., YILMAZ, O. H., IWASHITA, T., TERHORST, C. and MORRISON, S. J., 2005. 
SLAM family receptors distinguish hematopoietic stem and progenitor cells and 
reveal endothelial niches for stem cells. Cell 121: 1109-1121. 
KIM, T. K., HEMBERG, M., GRAY, J. M., COSTA, A. M., BEAR, D. M. et al., 2010. 
Widespread transcription at neuronal activity-regulated enhancers. Nature 465: 
182-187. 
KING, B., TRIMARCHI, T., REAVIE, L., XU, L., MULLENDERS, J. et al., 2013. The 
ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating 
MYC stability. Cell 153: 1552-1566. 
KNOEPFLER, P. S., CHENG, P. F. and EISENMAN, R. N., 2002. N-myc is essential during 
neurogenesis for the rapid expansion of progenitor cell populations and the 
inhibition of neuronal differentiation. Genes Dev 16: 2699-2712. 
KOCH, F., FENOUIL, R., GUT, M., CAUCHY, P., ALBERT, T. K. et al., 2011. Transcription 
initiation platforms and GTF recruitment at tissue-specific enhancers and 
promoters. Nat Struct Mol Biol 18: 956-963. 
KOHL, N. E., KANDA, N., SCHRECK, R. R., BRUNS, G., LATT, S. A., GILBERT, F. and 
ALT, F. W., 1983. Transposition and amplification of oncogene-related sequences 
in human neuroblastomas. Cell 35: 359-367. 
BIBLIOGRAPHY 
 
 158
KOMURO, K., ITAKURA, K., BOYSE, A. and JOHN, M., 1975. Ly-5; A New T-
Lymphocyte Antigen System. Immunogenetics: 452-456. 
KONDO, M., WEISSMAN, I. L. and AKASHI, K., 1997. Identification of clonogenic 
common lymphoid progenitors in mouse bone marrow. Cell 91: 661-672. 
KOPECKY, B., SANTI, P., JOHNSON, S., SCHMITZ, H. and FRITZSCH, B., 2011. Conditional 
deletion of N-Myc disrupts neurosensory and non-sensory development of the ear. 
Dev Dyn 240: 1373-1390. 
KOPECKY, B. J., DECOOK, R. and FRITZSCH, B., 2012. N-Myc and L-Myc are essential 
for hair cell formation but not maintenance. Brain Res 1484: 1-14. 
KOULNIS, M., POP, R., PORPIGLIA, E., SHEARSTONE, J. R., HIDALGO, D. and 
SOCOLOVSKY, M., 2011. Identification and analysis of mouse erythroid 
progenitors using the CD71/TER119 flow-cytometric assay. J Vis Exp. 
KOUZARIDES, T., 2007. Chromatin modifications and their function. Cell 128: 693-705. 
KROON, E., KROSL, J., THORSTEINSDOTTIR, U., BABAN, S., BUCHBERG, A. M. and 
SAUVAGEAU, G., 1998. Hoxa9 transforms primary bone marrow cells through 
specific collaboration with Meis1a but not Pbx1b. EMBO J 17: 3714-3725. 
KUHN, M. W., RADTKE, I., BULLINGER, L., GOORHA, S., CHENG, J. et al., 2012. High-
resolution genomic profiling of adult and pediatric core-binding factor acute 
myeloid leukemia reveals new recurrent genomic alterations. Blood 119: e67-75. 
KÜHN, R., SCHWENK, F., AGUET, M. and RAJEWSKY, K., 1995. Inducible gene targeting 
in mice. Science 269: 1427-1429. 
KULKARNI, M. M., and ARNOSTI, D. N., 2003. Information display by transcriptional 
enhancers. Development 130: 6569-6575. 
KUMARAVELU, P., HOOK, L., MORRISON, A. M., URE, J., ZHAO, S., ZUYEV, S., ANSELL, 
J. and MEDVINSKY, A., 2002. Quantitative developmental anatomy of definitive 
haematopoietic stem cells/long-term repopulating units (HSC/RUs): role of the 
aorta-gonad-mesonephros (AGM) region and the yolk sac in colonisation of the 
mouse embryonic liver. Development 129: 4891-4899. 
KUZMICHEV, A., NISHIOKA, K., ERDJUMENT-BROMAGE, H., TEMPST, P. and REINBERG, 
D., 2002. Histone methyltransferase activity associated with a human multiprotein 
complex containing the Enhancer of Zeste protein. Genes Dev 16: 2893-2905. 
LACKNER, D. H., and BAHLER, J., 2008. Translational control of gene expression from 
transcripts to transcriptomes. Int Rev Cell Mol Biol 271: 199-251. 
LAHERTY, C. D., YANG, W. M., SUN, J. M., DAVIE, J. R., SETO, E. and EISENMAN, R. N., 
1997. Histone deacetylases associated with the mSin3 corepressor mediate mad 
transcriptional repression. Cell 89: 349-356. 
BIBLIOGRAPHY 
 
 159
LAM, M. T., CHO, H., LESCH, H. P., GOSSELIN, D., HEINZ, S. et al., 2013. Rev-Erbs 
repress macrophage gene expression by inhibiting enhancer-directed transcription. 
Nature 498: 511-515. 
LANDER, E. S., LINTON, L. M., BIRREN, B., NUSBAUM, C., ZODY, M. C. et al., 2001. 
Initial sequencing and analysis of the human genome. Nature 409: 860-921. 
LARA-ASTIASO, D., WEINER, A., LORENZO-VIVAS, E., ZARETSKY, I., JAITIN, D. A. et al., 
2014. Immunogenetics. Chromatin state dynamics during blood formation. 
Science 345: 943-949. 
LAURENTI, E., VARNUM-FINNEY, B., WILSON, A., FERRERO, I., BLANCO-BOSE, W. E. et 
al., 2008. Hematopoietic stem cell function and survival depend on c-Myc and N-
Myc activity. Cell Stem Cell 3: 611-624. 
LAURENTI, E., WILSON, A. and TRUMPP, A., 2009. Myc's other life: stem cells and 
beyond. Curr Opin Cell Biol 21: 844-854. 
LAVENU, A., POURNIN, S., BABINET, C. and MORELLO, D., 1994. The cis-acting 
elements known to regulate c-myc expression ex vivo are not sufficient for correct 
transcription in vivo. Oncogene 9: 527-536. 
LEDER, A., PATTENGALE, P. K., KUO, A., STEWART, T. A. and LEDER, P., 1986. 
Consequences of widespread deregulation of the c-myc gene in transgenic mice: 
multiple neoplasms and normal development. Cell 45: 485-495. 
LEE, L. K., UENO, M., VAN HANDEL, B. and MIKKOLA, H. K., 2010. Placenta as a newly 
identified source of hematopoietic stem cells. Curr Opin Hematol 17: 313-318. 
LEE, T. I., JENNER, R. G., BOYER, L. A., GUENTHER, M. G., LEVINE, S. S. et al., 2006. 
Control of developmental regulators by Polycomb in human embryonic stem 
cells. Cell 125: 301-313. 
LEHNERTZ, B., UEDA, Y., DERIJCK, A. A., BRAUNSCHWEIG, U., PEREZ-BURGOS, L. et al., 
2003. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation 
to major satellite repeats at pericentric heterochromatin. Curr Biol 13: 1192-1200. 
LEMISCHKA, I. R., RAULET, D. H. and MULLIGAN, R. C., 1986. Developmental potential 
and dynamic behavior of hematopoietic stem cells. Cell 45: 917-927. 
LETTICE, L. A., HEANEY, S. J., PURDIE, L. A., LI, L., DE BEER, P. et al., 2003. A long-
range Shh enhancer regulates expression in the developing limb and fin and is 
associated with preaxial polydactyly. Hum Mol Genet 12: 1725-1735. 
LEVENS, D., 2010. You Don't Muck with MYC. Genes Cancer 1: 547-554. 
LEWIS, E. B., 1978. A gene complex controlling segmentation in Drosophila. Nature 
276: 565-570. 
LEY, T. J., DING, L., WALTER, M. J., MCLELLAN, M. D., LAMPRECHT, T. et al., 2010. 
DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424-2433. 
BIBLIOGRAPHY 
 
 160
LI, G., RUAN, X., AUERBACH, R. K., SANDHU, K. S., ZHENG, M. et al., 2012. Extensive 
promoter-centered chromatin interactions provide a topological basis for 
transcription regulation. Cell 148: 84-98. 
LI, H., ILIN, S., WANG, W., DUNCAN, E. M., WYSOCKA, J., ALLIS, C. D. and PATEL, D. 
J., 2006. Molecular basis for site-specific read-out of histone H3K4me3 by the 
BPTF PHD finger of NURF. Nature 442: 91-95. 
LI, Q., PETERSON, K. R., FANG, X. and STAMATOYANNOPOULOS, G., 2002. Locus 
control regions. Blood 100: 3077-3086. 
LI, W., NOTANI, D., MA, Q., TANASA, B., NUNEZ, E. et al., 2013. Functional roles of 
enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 498: 
516-520. 
LI, Z., VAN CALCAR, S., QU, C., CAVENEE, W. K., ZHANG, M. Q. and REN, B., 2003. A 
global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc 
Natl Acad Sci U S A 100: 8164-8169. 
LIEBERMAN, L., BERCOVITZ, R. S., SHOLAPUR, N. S., HEDDLE, N. M., STANWORTH, S. J. 
and ARNOLD, D. M., 2014. Platelet transfusions for critically ill patients with 
thrombocytopenia. Blood 123: 1146-1151; quiz 1280. 
LIEBERMAN-AIDEN, E., VAN BERKUM, N. L., WILLIAMS, L., IMAKAEV, M., RAGOCZY, T. 
et al., 2009. Comprehensive mapping of long-range interactions reveals folding 
principles of the human genome. Science 326: 289-293. 
LIN, C. Y., LOVEN, J., RAHL, P. B., PARANAL, R. M., BURGE, C. B., BRADNER, J. E., LEE, 
T. I. and YOUNG, R. A., 2012. Transcriptional amplification in tumor cells with 
elevated c-Myc. Cell 151: 56-67. 
LIU, J., and LEVENS, D., 2006. Making myc. Curr Top Microbiol Immunol 302: 1-32. 
LIVAK, K. J., and SCHMITTGEN, T. D., 2001. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
25: 402-408. 
LOHAN, S., SPIELMANN, M., DOELKEN, S. C., FLOTTMANN, R., MUHAMMAD, F. et al., 
2014. Microduplications encompassing the Sonic hedgehog limb enhancer ZRS 
are associated with Haas-type polysyndactyly and Laurin-Sandrow syndrome. 
Clin Genet. 
LOVEN, J., HOKE, H. A., LIN, C. Y., LAU, A., ORLANDO, D. A., VAKOC, C. R., BRADNER, 
J. E., LEE, T. I. and YOUNG, R. A., 2013. Selective inhibition of tumor oncogenes 
by disruption of super-enhancers. Cell 153: 320-334. 
LUGER, K., MADER, A. W., RICHMOND, R. K., SARGENT, D. F. and RICHMOND, T. J., 
1997. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 
389: 251-260. 
BIBLIOGRAPHY 
 
 161
LUO, G., IVICS, Z., IZSVAK, Z. and BRADLEY, A., 1998. Chromosomal transposition of a 
Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S 
A 95: 10769-10773. 
LUO, H., LI, Q., O'NEAL, J., KREISEL, F., LE BEAU, M. M. and TOMASSON, M. H., 2005. 
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of 
lymphoma-associated antiapoptotic mutations. Blood 106: 2452-2461. 
MALYNN, B. A., DE ALBORAN, I. M., O'HAGAN, R. C., BRONSON, R., DAVIDSON, L., 
DEPINHO, R. A. and ALT, F. W., 2000. N-myc can functionally replace c-myc in 
murine development, cellular growth, and differentiation. Genes Dev 14: 1390-
1399. 
MANZ, M. G., TRAVER, D., MIYAMOTO, T., WEISSMAN, I. L. and AKASHI, K., 2001. 
Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97: 
3333-3341. 
MARTINS, R. A., ZINDY, F., DONOVAN, S., ZHANG, J., POUNDS, S. et al., 2008. N-myc 
coordinates retinal growth with eye size during mouse development. Genes Dev 
22: 179-193. 
MASTON, G. A., EVANS, S. K. and GREEN, M. R., 2006. Transcriptional regulatory 
elements in the human genome. Annu Rev Genomics Hum Genet 7: 29-59. 
MATSUOKA, S., EBIHARA, Y., XU, M., ISHII, T., SUGIYAMA, D. et al., 2001. CD34 
expression on long-term repopulating hematopoietic stem cells changes during 
developmental stages. Blood 97: 419-425. 
MATSUZAKI, Y., KINJO, K., MULLIGAN, R. C. and OKANO, H., 2004. Unexpectedly 
efficient homing capacity of purified murine hematopoietic stem cells. Immunity 
20: 87-93. 
MAURANO, M. T., HUMBERT, R., RYNES, E., THURMAN, R. E., HAUGEN, E. et al., 2012. 
Systematic localization of common disease-associated variation in regulatory 
DNA. Science 337: 1190-1195. 
MAUTNER, J., BEHRENDS, U., HORTNAGEL, K., BRIELMEIER, M., HAMMERSCHMIDT, W., 
STROBL, L., BORNKAMM, G. W. and POLACK, A., 1996. c-myc expression is 
activated by the immunoglobulin kappa-enhancers from a distance of at least 30 
kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo. 
Oncogene 12: 1299-1307. 
MAYOR, C., BRUDNO, M., SCHWARTZ, J. R., POLIAKOV, A., RUBIN, E. M., FRAZER, K. 
A., PACHTER, L. S. and DUBCHAK, I., 2000. VISTA : visualizing global DNA 
sequence alignments of arbitrary length. Bioinformatics 16: 1046-1047. 
MCGAUGHEY, D. M., VINTON, R. M., HUYNH, J., AL-SAIF, A., BEER, M. A. and 
MCCALLION, A. S., 2008. Metrics of sequence constraint overlook regulatory 
sequences in an exhaustive analysis at phox2b. Genome Res 18: 252-260. 
BIBLIOGRAPHY 
 
 162
MCGRATH, K. E., FRAME, J. M., FROMM, G. J., KONISKI, A. D., KINGSLEY, P. D., 
LITTLE, J., BULGER, M. and PALIS, J., 2011. A transient definitive erythroid 
lineage with unique regulation of the beta-globin locus in the mammalian embryo. 
Blood 117: 4600-4608. 
MCKNIGHT, S. L., and KINGSBURY, R., 1982. Transcriptional control signals of a 
eukaryotic protein-coding gene. Science 217: 316-324. 
MCMAHON, S. B., WOOD, M. A. and COLE, M. D., 2000. The essential cofactor TRRAP 
recruits the histone acetyltransferase hGCN5 to c-Myc. Mol Cell Biol 20: 556-
562. 
MEDVINSKY, A., and DZIERZAK, E., 1996. Definitive hematopoiesis is autonomously 
initiated by the AGM region. Cell 86: 897-906. 
MELGAR, M. F., COLLINS, F. S. and SETHUPATHY, P., 2011. Discovery of active 
enhancers through bidirectional expression of short transcripts. Genome Biol 12: 
R113. 
MELO, C. A., DROST, J., WIJCHERS, P. J., VAN DE WERKEN, H., DE WIT, E. et al., 2013. 
eRNAs are required for p53-dependent enhancer activity and gene transcription. 
Mol Cell 49: 524-535. 
MERIKA, M., WILLIAMS, A. J., CHEN, G., COLLINS, T. and THANOS, D., 1998. 
Recruitment of CBP/p300 by the IFN beta enhanceosome is required for 
synergistic activation of transcription. Mol Cell 1: 277-287. 
MEYER, N., and PENN, L. Z., 2008. Reflecting on 25 years with MYC. Nat Rev Cancer 
8: 976-990. 
MIKKOLA, H. K., and ORKIN, S. H., 2006. The journey of developing hematopoietic 
stem cells. Development 133: 3733-3744. 
MILLER, B. A., ANTOGNETTI, G. and SPRINGER, T. A., 1985. Identification of cell 
surface antigens present on murine hematopoietic stem cells. J Immunol 134: 
3286-3290. 
MILLER, C. L., and EAVES, C. J., 1997. Expansion in vitro of adult murine hematopoietic 
stem cells with transplantable lympho-myeloid reconstituting ability. Proc Natl 
Acad Sci U S A 94: 13648-13653. 
MIN, J., ZHANG, Y. and XU, R. M., 2003. Structural basis for specific binding of 
Polycomb chromodomain to histone H3 methylated at Lys 27. Genes Dev 17: 
1823-1828. 
MORRISON, S. J., HEMMATI, H. D., WANDYCZ, A. M. and WEISSMAN, I. L., 1995. The 
purification and characterization of fetal liver hematopoietic stem cells. Proc Natl 
Acad Sci U S A 92: 10302-10306. 
BIBLIOGRAPHY 
 
 163
MOUSAVI, K., ZARE, H., DELL'ORSO, S., GRONTVED, L., GUTIERREZ-CRUZ, G., 
DERFOUL, A., HAGER, G. L. and SARTORELLI, V., 2013. eRNAs promote 
transcription by establishing chromatin accessibility at defined genomic loci. Mol 
Cell 51: 606-617. 
MÜLLER, A. M., MEDVINSKY, A., STROUBOULIS, J., GROSVELD, F. and DZIERZAK, E., 
1994. Development of hematopoietic stem cell activity in the mouse embryo. 
Immunity 1: 291-301. 
MÜLLER, J., HART, C. M., FRANCIS, N. J., VARGAS, M. L., SENGUPTA, A. et al., 2002. 
Histone methyltransferase activity of a Drosophila Polycomb group repressor 
complex. Cell 111: 197-208. 
MÜLLER-SIEBURG, C. E., CHO, R. H., KARLSSON, L., HUANG, J. F. and SIEBURG, H. B., 
2004. Myeloid-biased hematopoietic stem cells have extensive self-renewal 
capacity but generate diminished lymphoid progeny with impaired IL-7 
responsiveness. Blood 103: 4111-4118. 
MÜLLER-SIEBURG, C. E., CHO, R. H., THOMAN, M., ADKINS, B. and SIEBURG, H. B., 
2002. Deterministic regulation of hematopoietic stem cell self-renewal and 
differentiation. Blood 100: 1302-1309. 
MÜLLER-SIEBURG, C. E., TOWNSEND, K., WEISSMAN, I. L. and RENNICK, D., 1988. 
Proliferation and differentiation of highly enriched mouse hematopoietic stem 
cells and progenitor cells in response to defined growth factors. J Exp Med 167: 
1825-1840. 
MÜLLER-SIEBURG, C. E., WHITLOCK, C. A. and WEISSMAN, I. L., 1986. Isolation of two 
early B lymphocyte progenitors from mouse marrow: a committed pre-pre-B cell 
and a clonogenic Thy-1-lo hematopoietic stem cell. Cell 44: 653-662. 
MULLIS, K. B., 1990. Target amplification for DNA analysis by the polymerase chain 
reaction. Ann Biol Clin (Paris) 48: 579-582. 
MUNCAN, V., SANSOM, O. J., TERTOOLEN, L., PHESSE, T. J., BEGTHEL, H. et al., 2006. 
Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target 
gene c-Myc. Mol Cell Biol 26: 8418-8426. 
MURAVYOVA, E., GOLOVNIN, A., GRACHEVA, E., PARSHIKOV, A., BELENKAYA, T., 
PIRROTTA, V. and GEORGIEV, P., 2001. Loss of insulator activity by paired 
Su(Hw) chromatin insulators. Science 291: 495-498. 
MURRAY, P. D. F., 1932. The development in vitro of the blood of the early chicken 
embryo. Proc R Soc Lond B Biol Sci 11: 497-521. 
NAGAO, M., CAMPBELL, K., BURNS, K., KUAN, C. Y., TRUMPP, A. and NAKAFUKU, M., 
2008. Coordinated control of self-renewal and differentiation of neural stem cells 
by Myc and the p19ARF-p53 pathway. J Cell Biol 183: 1243-1257. 
BIBLIOGRAPHY 
 
 164
NALLS, M. A., COUPER, D. J., TANAKA, T., VAN ROOIJ, F. J., CHEN, M. H. et al., 2011. 
Multiple loci are associated with white blood cell phenotypes. PLoS Genet 7: 
e1002113. 
NATOLI, G., and ANDRAU, J. C., 2012. Noncoding transcription at enhancers: general 
principles and functional models. Annu Rev Genet 46: 1-19. 
NAU, M. M., BROOKS, B. J., BATTEY, J., SAUSVILLE, E., GAZDAR, A. F. et al., 1985. L-
myc, a new myc-related gene amplified and expressed in human small cell lung 
cancer. Nature 318: 69-73. 
NEELY, K. E., HASSAN, A. H., WALLBERG, A. E., STEGER, D. J., CAIRNS, B. R., WRIGHT, 
A. P. and WORKMAN, J. L., 1999. Activation domain-mediated targeting of the 
SWI/SNF complex to promoters stimulates transcription from nucleosome arrays. 
Mol Cell 4: 649-655. 
NEGRE, N., HENNETIN, J., SUN, L. V., LAVROV, S., BELLIS, M., WHITE, K. P. and 
CAVALLI, G., 2006. Chromosomal distribution of PcG proteins during Drosophila 
development. PLoS Biol 4: e170. 
NIE, Z., HU, G., WEI, G., CUI, K., YAMANE, A. et al., 2012. c-Myc is a universal 
amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 
68-79. 
NISHIOKA, K., CHUIKOV, S., SARMA, K., ERDJUMENT-BROMAGE, H., ALLIS, C. D., 
TEMPST, P. and REINBERG, D., 2002. Set9, a novel histone H3 methyltransferase 
that facilitates transcription by precluding histone tail modifications required for 
heterochromatin formation. Genes Dev 16: 479-489. 
NOCKA, K., TAN, J. C., CHIU, E., CHU, T. Y., RAY, P., TRAKTMAN, P. and BESMER, P., 
1990. Molecular bases of dominant negative and loss of function mutations at the 
murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 9: 1805-1813. 
NORA, E. P., LAJOIE, B. R., SCHULZ, E. G., GIORGETTI, L., OKAMOTO, I. et al., 2012. 
Spatial partitioning of the regulatory landscape of the X-inactivation centre. 
Nature 485: 381-385. 
NOWELL, P. C., COLE, L. J., HABERMEYER, J. G. and ROAN, P. L., 1956. Growth and 
continued function of rat marrow cells in x-radiated mice. Cancer Res 16: 258-
261. 
O'DONNELL, K. A., WENTZEL, E. A., ZELLER, K. I., DANG, C. V. and MENDELL, J. T., 
2005. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-
843. 
OGAWA, M., MATSUZAKI, Y., NISHIKAWA, S., HAYASHI, S., KUNISADA, T., SUDO, T., 
KINA, T. and NAKAUCHI, H., 1991. Expression and function of c-kit in 
hemopoietic progenitor cells. J Exp Med 174: 63-71. 
BIBLIOGRAPHY 
 
 165
OGBOURNE, S., and ANTALIS, T. M., 1998. Transcriptional control and the role of 
silencers in transcriptional regulation in eukaryotes. Biochem J 331 ( Pt 1): 1-14. 
OKADA, Y., HIROTA, T., KAMATANI, Y., TAKAHASHI, A., OHMIYA, H. et al., 2011. 
Identification of nine novel loci associated with white blood cell subtypes in a 
Japanese population. PLoS Genet 7: e1002067. 
OKANO, M., BELL, D. W., HABER, D. A. and LI, E., 1999. DNA methyltransferases 
Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian 
development. Cell 99: 247-257. 
OKUBO, T., KNOEPFLER, P. S., EISENMAN, R. N. and HOGAN, B. L., 2005. Nmyc plays an 
essential role during lung development as a dosage-sensitive regulator of 
progenitor cell proliferation and differentiation. Development 132: 1363-1374. 
ONG, C. T., and CORCES, V. G., 2011. Enhancer function: new insights into the 
regulation of tissue-specific gene expression. Nat Rev Genet 12: 283-293. 
OOI, A. G., KARSUNKY, H., MAJETI, R., BUTZ, S., VESTWEBER, D., ISHIDA, T., 
QUERTERMOUS, T., WEISSMAN, I. L. and FORSBERG, E. C., 2009. The adhesion 
molecule esam1 is a novel hematopoietic stem cell marker. Stem Cells 27: 653-
661. 
ORIAN, A., VAN STEENSEL, B., DELROW, J., BUSSEMAKER, H. J., LI, L. et al., 2003. 
Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor 
network. Genes Dev 17: 1101-1114. 
OSAWA, M., HANADA, K., HAMADA, H. and NAKAUCHI, H., 1996. Long-term 
lymphohematopoietic reconstitution by a single CD34-low/negative 
hematopoietic stem cell. Science 273: 242-245. 
OSKARSSON, T., ESSERS, M. A., DUBOIS, N., OFFNER, S., DUBEY, C. et al., 2006. Skin 
epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can 
reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev 20: 
2024-2029. 
OTA, S., ZHOU, Z. Q., KEENE, D. R., KNOEPFLER, P. and HURLIN, P. J., 2007. Activities 
of N-Myc in the developing limb link control of skeletal size with digit 
separation. Development 134: 1583-1592. 
PANNE, D., 2008. The enhanceosome. Curr Opin Struct Biol 18: 236-242. 
PATEL, J. H., LOBODA, A. P., SHOWE, M. K., SHOWE, L. C. and MCMAHON, S. B., 2004. 
Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 
4: 562-568. 
PATEL, S. R., RICHARDSON, J. L., SCHULZE, H., KAHLE, E., GALJART, N., DRABEK, K., 
SHIVDASANI, R. A., HARTWIG, J. H. and ITALIANO, J. E., JR., 2005. Differential 
roles of microtubule assembly and sliding in proplatelet formation by 
megakaryocytes. Blood 106: 4076-4085. 
BIBLIOGRAPHY 
 
 166
PENGELLY, A. R., COPUR, O., JACKLE, H., HERZIG, A. and MULLER, J., 2013. A histone 
mutant reproduces the phenotype caused by loss of histone-modifying factor 
Polycomb. Science 339: 698-699. 
PENN, L. J., BROOKS, M. W., LAUFER, E. M. and LAND, H., 1990a. Negative 
autoregulation of c-myc transcription. EMBO J 9: 1113-1121. 
PENN, L. J., LAUFER, E. M. and LAND, H., 1990b. C-MYC: evidence for multiple 
regulatory functions. Semin Cancer Biol 1: 69-80. 
PENNACCHIO, L. A., AHITUV, N., MOSES, A. M., PRABHAKAR, S., NOBREGA, M. A. et al., 
2006. In vivo enhancer analysis of human conserved non-coding sequences. 
Nature 444: 499-502. 
PESCHON, J. J., BEHRINGER, R. R., PALMITER, R. D. and BRINSTER, R. L., 1989. 
Expression of mouse protamine 1 genes in transgenic mice. Ann N Y Acad Sci 
564: 186-197. 
PETRIE, H. T., 2003. Cell migration and the control of post-natal T-cell lymphopoiesis in 
the thymus. Nat Rev Immunol 3: 859-866. 
PEUKERT, K., STALLER, P., SCHNEIDER, A., CARMICHAEL, G., HANEL, F. and EILERS, M., 
1997. An alternative pathway for gene regulation by Myc. EMBO J 16: 5672-
5686. 
PHILLIPS-CREMINS, J. E., SAURIA, M. E., SANYAL, A., GERASIMOVA, T. I., LAJOIE, B. R. 
et al., 2013. Architectural protein subclasses shape 3D organization of genomes 
during lineage commitment. Cell 153: 1281-1295. 
PLANK, J. L., and DEAN, A., 2014. Enhancer function: mechanistic and genome-wide 
insights come together. Mol Cell 55: 5-14. 
PLOEMACHER, R. E., VAN DER SLUIJS, J. P., VOERMAN, J. S. and BRONS, N. H., 1989. An 
in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells 
in the mouse. Blood 74: 2755-2763. 
POMERANTZ, M. M., AHMADIYEH, N., JIA, L., HERMAN, P., VERZI, M. P. et al., 2009. 
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC 
in colorectal cancer. Nat Genet 41: 882-884. 
PRONK, C. J., ROSSI, D. J., MANSSON, R., ATTEMA, J. L., NORDDAHL, G. L., CHAN, C. K., 
SIGVARDSSON, M., WEISSMAN, I. L. and BRYDER, D., 2007. Elucidation of the 
phenotypic, functional, and molecular topography of a myeloerythroid progenitor 
cell hierarchy. Cell Stem Cell 1: 428-442. 
PSHENICHNAYA, I., SCHOUWEY, K., ARMARO, M., LARUE, L., KNOEPFLER, P. S., 
EISENMAN, R. N., TRUMPP, A., DELMAS, V. and BEERMANN, F., 2012. Constitutive 
gray hair in mice induced by melanocyte-specific deletion of c-Myc. Pigment Cell 
Melanoma Res 25: 312-325. 
BIBLIOGRAPHY 
 
 167
PTASHNE, M., 1986. Gene regulation by proteins acting nearby and at a distance. Nature 
322: 697-701. 
PURTON, L. E., and SCADDEN, D. T., 2007. Limiting factors in murine hematopoietic 
stem cell assays. Cell Stem Cell 1: 263-270. 
RADA-IGLESIAS, A., BAJPAI, R., SWIGUT, T., BRUGMANN, S. A., FLYNN, R. A. and 
WYSOCKA, J., 2011. A unique chromatin signature uncovers early developmental 
enhancers in humans. Nature 470: 279-283. 
RADTKE, I., MULLIGHAN, C. G., ISHII, M., SU, X., CHENG, J. et al., 2009. Genomic 
analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc 
Natl Acad Sci U S A 106: 12944-12949. 
RAHL, P. B., LIN, C. Y., SEILA, A. C., FLYNN, R. A., MCCUINE, S., BURGE, C. B., SHARP, 
P. A. and YOUNG, R. A., 2010. c-Myc regulates transcriptional pause release. Cell 
141: 432-445. 
RALPH, S. J., and BERRIDGE, M. V., 1984. Expression of antigens of the 'T200' family of 
glycoproteins on hemopoietic stem cells: evidence that thymocyte cell lineage 
antigens are represented on 'T200'. J Immunol 132: 2510-2514. 
RAMALHO-SANTOS, M., and WILLENBRING, H., 2007. On the origin of the term "stem 
cell". Cell Stem Cell 1: 35-38. 
REAVIE, L., BUCKLEY, S. M., LOIZOU, E., TAKEISHI, S., ARANDA-ORGILLES, B. et al., 
2013. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia 
initiation and progression. Cancer Cell 23: 362-375. 
REAVIE, L., DELLA GATTA, G., CRUSIO, K., ARANDA-ORGILLES, B., BUCKLEY, S. M. et 
al., 2010. Regulation of hematopoietic stem cell differentiation by a single 
ubiquitin ligase-substrate complex. Nat Immunol 11: 207-215. 
REINBERG, D., ORPHANIDES, G., EBRIGHT, R., AKOULITCHEV, S., CARCAMO, J. et al., 
1998. The RNA polymerase II general transcription factors: past, present, and 
future. Cold Spring Harb Symp Quant Biol 63: 83-103. 
RHODES, K. E., GEKAS, C., WANG, Y., LUX, C. T., FRANCIS, C. S. et al., 2008. The 
emergence of hematopoietic stem cells is initiated in the placental vasculature in 
the absence of circulation. Cell Stem Cell 2: 252-263. 
RIETHOVEN, J. J., 2010. Regulatory regions in DNA: promoters, enhancers, silencers, 
and insulators. Methods Mol Biol 674: 33-42. 
ROSS, M. E., MAHFOUZ, R., ONCIU, M., LIU, H. C., ZHOU, X. et al., 2004. Gene 
expression profiling of pediatric acute myelogenous leukemia. Blood 104: 3679-
3687. 
BIBLIOGRAPHY 
 
 168
RUF, S., SYMMONS, O., USLU, V. V., DOLLE, D., HOT, C., ETTWILLER, L. and SPITZ, F., 
2011. Large-scale analysis of the regulatory architecture of the mouse genome 
with a transposon-associated sensor. Nat Genet 43: 379-386. 
SABIN, F. R., 1920. Studies on the origin of blood vessels and of red corpuscles as seen 
in the living blastoderm of chicks during the second day of incubation. Contrib. 
Embryol. 9: 213-262. 
SABÒ, A., KRESS, T. R., PELIZZOLA, M., DE PRETIS, S., GORSKI, M. M. et al., 2014. 
Selective transcriptional regulation by Myc in cellular growth control and 
lymphomagenesis. Nature 511: 488-492. 
SABO, P. J., HAWRYLYCZ, M., WALLACE, J. C., HUMBERT, R., YU, M. et al., 2004a. 
Discovery of functional noncoding elements by digital analysis of chromatin 
structure. Proc Natl Acad Sci U S A 101: 16837-16842. 
SABO, P. J., HUMBERT, R., HAWRYLYCZ, M., WALLACE, J. C., DORSCHNER, M. O., 
MCARTHUR, M. and STAMATOYANNOPOULOS, J. A., 2004b. Genome-wide 
identification of DNaseI hypersensitive sites using active chromatin sequence 
libraries. Proc Natl Acad Sci U S A 101: 4537-4542. 
SAHA, A., WITTMEYER, J. and CAIRNS, B. R., 2006. Chromatin remodelling: the 
industrial revolution of DNA around histones. Nat Rev Mol Cell Biol 7: 437-447. 
SALVATORI, B., IOSUE, I., DJODJI DAMAS, N., MANGIAVACCHI, A., CHIARETTI, S. et al., 
2011. Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct 
Regulation of miR-26a and Histone Methyltransferase EZH2. Genes Cancer 2: 
585-592. 
SANDELIN, A., CARNINCI, P., LENHARD, B., PONJAVIC, J., HAYASHIZAKI, Y. and HUME, 
D. A., 2007. Mammalian RNA polymerase II core promoters: insights from 
genome-wide studies. Nat Rev Genet 8: 424-436. 
SANJUAN-PLA, A., MACAULAY, I. C., JENSEN, C. T., WOLL, P. S., LUIS, T. C. et al., 
2013. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell 
hierarchy. Nature 502: 232-236. 
SATO, T., ONAI, N., YOSHIHARA, H., ARAI, F., SUDA, T. and OHTEKI, T., 2009. 
Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from 
type I interferon-dependent exhaustion. Nat Med 15: 696-700. 
SAUER, B., and HENDERSON, N., 1988. Site-specific DNA recombination in mammalian 
cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A 85: 
5166-5170. 
SAWAI, S., SHIMONO, A., WAKAMATSU, Y., PALMES, C., HANAOKA, K. and KONDOH, 
H., 1993. Defects of embryonic organogenesis resulting from targeted disruption 
of the N-myc gene in the mouse. Development 117: 1445-1455. 
BIBLIOGRAPHY 
 
 169
SAXONOV, S., BERG, P. and BRUTLAG, D. L., 2006. A genome-wide analysis of CpG 
dinucleotides in the human genome distinguishes two distinct classes of 
promoters. Proc Natl Acad Sci U S A 103: 1412-1417. 
SCHEID, M. P., and TRIGLIA, D., 1979. Further description of the Ly-5 system. 
Immunogenetics: 423-433. 
SCHMITT, T. M., and ZUNIGA-PFLUCKER, J. C., 2002. Induction of T cell development 
from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity 17: 749-
756. 
SCHNEIDER, R., BANNISTER, A. J., WEISE, C. and KOUZARIDES, T., 2004. Direct binding 
of INHAT to H3 tails disrupted by modifications. J Biol Chem 279: 23859-23862. 
SCHOENFELDER, S., CLAY, I. and FRASER, P., 2010. The transcriptional interactome: 
gene expression in 3D. Curr Opin Genet Dev 20: 127-133. 
SCHREIBER-AGUS, N., CHIN, L., CHEN, K., TORRES, R., RAO, G., GUIDA, P., SKOULTCHI, 
A. I. and DEPINHO, R. A., 1995. An amino-terminal domain of Mxi1 mediates 
anti-Myc oncogenic activity and interacts with a homolog of the yeast 
transcriptional repressor SIN3. Cell 80: 777-786. 
SCHWAB, M., ALITALO, K., KLEMPNAUER, K. H., VARMUS, H. E., BISHOP, J. M., 
GILBERT, F., BRODEUR, G., GOLDSTEIN, M. and TRENT, J., 1983. Amplified DNA 
with limited homology to myc cellular oncogene is shared by human 
neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248. 
SCHWARTZ, Y. B., KAHN, T. G., NIX, D. A., LI, X. Y., BOURGON, R., BIGGIN, M. and 
PIRROTTA, V., 2006. Genome-wide analysis of Polycomb targets in Drosophila 
melanogaster. Nat Genet 38: 700-705. 
SEMPLE, J. W., ITALIANO, J. E., JR. and FREEDMAN, J., 2011. Platelets and the immune 
continuum. Nat Rev Immunol 11: 264-274. 
SEOANE, J., LE, H. V. and MASSAGUE, J., 2002. Myc suppression of the p21(Cip1) Cdk 
inhibitor influences the outcome of the p53 response to DNA damage. Nature 
419: 729-734. 
SEOANE, J., POUPONNOT, C., STALLER, P., SCHADER, M., EILERS, M. and MASSAGUE, J., 
2001. TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor 
p15INK4b. Nat Cell Biol 3: 400-408. 
SHEINESS, D., FANSHIER, L. and BISHOP, J. M., 1978. Identification of nucleotide 
sequences which may encode the oncogenic capacity of avian retrovirus MC29. J 
Virol 28: 600-610. 
SHEN, Y., YUE, F., MCCLEARY, D. F., YE, Z., EDSALL, L. et al., 2012. A map of the cis-
regulatory sequences in the mouse genome. Nature 488: 116-120. 
BIBLIOGRAPHY 
 
 170
SHI, J., WHYTE, W. A., ZEPEDA-MENDOZA, C. J., MILAZZO, J. P., SHEN, C. et al., 2013. 
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc 
regulation. Genes Dev 27: 2648-2662. 
SHLUSH, L. I., ZANDI, S., MITCHELL, A., CHEN, W. C., BRANDWEIN, J. M. et al., 2014. 
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. 
Nature 506: 328-333. 
SIMINOVITCH, L., MCCULLOCH, E. A. and TILL, J. E., 1963. The Distribution of Colony-
Forming Cells among Spleen Colonies. J Cell Physiol 62: 327-336. 
SING, A., PANNELL, D., KARAISKAKIS, A., STURGEON, K., DJABALI, M., ELLIS, J., 
LIPSHITZ, H. D. and CORDES, S. P., 2009. A vertebrate Polycomb response 
element governs segmentation of the posterior hindbrain. Cell 138: 885-897. 
SMALE, S. T., and KADONAGA, J. T., 2003. The RNA polymerase II core promoter. 
Annu Rev Biochem 72: 449-479. 
SMITH, K. N., SINGH, A. M. and DALTON, S., 2010. Myc represses primitive endoderm 
differentiation in pluripotent stem cells. Cell Stem Cell 7: 343-354. 
SOTELO, J., ESPOSITO, D., DUHAGON, M. A., BANFIELD, K., MEHALKO, J. et al., 2010. 
Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci U S A 107: 
3001-3005. 
SPANGRUDE, G. J., HEIMFELD, S. and WEISSMAN, I. L., 1988. Purification and 
characterization of mouse hematopoietic stem cells. Science 241: 58-62. 
SPITZ, F., and FURLONG, E. E., 2012. Transcription factors: from enhancer binding to 
developmental control. Nat Rev Genet 13: 613-626. 
STADLER, M. B., MURR, R., BURGER, L., IVANEK, R., LIENERT, F. et al., 2011. DNA-
binding factors shape the mouse methylome at distal regulatory regions. Nature 
480: 490-495. 
STANTON, B. R., PERKINS, A. S., TESSAROLLO, L., SASSOON, D. A. and PARADA, L. F., 
1992. Loss of N-myc function results in embryonic lethality and failure of the 
epithelial component of the embryo to develop. Genes Dev 6: 2235-2247. 
STEIGER, D., FURRER, M., SCHWINKENDORF, D. and GALLANT, P., 2008. Max-
independent functions of Myc in Drosophila melanogaster. Nat Genet 40: 1084-
1091. 
STERNBERG, N., and HAMILTON, D., 1981. Bacteriophage P1 site-specific 
recombination. I. Recombination between loxP sites. J Mol Biol 150: 467-486. 
STIREWALT, D. L., MESHINCHI, S., KOPECKY, K. J., FAN, W., POGOSOVA-AGADJANYAN, 
E. L. et al., 2008. Identification of genes with abnormal expression changes in 
acute myeloid leukemia. Genes Chromosomes Cancer 47: 8-20. 
BIBLIOGRAPHY 
 
 171
STOCK, J. K., GIADROSSI, S., CASANOVA, M., BROOKES, E., VIDAL, M., KOSEKI, H., 
BROCKDORFF, N., FISHER, A. G. and POMBO, A., 2007. Ring1-mediated 
ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in 
mouse ES cells. Nat Cell Biol 9: 1428-1435. 
STOELZLE, T., SCHWARB, P., TRUMPP, A. and HYNES, N. E., 2009. c-Myc affects mRNA 
translation, cell proliferation and progenitor cell function in the mammary gland. 
BMC Biol 7: 63. 
SUN, D., LUO, M., JEONG, M., RODRIGUEZ, B., XIA, Z. et al., 2014. Epigenomic 
profiling of young and aged HSCs reveals concerted changes during aging that 
reinforce self-renewal. Cell Stem Cell 14: 673-688. 
SUR, I. K., HALLIKAS, O., VAHARAUTIO, A., YAN, J., TURUNEN, M. et al., 2012. Mice 
lacking a Myc enhancer that includes human SNP rs6983267 are resistant to 
intestinal tumors. Science 338: 1360-1363. 
SUTHERLAND, H. J., EAVES, C. J., EAVES, A. C., DRAGOWSKA, W. and LANSDORP, P. M., 
1989. Characterization and partial purification of human marrow cells capable of 
initiating long-term hematopoiesis in vitro. Blood 74: 1563-1570. 
SYKES, M., CHESTER, C. H., SUNDT, T. M., ROMICK, M. L., HOYLES, K. A. and SACHS, 
D. H., 1989. Effects of T cell depletion in radiation bone marrow chimeras. III. 
Characterization of allogeneic bone marrow cell populations that increase 
allogeneic chimerism independently of graft-vs-host disease in mixed marrow 
recipients. J Immunol 143: 3503-3511. 
SYMMONS, O., and SPITZ, F., 2013. From remote enhancers to gene regulation: charting 
the genome's regulatory landscapes. Philos Trans R Soc Lond B Biol Sci 368: 
20120358. 
SYMMONS, O., USLU, V. V., TSUJIMURA, T., RUF, S., NASSARI, S., SCHWARZER, W., 
ETTWILLER, L. and SPITZ, F., 2014. Functional and topological characteristics of 
mammalian regulatory domains. Genome Res 24: 390-400. 
SZILVASSY, S. J., HUMPHRIES, R. K., LANSDORP, P. M., EAVES, A. C. and EAVES, C. J., 
1990. Quantitative assay for totipotent reconstituting hematopoietic stem cells by 
a competitive repopulation strategy. Proc Natl Acad Sci U S A 87: 8736-8740. 
TASWELL, C., 1981. Limiting dilution assays for the determination of immunocompetent 
cell frequencies. I. Data analysis. J Immunol 126: 1614-1619. 
TAUB, R., KIRSCH, I., MORTON, C., LENOIR, G., SWAN, D., TRONICK, S., AARONSON, S. 
and LEDER, P., 1982. Translocation of the c-myc gene into the immunoglobulin 
heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. 
Proc Natl Acad Sci U S A 79: 7837-7841. 
TEWARI, R., GILLEMANS, N., HARPER, A., WIJGERDE, M., ZAFARANA, G., DRABEK, D., 
GROSVELD, F. and PHILIPSEN, S., 1996. The human beta-globin locus control 
BIBLIOGRAPHY 
 
 172
region confers an early embryonic erythroid-specific expression pattern to a basic 
promoter driving the bacterial lacZ gene. Development 122: 3991-3999. 
THON, J. N., and ITALIANO, J. E., 2010. Platelet formation. Semin Hematol 47: 220-226. 
THURMAN, R. E., RYNES, E., HUMBERT, R., VIERSTRA, J., MAURANO, M. T. et al., 2012. 
The accessible chromatin landscape of the human genome. Nature 489: 75-82. 
TILL, J. E., and MCCULLOCH, E. A., 1961. A direct measurement of the radiation 
sensitivity of normal mouse bone marrow cells. Radiat Res 14: 213-222. 
TOLHUIS, B., DE WIT, E., MUIJRERS, I., TEUNISSEN, H., TALHOUT, W., VAN STEENSEL, B. 
and VAN LOHUIZEN, M., 2006. Genome-wide profiling of PRC1 and PRC2 
Polycomb chromatin binding in Drosophila melanogaster. Nat Genet 38: 694-699. 
TOLHUIS, B., PALSTRA, R. J., SPLINTER, E., GROSVELD, F. and DE LAAT, W., 2002. 
Looping and interaction between hypersensitive sites in the active beta-globin 
locus. Mol Cell 10: 1453-1465. 
TRUMPP, A., REFAELI, Y., OSKARSSON, T., GASSER, S., MURPHY, M., MARTIN, G. R. and 
BISHOP, J. M., 2001. c-Myc regulates mammalian body size by controlling cell 
number but not cell size. Nature 414: 768-773. 
TSENG, Y. Y., MORIARITY, B. S., GONG, W., AKIYAMA, R., TIWARI, A. et al., 2014. 
PVT1 dependence in cancer with MYC copy-number increase. Nature 512: 82-
86. 
TZONEVA, G., and FERRANDO, A. A., 2012. Recent advances on NOTCH signaling in T-
ALL. Curr Top Microbiol Immunol 360: 163-182. 
USLU, V. V., PETRETICH, M., RUF, S., LANGENFELD, K., FONSECA, N. A., MARIONI, J. C. 
and SPITZ, F., 2014. Long-range enhancers regulating Myc expression are 
required for normal facial morphogenesis. Nat Genet 46: 753-758. 
VALK, P. J., VERHAAK, R. G., BEIJEN, M. A., ERPELINCK, C. A., BARJESTEH VAN 
WAALWIJK VAN DOORN-KHOSROVANI, S. et al., 2004. Prognostically useful gene-
expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628. 
VALLESPINOS, M., FERNANDEZ, D., RODRIGUEZ, L., ALVARO-BLANCO, J., BAENA, E. et 
al., 2011. B Lymphocyte commitment program is driven by the proto-oncogene c-
Myc. J Immunol 186: 6726-6736. 
VAN KEUREN, M. L., GAVRILINA, G. B., FILIPIAK, W. E., ZEIDLER, M. G. and 
SAUNDERS, T. L., 2009. Generating transgenic mice from bacterial artificial 
chromosomes: transgenesis efficiency, integration and expression outcomes. 
Transgenic Res 18: 769-785. 
VAN OS, R., KAMMINGA, L. M. and DE HAAN, G., 2004. Stem cell assays: something old, 
something new, something borrowed. Stem Cells 22: 1181-1190. 
BIBLIOGRAPHY 
 
 173
VAN RIGGELEN, J., YETIL, A. and FELSHER, D. W., 2010. MYC as a regulator of 
ribosome biogenesis and protein synthesis. Nat Rev Cancer 10: 301-309. 
VARLAKHANOVA, N. V., COTTERMAN, R. F., DEVRIES, W. N., MORGAN, J., DONAHUE, L. 
R., MURRAY, S., KNOWLES, B. B. and KNOEPFLER, P. S., 2010. myc maintains 
embryonic stem cell pluripotency and self-renewal. Differentiation 80: 9-19. 
VENNSTROM, B., SHEINESS, D., ZABIELSKI, J. and BISHOP, J. M., 1982. Isolation and 
characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian 
myelocytomatosis virus strain 29. J Virol 42: 773-779. 
VENTER, J. C., ADAMS, M. D., MYERS, E. W., LI, P. W., MURAL, R. J. et al., 2001. The 
sequence of the human genome. Science 291: 1304-1351. 
VIRE, E., BRENNER, C., DEPLUS, R., BLANCHON, L., FRAGA, M. et al., 2006. The 
Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 
871-874. 
VISEL, A., RUBIN, E. M. and PENNACCHIO, L. A., 2009. Genomic views of distant-acting 
enhancers. Nature 461: 199-205. 
WALSH, C. T., GARNEAU-TSODIKOVA, S. and GATTO, G. J., JR., 2005. Protein 
posttranslational modifications: the chemistry of proteome diversifications. 
Angew Chem Int Ed Engl 44: 7342-7372. 
WALZ, S., LORENZIN, F., MORTON, J., WIESE, K. E., VON EYSS, B. et al., 2014. 
Activation and repression by oncogenic MYC shape tumour-specific gene 
expression profiles. Nature 511: 483-487. 
WANG, D., GARCIA-BASSETS, I., BENNER, C., LI, W., SU, X. et al., 2011. 
Reprogramming transcription by distinct classes of enhancers functionally defined 
by eRNA. Nature 474: 390-394. 
WANG, H., WANG, L., ERDJUMENT-BROMAGE, H., VIDAL, M., TEMPST, P., JONES, R. S. 
and ZHANG, Y., 2004. Role of histone H2A ubiquitination in Polycomb silencing. 
Nature 431: 873-878. 
WASKOW, C., MADAN, V., BARTELS, S., COSTA, C., BLASIG, R. and RODEWALD, H. R., 
2009. Hematopoietic stem cell transplantation without irradiation. Nat Methods 6: 
267-269. 
WATERSTON, R. H., LINDBLAD-TOH, K., BIRNEY, E., ROGERS, J., ABRIL, J. F. et al., 
2002. Initial sequencing and comparative analysis of the mouse genome. Nature 
420: 520-562. 
WATT, F. M., FRYE, M. and BENITAH, S. A., 2008. MYC in mammalian epidermis: how 
can an oncogene stimulate differentiation? Nat Rev Cancer 8: 234-242. 
WENG, A. P., FERRANDO, A. A., LEE, W., MORRIS, J. P. T., SILVERMAN, L. B., SANCHEZ-
IRIZARRY, C., BLACKLOW, S. C., LOOK, A. T. and ASTER, J. C., 2004. Activating 
BIBLIOGRAPHY 
 
 174
mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 
306: 269-271. 
WHITE, R. J., 2011. Transcription by RNA polymerase III: more complex than we 
thought. Nat Rev Genet 12: 459-463. 
WHITLOCK, C. A., and WITTE, O. N., 1982. Long-term culture of B lymphocytes and 
their precursors from murine bone marrow. Proc Natl Acad Sci U S A 79: 3608-
3612. 
WIERSTRA, I., and ALVES, J., 2008. The c-myc promoter: still MysterY and challenge. 
Adv Cancer Res 99: 113-333. 
WILSON, A., LAURENTI, E., OSER, G., VAN DER WATH, R. C., BLANCO-BOSE, W. et al., 
2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal 
during homeostasis and repair. Cell 135: 1118-1129. 
WILSON, A., MURPHY, M. J., OSKARSSON, T., KALOULIS, K., BETTESS, M. D. et al., 
2004. c-Myc controls the balance between hematopoietic stem cell self-renewal 
and differentiation. Genes Dev 18: 2747-2763. 
WILSON, N. K., FOSTER, S. D., WANG, X., KNEZEVIC, K., SCHUTTE, J. et al., 2010. 
Combinatorial transcriptional control in blood stem/progenitor cells: genome-
wide analysis of ten major transcriptional regulators. Cell Stem Cell 7: 532-544. 
WINSTON, F., and ALLIS, C. D., 1999. The bromodomain: a chromatin-targeting 
module? Nat Struct Biol 6: 601-604. 
WOEHRER, S., MILLER, C. L. and EAVES, C. J., 2013. Long-term culture-initiating cell 
assay for mouse cells. Methods Mol Biol 946: 257-266. 
WOLF, N. S., KONE, A., PRIESTLEY, G. V. and BARTELMEZ, S. H., 1993. In vivo and in 
vitro characterization of long-term repopulating primitive hematopoietic cells 
isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp 
Hematol 21: 614-622. 
WOO, C. J., KHARCHENKO, P. V., DAHERON, L., PARK, P. J. and KINGSTON, R. E., 2010. 
A region of the human HOXD cluster that confers polycomb-group 
responsiveness. Cell 140: 99-110. 
WOYCHIK, N. A., and HAMPSEY, M., 2002. The RNA polymerase II machinery: 
structure illuminates function. Cell 108: 453-463. 
WU, A. M., TILL, J. E., SIMINOVITCH, L. and MCCULLOCH, E. A., 1967. A cytological 
study of the capacity for differentiation of normal hemopoietic colony-forming 
cells. J Cell Physiol 69: 177-184. 
WU, S., CETINKAYA, C., MUNOZ-ALONSO, M. J., VON DER LEHR, N., BAHRAM, F., 
BEUGER, V., EILERS, M., LEON, J. and LARSSON, L. G., 2003. Myc represses 
BIBLIOGRAPHY 
 
 175
differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with 
the p21 core promoter. Oncogene 22: 351-360. 
WU, S., YING, G., WU, Q. and CAPECCHI, M. R., 2007. Toward simpler and faster 
genome-wide mutagenesis in mice. Nat Genet 39: 922-930. 
XI, H., SHULHA, H. P., LIN, J. M., VALES, T. R., FU, Y. et al., 2007. Identification and 
characterization of cell type-specific and ubiquitous chromatin regulatory 
structures in the human genome. PLoS Genet 3: e136. 
YAMAMOTO, R., MORITA, Y., OOEHARA, J., HAMANAKA, S., ONODERA, M., RUDOLPH, 
K. L., EMA, H. and NAKAUCHI, H., 2013. Clonal analysis unveils self-renewing 
lineage-restricted progenitors generated directly from hematopoietic stem cells. 
Cell 154: 1112-1126. 
YANG, H., WANG, H. and JAENISCH, R., 2014. Generating genetically modified mice 
using CRISPR/Cas-mediated genome engineering. Nat Protoc 9: 1956-1968. 
YANT, S. R., and KAY, M. A., 2003. Nonhomologous-end-joining factors regulate DNA 
repair fidelity during Sleeping Beauty element transposition in mammalian cells. 
Mol Cell Biol 23: 8505-8518. 
YATES, L. R., and CAMPBELL, P. J., 2012. Evolution of the cancer genome. Nat Rev 
Genet 13: 795-806. 
YEE, S. P., and RIGBY, P. W., 1993. The regulation of myogenin gene expression during 
the embryonic development of the mouse. Genes Dev 7: 1277-1289. 
YING, Q. L., WRAY, J., NICHOLS, J., BATLLE-MORERA, L., DOBLE, B., WOODGETT, J., 
COHEN, P. and SMITH, A., 2008. The ground state of embryonic stem cell self-
renewal. Nature 453: 519-523. 
YOKOTA, T., ORITANI, K., BUTZ, S., KOKAME, K., KINCADE, P. W., MIYATA, T., 
VESTWEBER, D. and KANAKURA, Y., 2009. The endothelial antigen ESAM marks 
primitive hematopoietic progenitors throughout life in mice. Blood 113: 2914-
2923. 
YOON, Y. S., JEONG, S., RONG, Q., PARK, K. Y., CHUNG, J. H. and PFEIFER, K., 2007. 
Analysis of the H19ICR insulator. Mol Cell Biol 27: 3499-3510. 
YUAN, R., ASTLE, C. M., CHEN, J. and HARRISON, D. E., 2005. Genetic regulation of 
hematopoietic stem cell exhaustion during development and growth. Exp Hematol 
33: 243-250. 
YUDKOVSKY, N., LOGIE, C., HAHN, S. and PETERSON, C. L., 1999. Recruitment of the 
SWI/SNF chromatin remodeling complex by transcriptional activators. Genes 
Dev 13: 2369-2374. 
ZANET, J., PIBRE, S., JACQUET, C., RAMIREZ, A., DE ALBORAN, I. M. and GANDARILLAS, 
A., 2005. Endogenous Myc controls mammalian epidermal cell size, 
BIBLIOGRAPHY 
 
 176
hyperproliferation, endoreplication and stem cell amplification. J Cell Sci 118: 
1693-1704. 
ZELLER, K. I., ZHAO, X., LEE, C. W., CHIU, K. P., YAO, F. et al., 2006. Global mapping 
of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad 
Sci U S A 103: 17834-17839. 
ZERVOS, A. S., GYURIS, J. and BRENT, R., 1993. Mxi1, a protein that specifically 
interacts with Max to bind Myc-Max recognition sites. Cell 72: 223-232. 
ZHANG, Y., WONG, C. H., BIRNBAUM, R. Y., LI, G., FAVARO, R. et al., 2013. Chromatin 
connectivity maps reveal dynamic promoter-enhancer long-range associations. 
Nature 504: 306-310. 
ZHAO, H., and DEAN, A., 2004. An insulator blocks spreading of histone acetylation and 
interferes with RNA polymerase II transfer between an enhancer and gene. 
Nucleic Acids Res 32: 4903-4919. 
ZHOU, V. W., GOREN, A. and BERNSTEIN, B. E., 2011. Charting histone modifications 
and the functional organization of mammalian genomes. Nat Rev Genet 12: 7-18. 
ZHU, X., LING, J., ZHANG, L., PI, W., WU, M. and TUAN, D., 2007. A facilitated tracking 
and transcription mechanism of long-range enhancer function. Nucleic Acids Res 
35: 5532-5544. 
ZILBERMAN, D., COLEMAN-DERR, D., BALLINGER, T. and HENIKOFF, S., 2008. Histone 
H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature 
456: 125-129. 
ZILLER, M. J., GU, H., MULLER, F., DONAGHEY, J., TSAI, L. T. et al., 2013. Charting a 
dynamic DNA methylation landscape of the human genome. Nature 500: 477-
481. 
ZIMMERMAN, K., and ALT, F. W., 1990. Expression and function of myc family genes. 
Crit Rev Oncog 2: 75-95. 
 
 
